Document:

EX-10.10

 Exhibit 10.10 
  

					
	KUCTC-Reata	  	Confidential	  	[***]

 SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED.
THESE REDACTED TERMS HAVE BEEN MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

EXCLUSIVE LICENSE AGREEMENT 

between 
 Reata
Pharmaceuticals, Inc. 
 and 

KU Center for Technology Commercialization, Inc. 

Exclusive License Agreement 

  
 Page i of
34 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 TABLE OF CONTENTS 
  

					
	 ARTICLE l. DEFINITIONS
	  	 	4	  
	 ARTICLE 2. LICENSE GRANT
	  	 	6	  
	 ARTICLE 3. TERM OF AGREEMENT
	  	 	8	  
	 ARTICLE 4. FEES & ROYALTIES
	  	 	8	  
	 ARTICLE 5. COMMERCIAL DILIGENCE & MILESTONES
	  	 	10	  
	 ARTICLE 6. EQUITY OWNERSHIP
	  	 	13	  
	 ARTICLE 7. CONFIDENTIALITY
	  	 	13	  
	 ARTICLE 8. QUARTERLY & ANNUAL REPORTS
	  	 	14	  
	 ARTICLE 9. PAYMENTS, RECORDS and AUDITS
	  	 	15	  
	 ARTICLE 10. PATENT MARKING
	  	 	16	  
	 ARTICLE 11. PATENT PROSECUTION AND MAINTENANCE
	  	 	16	  
	 ARTICLE 12. TERMINATION BY LICENSOR
	  	 	17	  
	 ARTICLE 13. TERMINATION BY LICENSEE
	  	 	17	  
	 ARTICLE 14. DISPOSITION OF LICENSED PRODUCTS ON HAND
	  	 	17	  
	 ARTICLE 15. WARRANTY BY LICENSOR
	  	 	17	  
	 ARTICLE 16. INFRINGEMENT
	  	 	18	  
	 ARTICLE 17. INSURANCE
	  	 	19	  
	 ARTICLE 18. WAIVER
	  	 	19	  
	 ARTICLE 19. ASSIGNABILITY
	  	 	19	  
	 ARTICLE 20. INDEMNIFICATION BY LICENSEE
	  	 	19	  
	 ARTICLE 21. NOTICES
	  	 	20	  
	 ARTICLE 22. REGULATORY COMPLIANCE
	  	 	20	  
	 ARTICLE 23. GOVERNING LAW
	  	 	21	  
	 ARTICLE 24. RELATIONSHIP OF PARTIES
	  	 	21	  
	 ARTICLE 25. USE OF NAMES
	  	 	21	  
	 ARTICLE 26. DISPUTE RESOLUTION
	  	 	21	  
	 ARTICLE 27. GENERAL PROVISIONS
	  	 	22	  
	 EXHIBIT “A”
	  	 	24	  
	 PATENT RIGHTS
	  	 	24	  
	 EXHIBIT “B”
	  	 	25	  
	 LICENSE TO THE UNITED STATES GOVERNMENT
	  	 	25	  
	 EXHIBIT “C”
	  	 	26	  
	 2015 ROYALTY REPORT
	  	 	26	  
	 EXHIBIT “D”
	  	 	27	  
	 ANNUAL DEVELOPMENT and COMMERCIALIZATION REPORT
	  	 	27	  
	 EXHIBIT “E”
	  	 	29	  
	 CURRENT DEVELOPMENT PLAN
	  	 	29	  
	 EXHIBIT “F”
	  	 	30	  
	 INTER-INSTITUTIONAL AGREEMENT
	  	 	30	  
	 EXHIBIT “G”
	  	 	31	  
	 MATERIAL TRANSFER AGREEMENT TEMPLATE
	  	 	31	  

  
 Page ii of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 LICENSE AGREEMENT 

THIS LICENSE Agreement (“Agreement”) is entered into this 26th day of
September, 2014 by and between the KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC, a Kansas non-profit § 501(c)(3) corporation, having its principal place of business at 3901 Rainbow Boulevard, Kansas City, Kansas 66160, hereinafter referred
to as “KUCTC” or “Licensor,” and “REATA PHARMACEUTICALS, INC.” having its principal place of business at 2801 Gateway Drive, Suite 150, Irving, Texas 75063, hereinafter referred to as “Licensee.” 

WITNESSETH 

WHEREAS, certain inventions, generally characterized as small molecule modulators of heat shock proteins and assigned KUCTC Technology ID
numbers [***] and [***], hereinafter collectively referred to as “the Invention”, have been made in the course of research at the University of Kansas conducted by Dr. Brian Blagg, et al., and the Department of Health and Human
Services (“DHHS”) conducted by [***], and are Covered By Patent Rights (as defined below); 
 WHEREAS, the University of Kansas
and the University of Kansas Medical Center (hereinafter collectively referred to as “KU”) and KUCTC have an agreement wherein KUCTC is the manager of intellectual property owned by KU; 

WHEREAS, the United States Public Health Services (“PHS”) is a division of DHHS; 

WHEREAS, the National Institutes of Health is an agency within PHS; 

WHEREAS, prior to July 1, 2008, University of Kansas Center for Research, Inc. (“KUCR”) and KU had an agreement wherein KUCR
was the manager of intellectual property owned by KU; 
 WHEREAS, PHS and the KUCR entered into an Interinstitutional Agreement dated
March 22, 2005 in which PHS granted KUCR an exclusive license in Patent Rights (“the IIA”, which attached as Exhibit “F”) 

WHEREAS, after July 1, 2008, KUCR, KUCTC, and KU entered into an agreement wherein KUCTC was the manager of intellectual property owned
by KU; 
 WHEREAS, KUCR assigned all of its right, title, and interest in the IIA to its affiliate KUCTC effective July 1, 2008 such
that KUCTC is the manager of intellectual property owned by or licensed to KU, including the Invention and the Patent Rights; 
 WHEREAS,
the Inventions have been and/or will be developed by employees, students, or postdoctoral fellows of KU or DHHS; and 
 WHEREAS, KU and
KUCTC together own or are an exclusive licensee in all right, title and interest in the Inventions and the Patent Rights as provided in the IIA; and 

WHEREAS, Licensor desires that the Patent Rights be developed and utilized to the fullest extent so that their benefits can be enjoyed by the
general public; 
 WHEREAS, Licensee wishes to obtain from Licensor a license under certain patent rights for the commercial development,
production, manufacture, use and sale of Licensed Products and Licensor is willing to grant such a license upon the terms and conditions hereinafter set forth; 

  
 Page 3 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 WHEREAS, the Patent Rights were developed in the course of research sponsored in part by the
U.S. Government, and as a consequence are subject to overriding obligations of Licensor to the U.S. Government; 
 NOW THEREFORE, for and in
consideration of the covenants, conditions and undertakings hereinafter set forth, the parties hereby agree as follows: 
 ARTICLE l.
DEFINITIONS 
  

	1.1	“Affiliate” means any company or other business entity that, directly or indirectly, controls, or is controlled by, or is under common control by Licensee. Solely for purposes of this definition, the
term “control” means the possession of the power to direct or cause the direction of the management and policies of the entity, whether through ownership of voting securities or by contract. Control will be presumed if an entity owns,
either of record or beneficially, at least fifty percent (50%) of the voting stock of the other entity. An entity will be deemed an Affiliate only while such ownership or control relationship continues. 

 

	1.2	“Clinical Candidate” means a compound which, following Lead Optimization, has been designated by Licensee for entry into GLP Toxicology Studies and other IND-directed research activities.

  

	1.3	“...Covered By...” means a compound, composition, product, process, method or other substance or activity, the use, manufacture, or sale of which would infringe a Valid Claim within any pending or
issued patent included in the Patent Rights claiming all, a portion, or a component or step of a Licensed Product. 

  

	1.4	“Commercially Diligent Efforts” means, with respect to a Licensed Product, the diligent exercise, dedication and expenditure of efforts, money, personnel, and resources as reasonably needed to develop,
manufacture, market and sell the Licensed Product. Such efforts shall be documented and must be consistent with those utilized by companies of similar size and type that have successfully developed products and services similar to the Licensed
Product. In determining Commercially Diligent Efforts with respect to a particular Licensed Product, Licensee may not reduce such efforts due to the competitive, regulatory or other impact of any other product or method that it owns, licenses or is
developing or commercializing. 

  

	1.5	“Effective Date” means the latest date upon which an authorized representative of Licensee or Licensor signs this Agreement. 

 

	1.6	“Entity” means a corporation, an association, a joint venture, a partnership, a trust, a business, an institution, an individual, a government or political subdivision thereof, including an agency, or
any other organization that can exercise independent legal standing. 

  

	1.7	“Fair Market Value” means the cash consideration which Licensee or its Sublicensee would realize from an unaffiliated, unrelated buyer in an arm’s length sale of an identical item sold in the same
quantity, under the same terms, and at the same time and place. 

  

	1.8	“FDA” means the United States Food and Drug Administration. 

  

	1.9	“Field of Use” means all human and veterinary therapeutic and diagnostic uses. 

  

	1.10	“First Dosing”, with respect to human clinical trials, means the first administration of a Licensed Product to a subject in a specified clinical trial. 

 

	1.11	“GLP Toxicology Studies” means a non-clinical toxicology study conducted according to Good Laboratory Practices guidelines promulgated by the FDA, and intended to support submission of an IND.

  
 Page 4 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	1.12	“IND” means an investigational new drug application filed with the FDA for authorization to commence Clinical Studies in the U.S. or an equivalent application filed with the applicable Regulatory
Authority in another country or regulatory jurisdiction. 

  

	1.13	“IND Acceptance” means that either by issuing no comment during the 30-day IND review period or by providing some affirmative communication, the FDA has assented to the performance of the clinical trial
proposed in the IND application. 

  

	1.14	“Initiation” means, with respect to a study in non-human mammals, the first dosing of a live subject in a study. 

  

	1.15	“Insolvent” means being unable to meet one’s debt obligations to another Entity as such debt obligations become due and not being able to provide reasonable financial assurances of becoming able to
meet such obligations. 

  

	1.16	“Lead Compound” means an organic compound identified in screening assays and in vivo studies that shows sufficient activity to be a standard of comparison in medicinal chemistry research programs
intended to identify additional compounds having superior potency, selectivity, in vivo activity, or other superior drug-like qualities. 

  

	1.17	“Lead Optimization” means the program of medicinal chemistry research intended to identify structure-activity relationships and apply the knowledge of those relationships to produce compounds having
superior properties relative to a Lead Compound. 

  

	1.18	“Licensed Product” means any product, process, method of use, apparatus, kit or component part thereof, or any other subject matter, the manufacture, design, creation, use, importation, distribution, or
sale of which is Covered By any Valid Claim. 

  

	1.19	“NDA” means New Drug Application according to FDA regulations, or the foreign equivalent. 

  

	1.20	“NDA Acceptance” means receipt of a communication from the FDA stating that a filed NDA has been accepted for review. 

 

	1.21	“Net Sales” means the gross amount invoiced by LICENSEE, AFFILIATE and/or any Sublicensee for the SALE of LICENSED PRODUCTS to a third party less: (i) normal and customary trade, cash and other
discounts actually granted; (ii) charge back payments and rebates granted to managed health care organizations or to federal, state and local governments, their agencies and purchasers; (iii) commercially reasonable and customary fees paid
to distributors (other than AFFILIATES) that are included in the gross invoiced amount;(iv) credits or allowances actually granted for rejections or returns of LICENSED PRODUCTS, including recalls (not to exceed the original invoiced amount);
(v) sales or similar taxes, including without limitation, value added taxes or other governmental charges which are included in the invoiced amount; and (vi) freight, postage, shipping, customs duties and insurance charges for packaging
which are included in the invoiced amount, all as recorded by LICENSEE in LICENSEE’s official books and records in accordance with generally accepted accounting practices and consistent with LICENSEE’s published financial statements and/or
regulatory filings with the United States Securities and Exchange Commission, or as reported by any Sublicensee to Licensee in compliance with the terms of the relevant sublicense, as applicable. For the avoidance of doubt, sales and transfers among
Licensee and its Sublicensees (for example, transfer of finished drug product from Licensee to a Sublicensee for commercial distribution) of Licensed Products intended for ultimate sale to third parties shall be disregarded for purposes of computing
Net Sales. 

  
 Page 5 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	1.22	“Patent Rights” means and include all of the following Licensor intellectual property: The United States patents and/or patent applications listed in Exhibit “A”; United States patents issued
from the applications listed in Exhibit “A” and from divisionals and continuations (other than continuations-in-part) of these applications and any reissues of such United States patents; claims of continuation-in-part applications and
patents directed to subject matter specifically described in the patent(s) and/or patent application(s) listed in Exhibit “A”; and claims of all foreign applications and patents which are directed to subject matter specifically described
in the United States patents and/or patent applications listed in Exhibit “A”. 

  

	1.23	“Phase 1 Clinical Trials” means a human clinical trial of a Licensed Product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients or similar
clinical study prescribed by the FDA or a comparable foreign regulatory authority, including the trials referred to in 21 C.F.R. §312.21(a), as amended. 

  

	1.24	“Phase 2 Clinical Trials” means a human clinical trial of a Product or a New Collaboration Compound, the principal purpose of which is a determination of safety and efficacy in the target patient
population or a similar clinical study prescribed by the Regulatory Authorities, from time to time, pursuant to Applicable Law or otherwise, including the trials referred to in 21 C.F.R. §312.21(b), as amended. 

 

	1.25	“Phase 3 Clinical Trials” means a human clinical trial of a Product or New Collaboration Compound on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe
and efficacious for its intended use and to determine warnings, precautions, and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support marketing approval of
such Product or New Collaboration Compound, including all tests and studies that are required by the FDA from time to time, pursuant to Applicable Law or otherwise. 

 

	1.26	“Sublicensee” means any party other than an Affiliate which enters into an agreement or arrangement with Licensee or receives a license grant from Licensee under the Patent Rights, to manufacture, have
manufactured, offer for sale, sell, lease, use, practice, and/or import the Licensed Product, subject to the then-current applicable article, item, service, technology, and technical data-specific requirements of the U.S. export laws and
regulations. 

  

	1.27	“Territory” means worldwide. 

  

	1.28	“Valid Claim” means a claim of any issued and unexpired patent or patent application that is part of Patent Rights, whose validity, enforceability, or patentability has not been affected by any of the
following: (i) irretrievable lapse, abandonment, revocation, dedication to the public, or disclaimer, or (ii) a holding, finding, or decision of invalidity, unenforceability, or non-patentability by a court, governmental agency, national
or regional patent office, or other appropriate body that has competent jurisdiction, such holding, finding, or decision being final and unappealable or unappealed within the time allowed for appeal. 

ARTICLE 2. LICENSE GRANT 
  

	2.1	Exclusive Grant 

 Subject to the terms and conditions set forth herein, Licensor hereby
grants to Licensee a royalty-bearing exclusive license to make, have made, use and sell any Licensed Product in the Field of Use under Licensor’s Patent Rights throughout the Territory. This grant is subject to the payment by Licensee to
Licensor of all consideration required under this Agreement, and subject to any rights of the Government of the United States as set forth in Section 2.2. Upon request of Licensor or the National Institutes of Health, Licensee shall grant a
non-exclusive royalty-bearing sublicense to qualified third parties for use of Patent Rights solely for diagnostic purposes. This grant is further subject to rights retained by Licensor and KU to: 

  
 Page 6 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	a.	publish the general scientific findings from research conducted in whole or in part at KU related to the Patent Rights; 

  

	 	b.	manufacture, have manufactured, use, or practice the Patent Rights for research, teaching and other educationally-related purposes; and 

 

	 	c.	to permit other qualified non-profit and/or academic research institutions the limited right to use the Patent Rights, to make, have made, and use any Licensed Product for such organizations’ internal
non-commercial research purposes. Any such grant of limited rights to a third party institution, including the transfer of any Licensed Product to any such third party institution or any other third party, shall be contingent upon the execution of a
Material Transfer Agreement or equivalent agreement, substantially in the form of Exhibit “G”, limiting such third party’s activities to a specified research program for a specified period of time and providing Licensee with a right
of first negotiation for exclusive rights to any resulting inventions. No such grant of limited rights to a third party institution shall include the right to conduct any research whatsoever, without the express written consent of Licensee in each
and every instance, with a compound that has been designated by Licensee as a Clinical Candidate or which is under consideration for designation as a Clinical Candidate. As of the Effective Date, such compounds include KU-32. Any such grant of
limited rights to a third party institution shall explicitly exclude, at all times, the right to conduct any research whatsoever in humans or administer any Licensed Product to humans. 

 

	 	d.	Neither KU nor Licensor, nor any Affiliate thereof, shall at any time use any Licensed Product in humans for any purpose whatsoever without the express written consent of Licensee. 

 

	2.2	The license granted in Section 2.1 hereof is expressly made subject to a non-exclusive, irrevocable, royalty-free license heretofore granted to the U.S. Government and in the general form as attached hereto as
Exhibit “B” and incorporated herein by reference. The license granted in Section 2.1 hereof is also subject to the IIA attached hereto as Exhibit “F”. 

 

	2.3	Affiliates 

 Licensee may extend the license granted herein to any Affiliate if the
Affiliate consents in writing to be bound by this Agreement to the same extent as Licensee; provided, however, that any fee or other consideration paid to Licensee in consideration of such extension will be subject to the provisions of
Section 2.4 as if the Affiliate were a Sublicensee. Other agreements or arrangements with Affiliates relating to Patent Rights which result in the sale of Licensed Product(s) will be subject to the royalty payment and other applicable payment
provisions of this Agreement 
  

	2.4	Sublicensing 

 Licensor hereby grants to Licensee the right to enter into sublicensing
agreements with Sublicensees, provided that Licensee has current exclusive rights thereto in the Territory being sublicensed pursuant to Section 2.1 and subject to the following: 

 

	 	a.	Any sublicense granted by Licensee to a Sublicensee shall incorporate all of the terms and conditions of this Agreement, which shall be binding upon each Sublicensee as if such Sublicensee were a party to this
Agreement. Licensee shall collect and guarantee all payments due Licensor from Sublicensee(s). 

  

	 	b.	If Licensee becomes Insolvent, Licensor’s proportionate share of all payments then or thereafter due and owing to Licensee from its Sublicensees for the sublicense of the Patent Rights will, upon notice from
Licensor to any such Sublicensee, become payable directly to Licensor by Sublicensee for the account of Licensee. 

  
 Page 7 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	c.	Licensee shall within thirty (30) days of: (a) execution, provide Licensor with a copy of each sublicense granted by Licensee hereunder, and any amendments thereto or terminations thereof; and
(b) receipt, summarize and deliver copies of all reports due to Licensee from Sublicensee(s). 

  

	 	d.	If this Agreement is terminated for any reason, any existing Sublicensee(s) will have the right to assume Licensee’s rights and obligations hereunder in the territory covered by the Sublicense. If any of the United
States, Mexico, or Canada are not covered by any Sublicense, then the Sublicensee having rights in the countries of the European Union shall have the right to assume Licensee’s rights and obligations in any such non-sublicensed country.
Following the termination of this Agreement, the Sublicensee shall execute a license agreement with Licensor. 

 ARTICLE
3. TERM OF AGREEMENT 
 Unless otherwise terminated by operation of law or by acts of the parties pursuant to the terms of this
Agreement, this Agreement shall be in full force and effect from the Effective Date until the later of (a) the end of the term of the last-to-expire of Licensor’s Patent Rights licensed under this Agreement in each country, (b) ten
(10) years from the date of the First Commercial Sale in each country, or (c) the expiration of regulatory exclusivity in each country that effectively bars the commercial sale of a generic version of a Licensed Product by a third party.

 ARTICLE 4. FEES & ROYALTIES 
  

	4.1	License Issue Fee 

 Licensee shall pay to Licensor a non-refundable License Issue Fee of
[***] US Dollars ($[***]) upon execution of this Agreement. Such License Issue Fee shall be deemed earned and immediately payable upon execution of this Agreement; failure to deliver said fee to Licensor on or before ten (10) business days
following execution of this Agreement by both parties shall terminate this Agreement. 
  

	4.2	License Maintenance Fee 

 Licensee will pay an annual license maintenance fee in the
amount of [***] US Dollars ($[***]), due and payable on each anniversary of the Effective Date beginning on September 26, 2015. 
  

	4.3	Running Royalty 

 As consideration for the license under this Agreement, Licensee shall
pay to Licensor an earned royalty of [***] percent ([***]%) of Net Sales, whether Net Sales are achieved by Licensee or by a Sublicensee. For example, if Net Sales by Licensee in a territory are [***] dollars ($[***]), a royalty of [***] dollars
($[***]) will be due to Licensor. If Net Sales by any Sublicensee in a territory are [***] dollars, a royalty of [***] dollars will be due to Licensor, payable by Licensee. Earned royalties shall accrue in each country, the period of time commencing
on the date of the First Commercial Sale in that country and continuing until the later of (a) the expiration of the last to expire Valid Claim in that country covering the manufacture, use or sale of such Licensed Product in such country,
(b) ten (10) years from the date of the First Commercial Sale in that country, or (c) the expiration in that country of regulatory exclusivity that effectively bars the commercial sale of a generic version of a Licensed Product by a
third party. Upon the occurrence in any given country of the later of events (a) through (c) in the preceding sentence, no further royalty shall accrue to Licensor for Net Sales in that country regardless of the amount of sales achieved in
that country by Licensee or any Sublicensee. 

  
 Page 8 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	4.4	Minimum Royalty 

 Commencing with the first calendar quarter to occur following the date
of first occurrence of Net Sales, Licensee shall pay to Licensor within forty-five (45) days of the end of said quarter a minimum annual royalty as provided below: 
  

			
	YEAR 1	  	[***] US Dollars ($[***])
	YEAR 2	  	[***] US Dollars ($[***])
	YEAR 3	  	[***] US Dollars ($[***])
	YEAR 4	  	[***] US Dollars ($[***])
	YEAR 5	  	[***] US Dollars ($[***])         (and Beyond)

 Licensee shall continue to pay such minimum annual royalty until the end of the term of the last to expire of
Licensor’s Patent Rights. Licensor shall fully credit each payment of minimum annual royalties against any earned royalties payable by Licensee with respect to the year in which the minimum annual royalty is made. 

 

	4.5	Sublicense Fees and Royalties 

 Licensee shall pay to Licensor the percentage specified
below of any lump sum fee that is not an earned royalty, any fixed fee, license fee, milestone payment, unearned portion of any minimum royalty payment, joint marketing fee, intellectual property cross license, and any other property,
consideration or thing of value given or exchanged as compensation for a sublicense (collectively, “Sublicense Income”). All such consideration received by Licensee shall be fully auditable by Licensor. If a Sublicensee purchases equity in
Licensee in connection with the grant of a sublicense, Licensee and Licensor shall discuss in good faith to determine whether such equity investment was or was not purchased as compensation for the sublicense grant. Licensee shall not receive from
Sublicensee(s) anything of value in lieu of cash payments in consideration for any sublicense under this Agreement without the express prior written permission of Licensor. Any non-cash consideration, including, without limitation, equity in
other companies or equity investments in Licensee, received by the Licensee from any Sublicensee(s) will be valued at its Fair Market Value as of the date of receipt by Licensee. 

If additional technologies owned or licensed by Licensee are included in a sublicense agreement that grants rights under this Agreement, the
parties hereto will reasonably allocate value among the Patent Rights and the other technologies included in the sublicense and the Sublicense Income percentages set forth below shall be adjusted accordingly, resulting in the Sublicense Income
percentages below being applied only to the portion of the total license value that is allocated to the Patent Rights, provided that in no event shall the value allocated to the Patent Rights be less than % of the total value of the Patent Rights
and such other technologies. Additional technologies owned or licensed by Licensee are deemed to contribute no value if (1) they are a product, process or usage that falls within the scope of any Valid Claim and (2) the filing date of the
Patent Rights predates the filing date of the additional Licensee owned or licensed patent rights included in the sublicense. 

  
 Page 9 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

			
	 Project Status at Time of Sublicense
	  	 Sublicense Income Percentage

	[***]	  	[***] percent of Sublicense Income received by Licensee)
		
	[***]	  	[***] percent of Sublicense Income received by Licensee)
		
	[***]	  	[***] percent of Sublicense Income received by Licensee)
		
	[***]	  	[***] percent of Sublicense Income received by Licensee)
		
	[***]	  	[***] percent of Sublicense Income received by Licensee)
		
	[***]	  	[***] percent of Sublicense Income received by Licensee)

  

	4.6	Past Patent Expenses 

 Licensee shall reimburse past patent expenses incurred by Licensor
in filing and prosecuting patent applications included in the Patents Rights according to the following payment plan. As of September 15, 2014, these expenses are estimated at [***] US Dollars ($[***]) (“Past Patent Expenses”). 

As partial reimbursement of Past Patent Expenses, Licensee shall pay to Licensor [***] US Dollars ($[***]) within Fifteen (15) calendar
days following initiation of GLP Toxicology Studies for the Lead Compound by Licensee. 
 As partial reimbursement of Past Patent Expenses,
Licensee shall pay to Licensor another [***] US Dollars ($[***]) within Fifteen (15) calendar days following successful completion of 28-day non-rodent GLP Toxicology Studies with an Acceptable Toxicity Profile. 

“Acceptable Toxicity Profile” shall be defined as a body of results that is suitable to support IND filing for the proposed
indication, including but not limited to a defined no-adverse-effect-level (NOAEL) that would provide an appropriate safety margin to support clinical development. 

Licensee shall pay all future patent expenses as set forth in Article 10 hereof. 

ARTICLE 5. COMMERCIAL DILIGENCE & MILESTONES 
  

	5.1	Commercial Diligence 

 Upon execution of this Agreement, Licensee shall diligently
proceed with Commercially Diligent Efforts to develop, manufacture, practice, sell and use the Licensed Products in order to make them readily available to the general public as soon as possible on commercially reasonable terms. Licensee shall
continue active, diligent Commercially Diligent Efforts for one or more Licensed Product(s) throughout the term of this Agreement (“Actively Commercializing”). In addition, Licensee shall perform at least the following obligations as part
of its due diligence activities hereunder: 
  

	 	(a)	Licensee shall [***]. 

  

	 	(b)	Licensee shall [***]. 

  

	 	(c)	Licensee shall [***]. 

  

	 	(d)	Licensee shall [***]. 

  
 Page 10 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 Meeting each milestone one time will satisfy Commercial Diligence requirements in
Section 5.1, regardless of the number of compounds that are ultimately developed. 
 If, despite using Commercially Diligent Efforts,
Licensee is unable to meet any of the foregoing due diligence milestones, Licensor will grant to Licensee, upon Licensee’s request, a one-year extension of time to meet any missed milestone, subject to the following: (i) Licensor would
have no obligation to grant Licensee more than [***] one-year extensions per milestone; (ii) In consideration of each one-year extension that Licensor grants, Licensee would be obligated to pay Licensor an extension fee of [***] Dollars
($[***]USD) for each of the [***] extensions, and (iii) Each extension granted shall be considered to apply to the specific milestone for which it is granted and to all subsequent milestones, but shall be considered one (1) extension for
purposes of clauses (i) and (ii). 

  
 Page 11 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	5.2	Milestones and Fees 

  

	 	a.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	b.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	c.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	d.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	e.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	f.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	g.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

  

	 	h.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon [***]. 

 Each
required payment will be paid to Licensor within thirty (30) days of completion of each milestone listed above. 
 Beginning with IND
acceptance, each milestone may be paid up to [***] times if different compounds are developed in different therapeutic areas, (e.g., [***]). If a back-up or replacement compound is substituted for an initial lead compound in a given indication,
milestones achieved with the back-up or replacement compound will not be payment-bearing until a previously unpaid milestone is reached. For example, if the initially developed compound has entered Phase I and is then replaced, no milestone payments
will be due for the replacement compound until first dosing in a Phase II trial is achieved. 
  

	5.3	Sales Milestones 

  

	 	a.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

 

	 	b.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

 

	 	c.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

 

	 	d.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

 

	 	e.	Licensee shall pay to Licensor a milestone fee of [***] US Dollars ($[***]) upon first achievement of worldwide Net Sales of [***] US Dollars ($[***]) for the first Licensed Product. 

Each required payment will be paid to Licensor within thirty (30) days of completion of each milestone listed above. 

  
 Page 12 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	5.4	Sponsored Research 

 Licensee shall spend at least [***] US dollars ($[***]) at KU within
one (1) year of the Effective Date for the development of Licensed Products (“Sponsored Research”). This sponsored research agreement will be renewable annually upon mutual agreement. The Parties agree to negotiate the terms of such
Sponsored Research Agreements in good faith. 
 ARTICLE 6. EQUITY OWNERSHIP 

The parties agree that no equity interest in Licensee will be granted to Licensor or KU in relation to this Agreement. 

ARTICLE 7. CONFIDENTIALITY 
  

	7.1	Licensee and Licensor acknowledge that either party may provide certain information to the other with regard to the Inventions that is considered to be confidential. It is therefore agreed that any information received
by one party from the other, and clearly designated at the time of disclosure or promptly thereafter as “CONFIDENTIAL” (“Confidential Information”), shall not be disclosed by either party to any third party other than its outside
legal, accounting, tax and financial advisors, bona fide potential acquirors and potential investors, and potential and existing lenders, financing sources, Sublicensees, consultants, and contractors, provided that they have been informed of the
confidential nature of such information and are bound by confidentiality obligations no less stringent than the obligations contained herein. It is acknowledged and agreed that the financial information contained in this Agreement is Confidential
Information. Confidential Information shall not be used by either party hereto or the third parties enumerated above for purposes other than those contemplated by this Agreement for a period of five (5) years from the termination of this
Agreement, unless or until – 

  

	 	a.	said information becomes known to third parties not under any obligation of confidentiality to the disclosing party, or becomes publicly known through no fault of the receiving party; 

 

	 	b.	contemporaneously dated written records demonstrate that said information was already in the receiving party’s possession prior to the disclosure of said information to the receiving party, except in cases when the
information has been covered by a preexisting confidentiality agreement; 

  

	 	c.	said information is subsequently disclosed to the receiving party by a third party not under any obligation of confidentiality to the disclosing party; 

 

	 	d.	said information is approved for disclosure by prior written consent of the disclosing party; 

  

	 	e.	said information is required to be disclosed by court order or governmental law or regulation, provided that, except with respect to disclosures required by applicable securities laws or regulations, the receiving party
gives the disclosing party prompt notice of any such requirement and cooperates with the disclosing party in attempting to limit such disclosure; or 

  

	 	f.	said information is proven by contemporaneously dated written records to have been independently developed by the receiving party without recourse or access to the information. 

 

	7.2	 Each party hereto acknowledges that the obligations undertaken by it pursuant to this Section are unique and that the other party will have no
adequate remedy at law if such party shall fail to perform any of its obligations hereunder, and such party therefor confirms the other party’s right to specific performance of the terms of this Section is essential to protect the rights and
interests of the other party. Accordingly, each party agrees that, in addition to any other remedies that the other party may have at law or in equity, the other party shall have the right to sue in equity to have all obligations of such party
pursuant to this Section specifically performed by such party, and the other party shall have the right to 

  
 Page 13 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	
seek preliminary and permanent injunctive relief to secure specific performance and to prevent a breach or contemplated breach of this Section by such party. Each party hereby expressly waives
the defense that a remedy in damages will be adequate for a breach by it under this Section. Each party further agrees that the other party shall not be required to post a bond as a condition to obtaining or exercising such remedies, and such party
hereby waives any such requirement or condition. 

  

	7.3	Licensee acknowledges that Licensor is subject to the Kansas Open Records Act, K.S.A. 45-215 et seq.. Licensor shall keep confidential any information provided to Licensor by Licensee that Licensee considers
confidential, to the extent allowable under the Kansas Open Records Act. 

 ARTICLE 8. QUARTERLY & ANNUAL
REPORTS 
  

	8.1	Annual and Quarterly Royalty Report 

 Within sixty (60) days after the end of the
calendar year in which Net Sales first occur, and within sixty (60) days after the end of each calendar quarter thereafter, Licensee shall provide Licensor with a written report detailing all sales and uses, if any, made of Licensed Products
during the preceding calendar quarter, and detailing the amount of Net Sales made during such quarter and calculating the royalties due to Licensor pursuant to Article 4 hereof. Each report shall include at least the following: 

 

	 	g.	Amount of Net Sales, on a country-by-country basis, of Licensed Products sold by and/or for Licensee, Affiliates and all Sublicensees; 

 

	 	h.	accounting for Net Sales, noting the deductions applicable as provided in Section 1.21; 

  

	 	i.	total royalties due to Licensor; and 

  

	 	j.	names and addresses of all Sublicensees. 

 Each report shall be in substantially similar form as
Exhibit “C” attached hereto. Each such report shall be signed by an officer of Licensee (or the officer’s designee). With each such report submitted, Licensee shall pay to Licensor the royalties and fees due and payable under this
Agreement. If no royalties shall be due, Licensee shall so report. Licensee’s failure to submit a royalty report in the required form will constitute a breach of this Agreement. Prior to achievement of Net Sales, no report shall be due to
Licensor other than as specified in Section 8.2 or in association with a payment based on one or more developmental milestones as listed in Section 5.2. 
  

	8.2	Progress Report and Commercialization Plan 

 Commencing thirty days after January 1,
2015, and thirty days after each January 1 thereafter, Licensee shall submit to Licensor a written report covering Licensee’s (and any Sublicensee’s) progress in (a) development and testing of all Licensed Products;
(b) achieving the due diligence milestones specified herein; (c) preparing, filing, and obtaining of any approvals necessary for marketing the Licensed Products; and (d) plans for the upcoming year in commercializing the Licensed
Product(s). Each report shall be in substantially similar form and contain at least the information required by Exhibit “D” attached hereto and incorporated herein by this reference. 

 

	8.3	On or before the ninetieth (90th) day following the close of Licensee’s fiscal year, Licensee shall provide Licensor with Licensee’s certified
financial statements for the preceding fiscal year including, at a minimum, a balance sheet. Provision of more than a balance sheet will be at Licensee’s sole option. 

  
 Page 14 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	8.4	In addition to the regular reports required by Section 8.1 and 8.2, hereof, Licensee shall provide a written report to Licensor of the date of first occurrence of Net Sales in each country within sixty
(60) days of the occurrence thereof. 

 ARTICLE 9. PAYMENTS, RECORDS and AUDITS 

 

	9.1	Payments 

 Licensee shall pay all royalties accruing to Licensor in U.S. Dollars, without
deduction of exchange, collection, wiring fees, bank fees, or any other charges, within thirty (30) days following the calendar quarter in which Net Sales occur. Each payment will reference KUCTC License ID #[***]. All payments to Licensor will
be made in United States Dollars by wire transfer or check payable to the [***], and sent to: 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

Wire Transfer Information: 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 For converting any Net
Sales made in a currency other than United States Dollars, the parties will use the conversion rate published in the Wall Street Journal/Telegraphic Transfer Selling conversion rate reported by the Sumitomo Bank, Tokyo, or other industry
standard conversion rate approved in writing by Licensor for the last day of the calendar quarter for which such royalty payment is due or, if the last day is not a business day, the closest preceding business day. 

 

	9.2	Late Payments 

 In the event royalty payments or other fees are not received by Licensor
when due hereunder, Licensee shall pay to Licensor interest charges at the rate of twelve percent (12%) per annum on the total royalties or fees due for the reporting period. 

 

	9.3	Records 

 Licensee shall keep, and require its Sublicensees and Affiliates to keep,
complete, true and accurate records and books containing all particulars that may be necessary for the purpose of showing the amounts payable to Licensor hereunder. Records and books shall be kept at Licensee’s principal place of business or
the principal place of business of the appropriate division of Licensee to which this Agreement relates. 

  
 Page 15 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	9.4	Audit 

 The books and the supporting data referred to in Section 9.3 shall be open
to inspection by Licensor or its agents, upon reasonable prior notice to Licensee, at all reasonable times for a term of five (5) years following the end of the calendar year to which they pertain, upon reasonable prior notice to Licensee, for
the purpose of verifying Licensee’s royalty statement or compliance in other respects with this Agreement. Such access will be available to Licensor upon not less than ten (10) days written notice to Licensee, not more than once each
calendar year until termination of this Agreement, during normal business hours, and once a year for three (3) years after the expiration or termination of this Agreement. Should such inspection lead to the discovery of a discrepancy in
reporting to Licensor’s detriment exceeding [***] percent ([***]%) of the amount due or [***] dollar ($[***]) US, whichever is greater, Licensee agrees to pay the full cost of such inspection and shall pay such cost within thirty (30) days
after receiving written notice that such inspection showed such underpayment. If the audit determines that there has been an overpayment by Licensee, the amount of the overpayment will be deducted from the next payment due to Licensor. 

ARTICLE 10. PATENT MARKING 

Licensee shall permanently and legibly mark all Licensed Products made, used or sold under the terms of this Agreement, or their containers,
in accordance with all applicable patent-marking and notice provisions under Title 35, United States Code. 
 ARTICLE 11. PATENT
PROSECUTION AND MAINTENANCE 
  

	11.1	Future Patent Expenses 

 Licensee will pay, within thirty (30) days of invoice, all
future expenses for filing, prosecuting, enforcing, and maintaining the Patent Rights that are licensed to Licensee hereunder, including without limitation, any taxes on such Patent Rights. Licensee will receive such invoices directly from patent
counsel; Licensor will receive a copy of such invoice. Licensee shall pay such invoices directly to patent counsel with written confirmation of payment to Licensor. 
  

	11.2	Patent Counsel 

 Licensor will work closely with Licensee to develop a suitable strategy
for the prosecution and maintenance of all Patents Rights. Licensee may select patent counsel for the prosecution and maintenance of Patent Rights, provided such counsel is reasonably acceptable to Licensor. The selected patent attorney will agree
to keep both Licensee and Licensor, as co-clients, equally informed and involved as to all material information, material communications with governmental patent offices, material issues and decisions, and related matters applicable to prosecuting
the patent applications for the Patent Rights and for maintaining the Patent Rights in good standing. Decisions for prosecuting the patent applications will be made so as to obtain the broadest patent protection that is reasonable and practical
under the circumstances. Licensee will request that copies of all documents prepared by the patent attorney selected by Licensee be provided to Licensor for review and comment prior to filing to the extent practicable under the circumstances. All
patent applications and patents will be in the name of Licensor, owned by Licensor and included as part of the Patent Rights licensed pursuant to this Agreement. Licensee will promptly notify Licensor of its plans to file, revise or drop any patent
application or claim which may adversely affect the Patent Rights or the rights or royalties of Licensor in the Licensed Product(s) under this Agreement. Licensee and the selected patent attorney shall not change any inventorship designations and
shall not drop or reduce any claim in a pending patent application which may adversely affect the Patent Rights or royalties of Licensor without the written consent of Licensor. Licensee shall notify Licensor at least forty five (45) days prior
to abandonment of any patent application and/or patents under Patent Rights. 

  
 Page 16 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 ARTICLE 12. TERMINATION BY LICENSOR 

 

	12.1	If Licensee should: (a) fail to deliver to Licensor any statement or report required hereunder when due; (b) fail to make any payment at the time that the same should be due; (c) violate or fail to
perform any covenant, condition, or undertaking of this Agreement to be performed by it hereunder; (d) cease active Commercially Reasonable Effort to commercialize a Licensed Product(s); (e) file a bankruptcy action, or have a bankruptcy
action against it, or become Insolvent; or (f) enter into a composition with creditors, or have a receiver appointed for it; then Licensor may give written notice of such default to Licensee. If Licensee should fail to cure such default within
thirty (30) days of such notice, the rights, privileges, and license granted hereunder shall automatically terminate. 

  

	12.2	No termination of this Agreement by Licensor shall relieve Licensee of its obligation to pay any monetary obligation due or owing at the time of such termination and shall not impair any accrued right of Licensor.
Licensee shall pay all attorneys’ fees and costs incurred by Licensor in enforcing any obligation of Licensee or accrued right of Licensor. Articles 7, 9, 20, 22, 25, 26, and Section 12.2, 15.2, 15.3, and 27.7 hereof shall survive any
termination of this Agreement. 

 ARTICLE 13. TERMINATION BY LICENSEE 

 

	13.1	Licensee may terminate this Agreement, in whole or as to any specified patent, at any time and from time to time without cause, by giving written notice thereof to Licensor. Such termination shall be effective one
hundred twenty (90) days after such notice and all Licensee’s rights associated therewith shall cease as of that date. 

  

	13.2	Any termination pursuant to Section 13.1 hereof shall not relieve Licensee of any obligation or liability accrued hereunder prior to the effective date of such termination, or rescind or give rise to any right to
rescind any payments made or other consideration given to Licensor hereunder prior to the time such termination becomes effective. Such termination shall not affect in any manner any rights of Licensor arising under this Agreement prior to the date
of such termination. 

 ARTICLE 14. DISPOSITION OF LICENSED PRODUCTS ON HAND 

Upon termination of this Agreement by either party pursuant to section 13.1 or 12.1, Licensee shall provide Licensor with a written inventory
of all Licensed Products in process of manufacture, in use or in stock. Licensee may dispose of any such Licensed Products within the ninety (90) day period following such termination, provided, however, that Licensee shall pay royalties and
render reports to Licensor thereon in the manner specified herein. 
 ARTICLE 15. WARRANTY BY LICENSOR 

 

	15.1	Licensor warrants that it has the lawful right to grant the license set forth in this Agreement. 

  

	15.2	EXCEPT AS EXPRESSLY PROVIDED IN SECTION 15.1, THE PARTIES ACKNOWLEDGE AND AGREE THAT KU, LICENSOR, ITS AFFILIATES, AGENTS, EMPLOYEES, AND THE INVENTORS HAVE MADE NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, OR THE VALIDITY OR ENFORCEABILITY OF PATENT RIGHTS IN NO EVENT SHALL LICENSOR, ITS
AFFILIATES, AGENTS, EMPLOYEES, AND THE INVENTORS BE HELD RESPONSIBLE FOR ANY DIRECT, SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THE EXERCISE OF PATENT RIGHTS, EVEN IF LICENSOR IS ADVISED IN ADVANCE OF THE
POSSIBILITY OF SUCH DAMAGES. 

  
 Page 17 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	15.3	Nothing in this Agreement shall be construed as: 

  

	 	a.	a warranty or representation by Licensor as to the validity, enforceability, or scope of any Patent Rights. 

  

	 	b.	a warranty or representation by Licensor that the exercise or practice by the Licensee of the license granted herein (including making, using, selling, offering for sale, or importing the Licensed Product) is or will be
free from infringement of intellectual property rights of third parties. 

  

	 	c.	an obligation by Licensor or KU to bring or prosecute actions or suits against third parties for patent infringement, except as expressly provided in Article 16 hereof. 

 

	 	d.	an obligation to furnish any know-how not provided in the Patent Rights. 

  

	 	e.	conferring by implication, estoppel or otherwise any license or rights under any patents of Licensor other than Patent Rights. 

  

	15.4	Any breach of the representations or warranties made in this Article 15 shall entitle Licensee to a refund of all payments made to Licensor as consideration for the rights granted under this Agreement, and said refund
shall be the sole remedy available to Licensee for breach or violation of any provisions contained in this Article 15. 

ARTICLE 16. INFRINGEMENT 
  

	16.1	If either party learns of a claim of infringement of any of Licensor’s Patent Rights licensed under this Agreement, that party shall give written notice of such claim to the other party. Licensor, in consultation
with Licensee, shall then use reasonable efforts to terminate such infringement if the parties mutually agree that such efforts are appropriate under the circumstances. In the event Licensor fails to abate the infringing activity within ninety
(90) days after such written notice or to bring legal action against the third party, Licensee may bring suit for patent infringement. No settlement, consent judgment or other voluntary final disposition of the suit may be entered into without
the consent of Licensor, which consent shall not be unreasonably withheld. 

  

	16.2	Any such legal action shall be at the expense of the party by whom suit is filed, hereinafter referred to as the “Litigating Party”. Any damages or costs recovered by the Litigating Party in connection with a
legal action filed by it hereunder, and provided that the Litigating Party is reimbursed for its costs and expenses reasonably incurred in the lawsuit, and after any royalties or other payments due to Licensor under Article 4 are paid, shall be
retained by Licensee under the following conditions: (a) damages for lost sales shall be treated as Net Sales (after reasonable costs and expenses of litigation are subtracted), and the royalty due on the corresponding amount of Net Sales shall
be paid to Licensor; (b) [***] percent ([***]%) of punitive damages, if any, in excess of damages for lost sales shall be paid to Licensor and the remainder shall be retained by Licensee. 

 

	16.3	Licensee and Licensor shall cooperate with each other in litigation proceedings instituted hereunder, provided that such cooperation shall be at the expense of the Litigating Party, and such litigation shall be
controlled by the Litigating Party. 

  
 Page 18 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 ARTICLE 17. INSURANCE 

 

	17.1	Insurance Requirements 

 Beginning at the time any Licensed Product is being distributed
or sold (including for the purpose of obtaining any required regulatory approvals) by Licensee, Affiliate, or a Sublicensee, Licensee will, at its sole cost and expense, procure and maintain commercial general liability insurance issued by an
insurance carrier with an A.M. Best rating of “A” or better in amounts not less than $[***] per incident and $[***] annual aggregate. Licensee will have Licensor, KU, and their respective officers, employees and agents, named as additional
insureds. All rights of subrogation will be waived against Licensor and its insurers. Such commercial general liability insurance will provide (i) product liability coverage; (ii) broad form contractual liability coverage for
Licensee’s indemnification under this Agreement; and (iii) coverage for litigation costs. The specified minimum insurance amounts will not constitute a limitation on Licensee’s obligation to indemnify Licensor, KU, and their
respective officers, employees and agents, under this Agreement. 
  

	17.2	Evidence of Insurance and Notice of Changes 

 Licensee will provide Licensor with written
evidence of such insurance upon request by Licensor. Licensee will provide Licensor with written notice of at least thirty (30) days prior to the cancellation, non-renewal, or material change in such insurance. 

 

	17.3	Continuing Insurance Obligations 

 Licensee will maintain such commercial general
liability insurance beyond the expiration or termination of this Agreement during (i) the period that any Licensed Product(s) and/or Licensed Service(s) developed pursuant to this Agreement is being commercially distributed or sold by Licensee,
any Affiliate, or any Sublicensee or agent of Licensee; and (ii) for five (5) years after such period. 
 ARTICLE 18. WAIVER

 No waiver by either party hereto of any breach or default of any of the covenants or agreements herein set forth shall be deemed
a waiver as to any subsequent and/or similar breach or default. 
 ARTICLE 19. ASSIGNABILITY 

This Agreement is not assignable or otherwise transferable by Licensee without the prior written consent of Licensor, except in conjunction
with a merger, acquisition, or similar transaction. The failure of Licensee to comply with the terms of this paragraph shall be grounds for termination of the Agreement by Licensor under Article 12. 

ARTICLE 20. INDEMNIFICATION BY LICENSEE 

Licensee shall indemnify, hold harmless and defend Licensor, KU, and their respective officers, employees, inventors, affiliates, and agents,
against any and all claims, suits, losses, damages, costs, liabilities, fees and expenses (including reasonable fees of attorneys) resulting from or arising out of or in connection with: (a) the exercise of any license granted under this
Agreement; (b) the breach of this Agreement by Licensee; (c) Licensee’s failure to comply with any applicable laws, rules, or regulations, or (d) any act, error, or omission of Licensee, its officers, agents, employees,
Affiliates, or Sublicensees, except where such claims, suits, losses, damages, costs, fees, or expenses result solely from the gross negligence, fraud, or intentional misconduct of the Licensor, its affiliates, officers, employees or agents.
Licensee shall give Licensor prompt and timely notice of any claim or suit instituted of which Licensee has knowledge that in any way, directly or indirectly, affects or might affect Licensor, and Licensor shall have the right at its own expense to
participate in the defense of the same. 

  
 Page 19 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 ARTICLE 21. NOTICES 

Any payment, notice or other communication required or permitted to be given to either party hereto shall be in writing and shall be deemed to
have been properly given and effective: (a) on the date of delivery if delivered in person during recipient’s normal business hours; or (b) on the date of attempted delivery if delivered by courier, express mail service or first-class
mail, registered or certified. Such notice shall be sent or delivered to the respective addresses given below, or to such other address as either party shall designate by written notice given to the other party as follows: 

In the case of Licensee: 
 Reata
Pharmaceuticals, Inc. 
 Attn: Robin Kral, VP of Licensing & Intellectual Property 

2801 Gateway Drive, Suite 150 

Irving, Texas 75063 
 In the case
of Licensor: 
 KU Center for Technology Commercialization, Inc. 

Attn: Director, KUCTC 
 KU Medical
Center 
 Wescoe Pavilion M.S. 1039 

3901 Rainbow Boulevard 
 Kansas
City, Kansas 66160 
 ARTICLE 22. REGULATORY COMPLIANCE 

 

	21.1	When required by local/national law, Licensee shall register this Agreement, pay all costs and legal fees connected therewith, and otherwise ensure that the local/national laws affecting this Agreement are fully
satisfied. 

  

	21.2	Licensee shall comply with all applicable U.S. laws dealing with the export and/or management of technology or information. Licensee understands that the Arms Export Control Act (AECA), including its implementing
International Traffic In Arms Regulations (ITAR,) and the Export Administration Act (EAA), including its Export Administration Regulations (EAR), are some (but not all) of the laws and regulations that comprise the U.S. export laws and regulations.
Licensee further understands that the U.S. export laws and regulations include (but are not limited to): (1) ITAR and EAR product/service/data-specific requirements; (2) ITAR and EAR ultimate destination-specific requirements;
(3) ITAR and EAR end user-specific requirements; (4) ITAR and EAR end use-specific requirements; (5) Foreign Corrupt Practices Act; and (6) anti-boycott laws and regulations. Licensee will comply with all then-current applicable
export laws and regulations of the U.S. Government (and other applicable U.S. laws and regulations) pertaining to the Licensed Product(s) (including any associated products, items, articles, computer software, media, services, technical data, and
other information). Licensee certifies that it will not, directly or indirectly, export (including any deemed export), nor re-export (including any deemed re-export) the Licensed Product(s) (including any associated products, items, articles,
computer software, media, services, technical data, and other information) in violation of U.S. export laws and regulations or other applicable U.S. laws and regulations. Licensee will include an appropriate provision in its agreements with its
authorized Sublicensees to assure that these parties comply with all then-current applicable U.S. export laws and regulations and other applicable U.S. laws and regulations 

 

	21.3	Licensee agrees to use commercially reasonable efforts to ensure that products used or sold in the United States embodying Licensed Products shall be manufactured substantially in the United States, unless a written
waiver is obtained in advance from the sponsoring federal agency. 

  
 Page 20 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 ARTICLE 23. GOVERNING LAW 

This Agreement shall be interpreted and construed in accordance with the laws of the State of Kansas, without application of any principles of
choice of laws. 
 ARTICLE 24. RELATIONSHIP OF PARTIES 

In assuming and performing the respective obligations under this Agreement, Licensee and Licensor are each acting as independent parties and
neither shall be considered or represent itself as a joint venture, partner, agent or employee of the other. 
 ARTICLE 25. USE OF
NAMES 
  

	25.1	By Licensee 

 Licensee shall not, without prior written consent of the Licensor, use the
name or any trademark or trade name owned by Licensor, KU, or by an affiliate of KU, in any publication, publicity, advertising, or otherwise, except that Licensee may identify KUCTC as licensor of the Patent Rights and Licensed Products. 

 

	25.2	By Licensor 

 Licensor may use Licensee’s name in connection with Licensor’s
publicity related to Licensor’s intellectual property and commercialization achievements. 
 ARTICLE 26. DISPUTE RESOLUTION

 Except for the right of either party to apply to a court of competent jurisdiction for a temporary restraining order, a
preliminary injunction, or other equitable relief to preserve the status quo or prevent irreparable harm, any and all claims, disputes or controversies arising under, out of, or in connection with the Agreement, including but not limited to any
dispute relating to patent validity or infringement, which the parties shall be unable to resolve within sixty (60) days shall be mediated in good faith. The party raising such dispute shall promptly advise the other party, in writing, of such
dispute. By not later than five (5) business days after the recipient has received such notice of dispute, each party shall have selected for itself a representative who shall have the authority to bind such party, and shall additionally have
advised the other party in writing of the name and title of such representative. By not later than ten (10) days after the date of such notice of dispute, the party against whom the dispute shall be raised shall select a mediator in the Kansas
City area and such representatives shall schedule a date with such mediator for a hearing. The parties shall enter into good faith mediation and shall share the costs equally. If the representatives of the parties have not been able to resolve the
dispute within fifteen (15) business days after such mediation hearing, then any and all claims, disputes or controversies arising under, out of, or in connection with this Agreement, including any dispute relating to patent validity or
infringement, shall be resolved through arbitration if the parties mutually consent, or through any judicial proceeding either in the courts of the State of Kansas or in the United States District Court for the District of Kansas, to whose
jurisdiction for such purposes Licensee and Licensor each hereby irrevocably consents and submits. All costs and expenses, including reasonable attorneys’ fees, of the prevailing party in connection with resolution of a dispute by arbitration
or litigation of such controversy or claim shall be borne by the other party. 

  
 Page 21 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 ARTICLE 27. GENERAL PROVISIONS 

 

	27.1	The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 

 

	27.2	This Agreement shall not be binding upon the parties until it has been signed below by or on behalf of each party. 

  

	27.3	No amendment or modification of this Agreement shall be valid or binding upon the parties unless made in writing and signed by both parties hereto. 

 

	27.4	This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or written, between the parties relating to the subject matter
thereof. 

  

	27.5	The provisions of this Agreement are severable, and in the event that any provision of this Agreement shall be determined to be invalid or unenforceable under any controlling body of the law, such invalidity or
unenforceability shall not in any way affect the validity or enforceability of the remaining provisions hereof. 

  

	27.6	This Agreement may be signed in counterparts, each of which when taken together shall constitute one fully executed document. Each individual executing this Agreement on behalf of a legal Entity does hereby represent
and warrant to each other person so signing that he or she has been duly authorized to execute this Agreement on behalf of such Entity. 

  

	27.7	In the event of any litigation, arbitration, judicial reference or other legal proceeding involving the parties to this Agreement to enforce any provision of this Agreement, to enforce any remedy available upon default
under this Agreement, or seeking a declaration of the rights of either party under this Agreement, the prevailing party shall be entitled to recover from the other such attorneys’ fees and costs as may be reasonably incurred, including the
costs of reasonable investigation, preparation and professional or expert consultation incurred by reason of such litigation, arbitration, judicial reference, or other legal proceeding. 

 

	27.8	Except as required by law, neither party may disclose the financial terms of this Agreement without the prior written consent of the other party. 

  
 Page 22 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 IN WITNESS WHEREOF, Licensor and Licensee have executed this Agreement by their respective officers hereunto
duly authorized, on the day and year hereinafter written. 
  

									
	“Licensee”	 		 	“Licensor”
			
	REATA PHARMACEUTICALS, INC.	 		 	KU CENTER FOR TECHNOLOGY COMMERCIALIZATION, INC.
					
	By	 	/s/ J. Warren Huff	 		 	By	 	/s/ Rajiv Kulkarni, Ph.D, MBA, CLP
		 	(Signature)	 		 		 	(Signature)
	Name	 	J. Warren Huff	 		 	Name:	 	Rajiv Kulkarni, Ph.D, MBA, CLP
	Title	 	Chief Executive Officer	 		 	Title:	 	Director
					
	Date	 	9/24/2014	 		 	Date	 	9/30/2014

  
 Page 23 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “A” 

PATENT RIGHTS 
  

									
	 KU Ref No.
	  	 Matter
	  	Application No.
Date of Filing	  	Title	  	Inventor(s)
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]
					
	[***]	  	[***]	  	[***]
 [***]
	  	[***]	  	[***]

  
 Page 24 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “B” 

LICENSE TO THE UNITED STATES GOVERNMENT 

This instrument confers to the United States Government, as represented by the Department of Health and Human Services and Department of Defense, a
non-exclusive, non-transferable, irrevocable, paid-up license to practice or have practiced on its behalf throughout the world the following subject inventions. This license will extend to all divisions or continuations of the patent application and
all patents or reissues, which may be granted thereon: 
 Invention Title: [***] (KUCTC ID # [***]), and [***] (KUCTC ID # [***]) 

Inventor(s): 

            [***] 

            [***] 

Patent Application Serial No.: All Patent Application Serial numbers in Exhibit A including foreign patent applications. 

The subject Inventions were conceived and/or first actually reduced to practice in performance of a government-funded project, Grant Nos.:
[***],[***],[***],[***], and [***] 
 Principal rights to this subject invention have been left with the University of Kansas, subject to the provisions of
37 CFR 401 and 45 CFR 8. 

									
					
	Signed:	 	 	 		 	Date:	 	 
	Name:	 	Rajiv Kulkarni, Ph.D, MBA, CLP	 		 	Title:	 	Director, KUCTC

  
 Page 25 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “C” 

2015 ROYALTY REPORT 
  

									
				
	LICENSEE:	 	 	 		 	KUCTC Technology ID #
                                        

				
	Period Covered:
From                                 Through:
                            	 		 		 	
				
	Prepared By:	 	 	 		 	Date:
                                        

				
	Approved By:	 	 	 		 	Date:
                                        

 If Licensee has several licensed products, please prepare separate reports for each. Then, compile all licensed products into
a summary report. 
  

																			
	     Country and    

        Patent        

	  	 Product or

Tradename
	  	Quantity
Sold	  	Unit
Price	  	Gross
Sales	  	* Less
Allowances	  	Net Sales	  	Royalty
Rate	  	Period Royalty Amount
	  	  	  	  	  	  	  	  	This Year	  	Last Year
										
	USA	  		  		  		  	$	  	$	  	$	  		  	$	  	$
										
	#	  		  		  		  		  		  		  		  		  	
										
	Canada	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	Europe:	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	Japan	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	Other:	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	Sublicense #1 (name)	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
										
	 Sublicense #2
 (name)
	  		  		  		  		  		  		  		  		  	
										
	#	  		  		  		  		  		  		  		  		  	
		  		  		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  

										
	TOTAL:	  		  		  		  	$	  	$	  	$	  		  	$	  	$
		  		  		  		  	  
	  	  
	  	  
	  	  
	  	  
	  	  

 Total Royalty Due: $
                                        

 Sales Milestone Payments: If any of the cumulative sales milestones in Section 5.3 of the Exclusive License Agreement have been achieved, specify
the milestone(s) achieved and the associated payment(s) due. If payment has not already been made in accordance with Section 5.3, please include such payment separately along with the total royalty due. 

 

	*	On a separate page, please indicate the reasons for adjustments, if significant. Please refer to the following examples as applicable: (1) cash, trade or quantity discounts actually allowed; (2) sales, use,
tariff, customs duties or other excise taxes directly imposed upon particular sales; (3) outbound transportation charges—prepaid or allowed, and (4) allowances or credits to third parties for rejections or returns. 

  
 Page 26 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “D” 

ANNUAL DEVELOPMENT AND COMMERCIALIZATION REPORT 

For 
 Reata Pharmaceuticals,
Inc. 
 [***] (if several, use oldest) 

For period beginning
                                 and ending
                             (“Period”) 

Date:
                                        

 Contact Person:
                                 Phone:
                                        
Email:
                                         
    
 1. Commercialization Efforts 
  

	 	A.	List all countries in which marketing approval was first received for a Licensed Product in the preceding calendar year. Provide the corresponding commercial name of any such newly approved Licensed Products.

  

	 	B.	List all countries in which an NDA or equivalent marketing application was filed for a Licensed Product in the preceding calendar year, providing details of the applicable indication(s). If any such application was not
accepted, or if the application was not approved, provide details. 

  

	 	C.	List all countries in which first commercial sales of a Licensed Product were achieved in the preceding calendar year. 

  

	 	D.	List any other material changes in the marketing status of any Licensed Product. 

  

	 	E.	If any of A-C above is associated with a milestone payment under Section 5 of the Exclusive License Agreement, please note this and confirm that the payment has been made. 

 

	        Yes        No	In the designated reporting period, did your company or any Sublicensee of the above-referenced technology have 500 or more employees? (This information is required to determine and report large or small entity
status in the United States.) 

 2. Product Development 
  

	 	A.	List all clinical trials of Licensed Products that were initiated in the preceding calendar year, whether by Licensee or a sublicensee. 

 

	 	B.	List all clinical trials of Licensed Products that were completed in the preceding calendar year. If the results are known and have been publicly disclosed, provide a summary of the results (if a press release or other
public disclosure concerning such results became available during the preceding calendar year, please provide if not previously communicated to Licensor). If a trial was initiated but not completed, describe the trial and the reasons for
non-completion. 

  
 Page 27 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	C.	If a Licensed Product has not yet entered clinical trials, list all major non-clinical studies completed during the preceding calendar year (i.e., GLP studies designed to support an IND or NDA filing) and provide a
summary of the results if known. 

  

	 	D.	List any significant manufacturing issues or achievements related to Licensed Products during the preceding calendar year. 

  
 Page 28 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “E” 

CURRENT DEVELOPMENT PLAN 

[***] Program 
 [***] 

Exhibit “E” 
 CURRENT DEVELOPMENT PLAN 

In addition to the activities shown above, manufacturing studies will address the feasibility of large-scale production of both [***] and [***]. Research at KU
sponsored by Licensee will support in vivo testing of these compounds, and others, in models of diabetic neuropathy. Studies with anti-cancer compounds will be directed towards further profiling and eventual selection of a lead compound for detailed
in vivo profiling. 

  
 Page 29 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “F” 

INTER-INSTITUTIONAL AGREEMENT 
 The
Inter-institutional Agreement between National Institutes of Health (NIH Ref. No. L-096-2005/0) and KU Center for 
 Technology Commercialization, Inc.
(KUCTC Ref. No. 05IIA003L) is incorporated by reference herein. 

  
 Page 30 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 EXHIBIT “G” 

MATERIAL TRANSFER AGREEMENT TEMPLATE 
 THIS
AGREEMENT, between                     having an address at
                    , hereinafter referred to as “RECIPIENT,” and the University of Kansas, having an address at Youngberg Hall, 2385
Irving Hill Road, Lawrence, KS 66045-7568, hereinafter referred to as “UNIVERSITY,” shall govern the conditions of disclosure by UNIVERSITY to RECIPIENT of certain confidential information (DATA) and/or materials (MATERIALS) listed in
Exhibit “A” relating to                     . MATERIALS, as used herein, include all such original materials actually provided to
RECIPIENT, plus any materials derived by RECIPIENT directly therefrom. 
 IN CONSIDERATION of the transfer of MATERIALS and/or disclosure of DATA, and the
mutual promises set forth in this Agreement, the parties intending to be legally bound and agree as follows: 
  

	 	1.	The Principal Investigator from RECIPIENT,                     , will receive the MATERIALS and/or DATA and is also
bound by the conditions of this Agreement. 

  

	 	2.	RECIPIENT hereby agrees: 

  

	 	a.	Not to use such MATERIALS or DATA for any commercial purpose, and limit use of DATA and MATERIALS only to the non-commercial research purpose described in Exhibit X (the “Research Plan”). Recipient agrees not
to analyze, have analyzed or otherwise attempt to ascertain the chemical composition, functional mechanisms, nor physical structure of said proprietary samples or MATERIAL outside the scope of the Purpose without the prior written consent of
UNIVERSITY. MATERIAL shall not be used for any purpose other than performance of the Research Plan, and shall not be used in humans under any circumstances. 

  

	 	b.	Except as provided in (c) below, not to disclose DATA to others (except to its employees who reasonably require same for the purposes hereof and who are bound to it by like obligation as to confidentiality) without
the express written permission of UNIVERSITY. 

  

	 	c.	RECIPIENT shall not be prevented from using or disclosing DATA: 

  

	 	i.	which RECIPIENT can demonstrate by written records was previously known to it; 

  

	 	ii.	which is now, or becomes in the future, public knowledge other than through acts or omissions of RECIPIENT; 

  

	 	iii.	which is independently developed by RECIPIENT by those not having access to the DATA and which can be proven through verifiable written records; or 

 

	 	iv.	which is lawfully obtained by RECIPIENT from sources independent of UNIVERSITY without any obligation of confidentiality to the UNIVERSITY; or 

 

	 	v.	to the extent such use or disclosure is required by law or by court order, providing such use and disclosure is limited to such purpose. 

 

	 	d.	To provide UNIVERSITY with a copy of information generated using DATA and/or MATERIALS. 

  

	 	e.	Not to transfer MATERIALS to any others (except to its employees who are bound to RECIPIENT by like obligations conditioning and restricting access, use, and continued use of MATERIALS) without the express written
consent of UNIVERSITY. 

  

	 	f.	To safeguard MATERIALS and/or DATA against disclosure and transmission to others with the same degree of care as it exercises with its own materials of a similar nature, but in no case less than a reasonable degree of
care. 

  
 Page 31 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

	 	g.	To return all MATERIALS and DATA within Fifteen (15) days of the expiration date of this Agreement, unless this deadline is extended by UNIVERSITY in writing before said Fifteen (15) days has elapsed.

  

	 	h.	To the extent permitted by law, to hold harmless UNIVERSITY against any claims, costs, or other liabilities which may arise as a result of: 1) RECIPIENT’S storage, use or disposal of MATERIAL or use of DATA; and 2)
RECIPIENT’S breach of this Agreement. RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of MATERIAL. 

  

	 	i.	The RECIPIENT agrees to use the MATERIAL and/or DATA in compliance with all applicable statutes and regulations, including Public Health Service and National Institutes of Health regulations and guidelines such as, for
example, those relating to research involving the use of animals or recombinant DNA. 

  

	 	j.	Recipient shall observe all applicable laws with respect to the transfer of the MATERIAL and related technical data to foreign countries, including without limitation, the International Traffic in Arms Regulations
(ITAR) and the Export Administration Regulations. 

  

	 	k.	With regard to any publications resulting from the use of DATA or MATERIALS, to include appropriate UNIVERSITY authors, where applicable, and submit to the UNIVERSITY any publications for review by UNIVERSITY ninety
(90) days prior to submission in order to file a patent application or take such other measures as UNIVERSITY deems necessary to establish and preserve its proprietary rights. 

 

	 	3.	UNIVERSITY MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF
MATERIALS, DATA OR INFORMATION WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. 

  

	 	4.	Title and all rights to DATA and MATERIALS provided under this Agreement shall remain vested in UNIVERSITY. It is further agreed that the furnishing of DATA or MATERIALS to RECIPIENT shall not constitute any express or
implied grant or license to RECIPIENT under any patents, patent application, trade secrets or other proprietary or legal rights now or hereinafter held by UNIVERSITY. RECIPIENT acknowledges that MATERIALS are the subject of an Exclusive License
Agreement between UNIVERSITY and its Licensee. If any invention arises from RECIPIENT’s use of MATERIALS, or derived from MATERIALS, RECIPIENT is free to file patent application(s) claiming such invention, but agrees to promptly notify
UNIVERSITY upon filing a patent application. RECIPIENT shall allow UNIVERSITY’s Licensee to enter into confidential, good faith negotiations for a license to such invention and any related patents that claim priority to such invention.
RECIPIENT hereby grants to UNIVERSITY a non-exclusive, royalty-free, transferrable license, to make and use any such invention(s) derived from Recipient’s use of the MATERIAL for non-commercial research purposes. 

 

	 	5.	RECIPIENT’s right to use the DATA and/or MATERIALS shall expire one (1) year from the date of RECIPIENT’s signature below. At the end of that period, RECIPIENT will either enter into good faith
negotiations with UNIVERSITY for a commercial license should one still be available at that time, or else return MATERIAL within fifteen (15) days. 

  

	 	6.	This AGREEMENT may be terminated by either party on thirty (30) days written notice to the other party. RECIPIENT’s obligations under section 1, 2(a), 2(b), and 2(d) through (k), and 4 shall survive
termination of the Agreement. 

  

	 	7.	The interpretation and validity of this AGREEMENT and the rights of the parties shall be governed by the laws of the State of Kansas. The Federal and State courts located in Kansas shall have sole and exclusive
jurisdiction over any disputes arising under the terms of this Agreement. 

  

	 	8.	This AGREEMENT may not be modified except by written instrument signed on behalf of each party. This AGREEMENT embodies the entire agreement and understanding of the parties and terminates and supersedes all prior
independent agreements and under takings between the parties. 

  
 Page 32 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

			
	 By:
                                         
               
 (Signature)
	  	 By:
                                         
               
 (Signature)

		
	Name:	  	Name:
		
	Title:	  	Title:
		
	Date:
                                         
           	  	Date:
                                         
           
		
	Recipient Scientist	  	

  

			
	 I,                     have read the
provisions of this agreement and agree to abide by and am bound by all conditions of this Agreement.
  

By:
                                         
               
 (Signature)
	  	
		
	 Name:
                                         
         
 (Please Print)
	  	
		
	Title:
                                         
           	  	
		
	Date:
                                         
           	  	

  
 Page 33 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

					
	KUCTC-Reata	  	Confidential	  	[***]

  

 Research plan of MTA Template in Exhibit G 

  
 Page 34 of
34 
 Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms
have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission.EX-10.11

 Exhibit 10.11 

SPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THESE REDACTED TERMS HAVE BEEN
MARKED IN THIS EXHIBIT WITH THREE ASTERISKS [***]. AN UNREDACTED VERSION OF THIS EXHIBIT HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. 

Execution Version 

EXCLUSIVE LICENSE 
 and

 SUPPLY AGREEMENT 

by and between 
 REATA
PHARMACEUTICALS, INC. 
 and 

KYOWA HAKKO KIRIN CO. LTD. 

 Execution Version 

 

 TABLE OF CONTENTS 

 

							
	ARTICLE I DEFINITIONS	  	 	1	  
			
	 1.1
	 	 Definitions
	  	 	1	  
	 1.2
	 	 Additional Definitions
	  	 	12	  
	 1.3
	 	 Financial Terms
	  	 	13	  
		
	ARTICLE II LICENSES	  	 	14	  
			
	 2.1
	 	 Licenses Regarding Licensed Compounds and Licensed Products
	  	 	14	  
	 2.2
	 	 License Regarding RTA 402 Class
	  	 	15	  
	 2.3
	 	 Reata Trademarks
	  	 	15	  
	 2.4
	 	 Kyowa Kirin Trademarks
	  	 	16	  
	 2.5
	 	 Product Trademarks
	  	 	16	  
	 2.6
	 	 Reservation of Rights
	  	 	17	  
		
	ARTICLE III JOINT STEERING COMMITTEE	  	 	17	  
			
	 3.1
	 	 Establishment and Membership
	  	 	17	  
	 3.2
	 	 Purpose of JSC
	  	 	17	  
	 3.3
	 	 Membership and Procedures
	  	 	17	  
	 3.4
	 	 Decision-Making
	  	 	19	  
	 3.5
	 	 Expenses
	  	 	20	  
	 3.6
	 	 Relationship of Parties
	  	 	20	  
		
	ARTICLE IV CLINICAL DEVELOPMENT	  	 	20	  
			
	 4.1
	 	 Kyowa Kirin Clinical Development Activities
	  	 	20	  
	 4.2
	 	 Clinical Development Data
	  	 	21	  
	 4.3
	 	 No Debarred Personnel
	  	 	22	  
	 4.4
	 	 Use of Animals
	  	 	22	  
	 4.5
	 	 Development Outside the Territory
	  	 	22	  
	 4.6
	 	 Development of the Licensed Compound
	  	 	22	  
		
	ARTICLE V REGULATORY MATTERS	  	 	23	  
			
	 5.1
	 	 Regulatory Activities
	  	 	23	  
	 5.2
	 	 Kyowa Kirin Regulatory Data and Regulatory Approvals
	  	 	23	  
	 5.3
	 	 Provision of Regulatory Information to Kyowa Kirin
	  	 	24	  
	 5.4
	 	 Safety; Adverse Event Reporting
	  	 	25	  
	 5.5
	 	 Recalls and Voluntary Withdrawals
	  	 	26	  
	 5.6
	 	 Inspection Rights
	  	 	26	  
	 5.7
	 	 Governmental Inspections and Inquiries
	  	 	26	  
	 5.8
	 	 Regulatory Matters Outside the Territory
	  	 	27	  
	 5.9
	 	 Development in China
	  	 	27	  

  
 i 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

							
		
	ARTICLE VI SALES AND MARKETING; DILIGENCE OBLIGATIONS	  	 	27	  
			
	 6.1
	 	 Sales and Marketing Activities
	  	 	27	  
	 6.2
	 	 Marketing Plan
	  	 	28	  
	 6.3
	 	 Sales Forecasts
	  	 	28	  
	 6.4
	 	 Pricing
	  	 	28	  
	 6.5
	 	 Labeling and Patent Rights Marking
	  	 	28	  
	 6.6
	 	 Medical Affairs Activities
	  	 	28	  
	 6.7
	 	 Medical Affairs Plan
	  	 	29	  
	 6.8
	 	 Marketing and Promotional Literature
	  	 	29	  
	 6.9
	 	 Marketing and Sales and Medical Affairs Outside the Territory
	  	 	29	  
		
	ARTICLE VII FINANCIAL TERMS	  	 	30	  
			
	 7.1
	 	 Upfront Payment
	  	 	30	  
	 7.2
	 	 Milestone Payments
	  	 	30	  
	 7.3
	 	 Sales Royalties
	  	 	32	  
	 7.4
	 	 Royalty Adjustments
	  	 	33	  
	 7.5
	 	 Method of Payment
	  	 	34	  
	 7.6
	 	 Interest on Overdue Payments
	  	 	34	  
	 7.7
	 	 Foreign Currency Exchange
	  	 	34	  
	 7.8
	 	 Taxes
	  	 	34	  
	 7.9
	 	 Prohibited Payments
	  	 	35	  
		
	ARTICLE VIII REATA SUPPLY OF LICENSED PRODUCT; SPECIFICATIONS	  	 	35	  
			
	 8.1
	 	 Reata Obligation to Supply Licensed Product
	  	 	35	  
	 8.2
	 	 Supply of Licensed Product for Development
	  	 	36	  
	 8.3
	 	 Commercial Supply of Licensed Product
	  	 	39	  
	 8.4
	 	 General Manufacturing and Supply Provisions
	  	 	41	  
	 8.5
	 	 Specifications
	  	 	43	  
		
	ARTICLE IX RECORDS AND REPORTING	  	 	46	  
			
	 9.1
	 	 Reports
	  	 	46	  
	 9.2
	 	 Royalty Records
	  	 	46	  
	 9.3
	 	 Audits
	  	 	46	  
		
	ARTICLE X INTELLECTUAL PROPERTY PROVISIONS	  	 	47	  
			
	 10.1
	 	 Patent Prosecution and Maintenance
	  	 	47	  
	 10.2
	 	 Ownership of Inventions
	  	 	48	  
	 10.3
	 	 Disclosure
	  	 	48	  

  
 ii 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

							
	 10.4
	 	 Cooperation
	  	 	49	  
	 10.5
	 	 Enforcement of Reata Patent Rights against Infringement in the Territory
	  	 	49	  
	 10.6
	 	 Defense of Infringement Claims
	  	 	51	  
		
	ARTICLE XI CONFIDENTIALITY, PUBLICATION AND PUBLICITY	  	 	52	  
			
	 11.1
	 	 Confidentiality
	  	 	52	  
	 11.2
	 	 Disclosure of this Agreement
	  	 	53	  
	 11.3
	 	 Disclosure of RTA 402 Class License
	  	 	53	  
	 11.4
	 	 Publications
	  	 	53	  
	 11.5
	 	 Publicity
	  	 	54	  
	 11.6
	 	 Employees and Consultants
	  	 	54	  
		
	ARTICLE XII REPRESENTATIONS AND WARRANTIES	  	 	54	  
			
	 12.1
	 	 Mutual Representations and Warranties
	  	 	54	  
	 12.2
	 	 Kyowa Kirin’s Representations and Warranties
	  	 	55	  
	 12.3
	 	 Reata’s Representations and Warranties
	  	 	55	  
	 12.4
	 	 Limitation on Warranties; No Implied Warranties
	  	 	57	  
		
	ARTICLE XIII OTHER COVENANTS AND AGREEMENTS	  	 	58	  
			
	 13.1
	 	 Compliance with Law
	  	 	58	  
	 13.2
	 	 Maintenance of Current License Agreements; No Inconsistent Rights
	  	 	58	  
	 13.3
	 	 Reata Restrictive Covenants
	  	 	58	  
	 13.4
	 	 Kyowa Kirin Covenants
	  	 	59	  
	 13.5
	 	 Coordination of Uses Outside the Field
	  	 	59	  
	 13.6
	 	 Marketing Rights Outside of the Territory
	  	 	60	  
	 13.7
	 	 Third Party Licenses
	  	 	61	  
	 13.8
	 	 Compliance with Dartmouth License
	  	 	61	  
	 13.9
	 	 Formal Notice of Identification of Backup Compound Required
	  	 	62	  
	 13.10
	 	 Performance Through Affiliates
	  	 	62	  
		
	ARTICLE XIV INDEMNIFICATION AND INSURANCE	  	 	62	  
			
	 14.1
	 	 Indemnity By Kyowa Kirin
	  	 	62	  
	 14.2
	 	 Indemnity by Reata
	  	 	63	  
	 14.3
	 	 Procedure for Indemnification
	  	 	63	  
	 14.4
	 	 Insurance
	  	 	64	  
		
	ARTICLE XV TERM AND TERMINATION	  	 	64	  
			
	 15.1
	 	 Term
	  	 	64	  
	 15.2
	 	 Termination by Reata
	  	 	64	  
	 15.3
	 	 Termination by Kyowa Kirin At Will
	  	 	64	  

  
 iii 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

							
	 15.4
	 	 Termination by Either Party for Breach or Insolvency
	  	 	64	  
	 15.5
	 	 Disputes Over Right to Terminate
	  	 	65	  
	 15.6
	 	 Effect of Expiration or Termination of this Agreement for Any Reason
	  	 	65	  
	 15.7
	 	 Effect of Expiration at End of Royalty Term
	  	 	66	  
	 15.8
	 	 Effect of Certain Terminations
	  	 	66	  
	 15.9
	 	 Remedies Cumulative and Nonexclusive
	  	 	68	  
	 15.10
	 	 Rights In Bankruptcy
	  	 	68	  
		
	ARTICLE XVI DISPUTE RESOLUTION	  	 	68	  
			
	 16.1
	 	 Disputes
	  	 	68	  
	 16.2
	 	 Informal Negotiation
	  	 	69	  
	 16.3
	 	 Mediation
	  	 	69	  
	 16.4
	 	 Agreement to Arbitrate
	  	 	69	  
	 16.5
	 	 Number and Appointment of Arbitrators
	  	 	69	  
	 16.6
	 	 Conduct of Arbitration
	  	 	70	  
	 16.7
	 	 Place of Arbitration
	  	 	70	  
	 16.8
	 	 Powers of the Arbitrators, Limitations on Remedies
	  	 	70	  
	 16.9
	 	 Arbitration Award
	  	 	70	  
	 16.10
	 	 Confidentiality
	  	 	70	  
	 16.11
	 	 Costs
	  	 	71	  
	 16.12
	 	 Injunctive or Other Interim Relief
	  	 	71	  
	 16.13
	 	 Continued Performance
	  	 	71	  
	 16.14
	 	 Governing Law; Jurisdiction; Venue
	  	 	71	  
	 16.15
	 	 Separability and Survival of the Agreement to Arbitrate
	  	 	71	  
		
	ARTICLE XVII OTHER PROVISIONS	  	 	71	  
			
	 17.1
	 	 Non-Solicitation of Employees
	  	 	71	  
	 17.2
	 	 Force Majeure
	  	 	72	  
	 17.3
	 	 Exclusions of Consequential Damages
	  	 	72	  
	 17.4
	 	 Assignment
	  	 	72	  
	 17.5
	 	 Severability
	  	 	73	  
	 17.6
	 	 Notices
	  	 	73	  
	 17.7
	 	 Entire Agreement; Amendments
	  	 	73	  
	 17.8
	 	 Headings
	  	 	74	  
	 17.9
	 	 Independent Contractors
	  	 	74	  
	 17.10
	 	 Waiver
	  	 	74	  
	 17.11
	 	 Counterparts
	  	 	74	  
	 17.12
	 	 Waiver of Rule of Construction
	  	 	74	  
	 17.13
	 	 Third Party Beneficiaries
	  	 	74	  
	 17.14
	 	 Further Assurances
	  	 	74	  
	 17.15
	 	 Construction of Agreement
	  	 	74	  

  
 iv 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 Exhibits: 

Exhibit A – Reata Patent Rights 

Exhibit B – Third Party License Agreements 

  
 v 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 EXCLUSIVE LICENSE AND SUPPLY AGREEMENT 

This Exclusive License and Supply Agreement (this “Agreement”) effective as of December 24, 2009 (the “Effective
Date”), is by and between Reata Pharmaceuticals, Inc., a corporation organized and existing under the laws of Delaware, USA, with an address at 2801 Gateway Drive, Suite 150, Irving, Texas 75063 (“Reata”), and Kyowa Hakko
Kirin Co., Ltd., a company organized and existing under the laws of Japan, with an address at 1-6-1 Ohtemachi, Chiyoda-ku, Tokyo, 100-8185, Japan (“Kyowa Kirin”). Reata and Kyowa Kirin are sometimes hereinafter referred to each as a
“Party” and collectively as the “Parties.” 
 WITNESSETH: 

WHEREAS, Reata has developed, and currently has in the United States ongoing studies that the United States Food and Drug Administration has
indicated could serve as a Phase III pivotal clinical trial for, a proprietary compound known as bardoxolone methyl, or as RTA 402, that is useful for the treatment of renal, cardiovascular and metabolic diseases, and 

WHEREAS Reata owns or has the right to license certain intellectual property rights and the use of clinical trial and development and
manufacturing data with respect thereto; and 
 WHEREAS, Kyowa Kirin wishes to obtain exclusive rights to develop, market and sell RTA 402
in the Territory, as more fully described below, and Reata wishes to grant such rights to Kyowa Kirin as set forth herein. 
 NOW,
THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the Parties hereby agree as follows: 

ARTICLE I 
 DEFINITIONS

 1.1 Definitions. When used in this Agreement, capitalized terms will have the meanings as defined below and throughout
the Agreement. 
 1.1.1 “Adverse Event” means any adverse medical occurrence in a patient or clinical investigation subject
to whom a Licensed Compound is administered and which could but does not necessarily have a causal relationship with the Licensed Compound, including any unfavorable and unintended sign (including an abnormal laboratory finding, for example),
symptom, or disease temporally associated with the administration of the Licensed Compound, whether or not considered related to Licensed Compound administration. 

1.1.2 “Affiliate” with respect to a Party means an individual, trust, business trust, joint venture, partnership, corporation,
association or other legal entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with that Party. For purposes of this definition only, “control” and, with
correlative meanings, the terms “controlled by” and “under common control with” means (a) the possession, directly or indirectly, 

  
 1 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
of the power to direct the management or policies of a legal entity, whether through the ownership of voting securities or by contract relating to voting rights or corporate governance, or
(b) the ownership, directly or indirectly, of 50% or more of the voting securities or other ownership interest of a legal entity; provided, that if local law restricts foreign ownership, control will be established by direct or indirect
ownership of the maximum ownership percentage that may, under such local law, be owned by foreign interests. 
 1.1.3 “Applicable
Laws” means any federal, state, local, national and supra-national laws, statutes, rules and/or regulations, including any rules, regulations, guidance, guidelines or requirements of Regulatory Authorities, national securities exchanges or
securities listing organizations, that may be in effect from time to time during the Term and apply to a particular activity hereunder and including laws, regulations and guidelines governing the import, export, development, manufacture, marketing,
distribution and/or sale of any Licensed Product in or for the Territory. 
 1.1.4 “Backup Compound” means the alternative
molecule (if any) that Reata (or its Affiliate, licensee or collaboration partner) develops and that Reata specifically identifies, pursuant to Section 13.9, as an alternative molecule to replace RTA 402 (or to replace any previous Backup
Compound) for Indications in the Field, together with any of its salt, free base, acid, polymorph, hydrate, solvate, chelate, stereoisomer, enantiomer, racemate, or tautomer forms. 

1.1.5 “Business Day” means a day that is not a Saturday, Sunday or a day on which banking institutions in either Tokyo, Japan,
or Dallas, Texas, are required by law to remain closed. 
 1.1.6 “Calendar Quarter” means the period beginning on the
Effective Date and ending on the last day of the Calendar Quarter in which the Effective Date falls, and thereafter each successive period of three (3) consecutive calendar months ending on
March 31, June 30, September 30 or December 31. 
 1.1.7 “Calendar Year” means the period
beginning on the Effective Date and ending on the last day of the Calendar Year in which the Effective Date falls, and thereafter each successive period of twelve (12) months commencing on January 1 and ending on December 31. 

1.1.8 “Commercialization Regulatory Approval” means, with respect to any Licensed Product, all Regulatory Approvals (including
pricing approvals and reimbursement approvals) required by Applicable Laws to market and sell such Licensed Product for use within the Field if applicable, in a country or region in the Territory. 

1.1.9 “Commercialize,” or “Commercialization” means any and all activities relating to seeking, obtaining
and/or maintaining any Regulatory Approval for a Licensed Product in the Field in the Territory, or relating to any registration, importing, manufacturing, distributing, marketing, selling, non-clinical and clinical development or testing of a
Licensed Product in the Field in the Territory, including labeling, packaging, finishing, promotion, advertising, launching, marketing, sales, distribution, development for label extensions, and conducting Medical Affairs Studies, whether conducted
by a Party or for such Party by another, and “Commercialization” will be interpreted accordingly. Clinical Development Activities, Regulatory Activities, and Sales and Marketing Activities are Commercialization activities. 

  
 2 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 1.1.10 “Commercially Reasonable Efforts” means, with respect to a Party in
the performance of its obligations hereunder in relation to Licensed Products, the application by or on behalf of such Party of a level of efforts that a similarly-situated pharmaceutical or biotechnology company, as the case may be, would apply to
such activities in relation to a similar pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential, profit potential and strategic value
(in each case as compared to the Licensed Product) taking into account efficacy, safety, expected labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, the likelihood of
regulatory approval given the regulatory structure involved, the profitability of the product including the royalties payable to licensors, or patent or other intellectual property rights, alternative products and other relevant factors, based on
conditions then prevailing. The Parties acknowledge and agree that failure to Commercialize, or the cessation of active Commercialization of, the Licensed Product with respect to a particular country in the Territory, where such Commercialization of
such Licensed Product in such country is not commercially reasonable or would have a negative impact on the value of such Licensed Product Territory-wide that outweighs the benefits of pursuing such Commercialization in such country (due to, for
example and without limitation, concerns with market or regulatory conditions, re-importation and grey market goods, pricing, or sufficient risk of harm to other more profitable countries), may not constitute under the circumstances a failure to use
Commercially Reasonable Efforts and therefore such Commercialization with respect to a particular country may not be required under the Commercially Reasonable Efforts standard. 

1.1.11 “Confidential Information” means information of a confidential or proprietary nature disclosed by a Party to the other
Party hereunder, whether disclosed in oral, written, graphic or electronic form, in connection with this Agreement or the performance of its obligations hereunder, including any such information related to any scientific, clinical, engineering,
manufacturing, marketing, financial or personnel matters relating to a Party, or related to a Party’s present or future products, sales, suppliers, customers, employees, investors, business plans, Know-How, regulatory filings, data, compounds,
research projects, work in progress, future developments or business, in all such cases whether disclosed in oral, written, graphic or electronic form, and whether or not specifically marked as confidential or proprietary, where under the
circumstances in which such disclosure was made or the nature of information disclosed, such information would be reasonably expected to be confidential by the disclosing party; provided, however, that in any event, Confidential Information excludes
any information that (a) is known by recipient at the time of its receipt, and not through a prior disclosure by or on behalf of the disclosing Party, as documented by contemporaneous business records; (b) is or becomes properly in the
public domain through no fault of the recipient; (c) is subsequently disclosed to the recipient by a Third Party who may lawfully do so and is not directly or indirectly under an obligation of confidentiality to the disclosing Party, as
documented by written business records in existence prior to the receipt of such information from the disclosing Party; or (d) is developed by the recipient independently of, and without reference to or use of, the information received from the
disclosing Party. 

  
 3 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 1.1.12 “Control” means with respect to any Know-How, patent, or other
intellectual property right, possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise, to grant a license, sublicense or other right to or under, such Know-How, patent or other intellectual property
right as provided for herein without violating the terms of any agreement or other arrangements with any Third Party at the time when such license, sublicense or other right is first granted hereunder. 

1.1.13 “Dartmouth License” means collectively (a) the Exclusive Patent License Agreement among the University of Texas
M.D. Anderson Cancer Center, Dartmouth College, and Reata dated July 15, 2004, a copy of which has been provided to Kyowa Kirin, and (b) the Reata Pharmaceuticals, Inc. – Dartmouth Exclusive License Agreement dated December 16,
2009, a copy of which has been provided to Kyowa Kirin, as each may be amended, supplemented or restated from time to time in accordance with Section 13.2. 

1.1.14 “Development Plan” means the plan for obtaining Commercialization Regulatory Approval (including the Clinical
Development Activities and Regulatory Activities with respect thereto), as amended or updated hereunder. 
 1.1.15 “Effective
Date” will have the meaning set forth in the preamble. 
 1.1.16 “FDA” means the United States Food and Drug
Administration or any successor agency thereto. 
 1.1.17 “Field” means all human therapeutic, preventative, mitigation,
prophylactic, curative, and diagnostic uses for any Indication. 
 1.1.18 “First Commercial Sale” means, with respect to a
country in the Territory, the first commercial sale of any Licensed Product to a Third Party for use, consumption or resale in that country after obtaining Commercialization Regulatory Approval in that country. For the avoidance of doubt, sales of
Licensed Products to an Affiliate of Kyowa Kirin shall not constitute a First Commercial Sale unless such Affiliate is an end user of the Licensed Product. 

1.1.19 “GAAP” means generally accepted accounting principles applicable to a Party in a particular country (e. g., Japanese
Accounting Standards or U.S. Generally Accepted Accounting Principles) as consistently applied throughout the applicable periods indicated herein by or on behalf of the relevant Party. 

1.1.20 “GMP” means the then-current good manufacturing practices required by the FDA and as set forth in the laws and
regulations in the United States with respect thereto, for the manufacture and testing of pharmaceutical materials, and comparable Applicable Laws and requirements of Regulatory Authorities applicable to the manufacture and testing of pharmaceutical
materials in jurisdictions within the Territory, as they may be updated from time to time, including applicable rules and guidelines promulgated under the International Conference on Harmonization. 

  
 4 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 1.1.21 “IND” means an Investigational New Drug Application filed with the
FDA pursuant to 21 CFR 312.20, or the corresponding filing required for the clinical testing in humans of a pharmaceutical product in any country or regulatory jurisdiction other than the United States. 

1.1.22 “Indication” means (a) any and all renal, cardiovascular and diabetes indications, including (i) renal
insufficiency, chronic kidney disease, acute kidney failure, ischemia-reperfusion injury of the kidney, glomerulonephritis, and all other forms of nephritis (whether acute or chronic); (ii) atherosclerosis, heart failure, myocardial infarction,
acute coronary syndrome, myocarditis, angina, restenosis, aneurysms, vasculitis, complications of vascular surgery and heart surgery, thrombosis, phlebitis, peripheral vascular disease, and hypertension; and (iii) the following metabolic
diseases: type II diabetes, insulin resistance, complications of diabetes (including retinopathy, neuropathy, and ulcers), obesity, metabolic syndrome, hypercholesterolemia, and hyperlipidemia, and (b) any indications added to this Agreement in
accordance with Section 13.5.1. For the avoidance of doubt, unless added to this Agreement in accordance with Section 13.5.1, Indication does not include any indications for: (i) any forms of cancer; (ii) any forms of organ
failure (other than renal failure or heart failure); (iii) respiratory disorders; (iv) allergies and autoimmune diseases; (v) neurological, psychiatric, or neuropsychiatric disorders (other than diabetic neuropathy);
(vi) infectious diseases; (vii) skin diseases (other than diabetic ulcers); (viii) gastrointestinal disorders; (ix) bone or cartilage disorders; (x) musculoskeletal disorders; (xi) eye diseases (other than diabetic
retinopathy); (xii) human immunodeficiency virus-associated complications; and (xiii) sepsis; provided that the foregoing exclusions will not limit Kyowa Kirin from marketing or selling Licensed Products for licensed Indications, even if
the use of a Licensed Product may have an incidental therapeutic benefit for one of the excluded indications, but in no event shall Kyowa Kirin be authorized to seek separate regulatory approval for any indication that is outside the licensed
Indications. 
 1.1.23 “Initiation” means, with respect to a human clinical trial, the first date that a subject or patient
is dosed in such clinical trial. 
 1.1.24 “Invention” means any Reata Invention or Kyowa Kirin Invention. 

1.1.25 “Know-How” means any non-public knowledge, experience, know-how, technology, information, and data, including clinical
and non-clinical study data, trade secrets, formulas and formulations, processes, techniques, unpatented inventions, methods, discoveries, specifications, formulations, compositions, materials, ideas, and developments, test procedures, and results,
together with all documents and files embodying the foregoing, but excluding, in any event, any patent rights in any of the foregoing. 

1.1.26 “Knowledge” of a Party means the actual or constructive knowledge of the chief executive officer, the president, the
executive vice-president, any vice president, the senior director of regulatory affairs, the senior patent counsel, the general counsel or the chief medical officer of a Party, or any personnel holding positions equivalent to such job titles (but
only to the extent such positions exist at such Party). 

  
 5 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 1.1.27 “Kyowa Kirin Invention” means any invention or discovery that relates
to a Licensed Product and that is conceived, made or generated during the Term in the performance of activities undertaken pursuant to this Agreement by employees, agents, or independent contractors of Kyowa Kirin or its Affiliates or Permitted
Sublicensees (including any enhancement or modification of a Licensed Product’s use, dosage form or formulation). 
 1.1.28
“Kyowa Kirin Regulatory Data” means all Regulatory Filings made by or on behalf of Kyowa Kirin (including its Affiliates and sublicensees) with respect to Licensed Products and all data generated by or on behalf of Kyowa Kirin
(including its Affiliates and sublicensees) in the performance of Clinical Development Activities or Regulatory Activities, including any information contained in any Regulatory Filings with respect to Licensed Products and the results of, and all
information generated in connection with, any Clinical Development Activities or Regulatory Activities performed by or on behalf of Kyowa Kirin pursuant to this Agreement. 

1.1.29 “Kyowa Kirin Trademark” means any trademark or trade name, and registrations and applications therefor, owned or
Controlled by Kyowa Kirin in the Territory and covering Kyowa Kirin’s (or its Affiliate’s) corporate name or company logo. 

1.1.30 “Licensed Compound” means (a) RTA 402 and (b) any Backup Compound designated by Reata pursuant to
Section 13.9. 
 1.1.31 “Licensed Product” means any formulation or product that is comprised of, in whole or in part,
or containing a Licensed Compound and any dosage, strength or size thereof. 
 1.1.32 “Licensed Technology” means the Reata
Patents Rights and the Reata Know-How. For the avoidance of doubt, all Reata Inventions (including Reata’s rights to any jointly owned Inventions) shall be included within the Licensed Technology. 

1.1.33 “Manufacturing Cost” means: 

(a) With respect to Licensed Product or API, as applicable, manufactured by Reata and supplied to Kyowa Kirin hereunder, [***]. 

(b) With respect to Licensed Product or API, as applicable, manufactured for Reata by one or more Third Party Manufacturers and supplied to
Kyowa Kirin hereunder, [***]. 
 1.1.34 “Medical Affairs Activities” means: (a) the coordination of medical information
requests and field based medical liaisons in the Territory with respect to Licensed Products commercially launched in the Territory; and (b) those clinical studies conducted in or for 

  
 6 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
the Territory after Commercialization Regulatory Approval of a Licensed Product has been obtained which are neither intended nor designed to support a Regulatory Filing including medical affairs
studies, post marketing studies and investigator and physician-initiated studies, in all such cases initiated by or under the control or direction of Kyowa Kirin. 

1.1.35 “Milestone Payments” means Regulatory Milestone Payments and Sales Milestone Payments. 

1.1.36 “NDA” means a new drug application (as defined in Title 21 of the United States Code of Federal Regulations, as amended
from time to time) filed with the FDA seeking regulatory approval to market and sell Licensed Product in the United States for a particular Indication or, with respect to each Licensed Product in a particular country or region in the Territory, an
application seeking Commercialization Regulatory Approval from the Regulatory Authority in such country or region, including such an application submitted to Japan’s Ministry of Health, Labor and Welfare (“MHLW”), to market and
sell Licensed Product in such particular country or region. 
 1.1.37 “Net Sales” means with respect to any Licensed
Product, the gross amounts invoiced by Kyowa Kirin or its Affiliates or its Permitted Sublicensees to any Third Party for sales of Licensed Products in the Territory, less the following items, provided that they are bona fide: 

(a) actual credits, refunds or allowances to Third Party customers for spoiled, damaged, rejected, recalled, outdated and
reasonably returned Licensed Product; 
 (b) discounts, including cash, volume, quantity and other trade discounts,
charge-back payments, and rebates and allowances actually granted, incurred or allowed in the ordinary course of business, as well as government-required discounts and allowances (including government rebates and other price reductions), and other
reductions, concessions and allowances that effectively reduce the selling price to Kyowa Kirin or its Affiliates or such sublicensees; 

(c) transportation charges, freight, postage and insurance (but only insurance related to protecting the particular shipment
against physical loss or damage) if shown separately in the invoice; and 
 (d) sales, use or excise Taxes and import/export
duties or tariffs and similar governmental charges actually due or incurred in connection with the sales of such Licensed Product, if shown separately in the invoice. 

Components of Net Sales shall be determined in the ordinary course of business in accordance with GAAP, consistently applied. For purposes of determining when
a sale of any Licensed Product occurs for purposes of calculating Net Sales, the sale will be deemed to occur on the earlier of (a) the date the Licensed Product is shipped or (b) the date of the invoice to the purchaser of the Licensed
Product. No deductions shall be made for commissions paid to individuals or agents, nor shall any deductions be permitted for the cost of collections. For purposes of 

  
 7 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
determining Net Sales, a “sale” shall not include transfers or dispositions, at no cost or below cost, of Licensed Products for charitable, pre-clinical, clinical or regulatory purposes
or for promotional samples or free goods. Amounts invoiced by Kyowa Kirin or its Affiliates or its Permitted Sublicensees for the sale of Licensed Products to or among such Affiliates or Permitted Sublicensees for resale shall not be included in the
computation of Net Sales hereunder. 
 In the event that Kyowa Kirin sells a Licensed Product (a) to a Third Party in a bona fide arm’s length
transaction, for material consideration, in whole or in part, other than cash (but excluding, for the avoidance of doubt, consideration in the form of non-financial legal terms and conditions incident to sale), (b) to a Third Party in other
than a bona fide arm’s length transaction, or (c) with discounts of Licensed Products that are disproportional to the discounts of other products sold by Kyowa Kirin in conjunction with such Licensed Products, the Net Sales price for such
Licensed Product shall be deemed to be the standard invoice price then being invoiced by Kyowa Kirin in an arm’s length transaction with similar customers in the same country within the Territory. In the event that Kyowa Kirin includes one or
more Licensed Product as part of a bundle of products, the price for such Licensed Product shall be deemed to be the standard invoice price for such Licensed Product when sold separately and not as part of a bundle of products. 

If a Licensed Product either (i) is sold in the form of a combination product containing both a Licensed Compound and one or more independently
therapeutically active pharmaceutical molecules other than a Licensed Compound or (ii) is sold in a form that contains (or is sold bundled with) a delivery device therefor (in either case of (i) or (ii), a “Combination
Product”), the Net Sales of such Licensed Product for the purpose of calculating royalties owed under this Agreement for sales of such Combination Product, shall be determined as follows: first, Kyowa Kirin shall determine the actual Net
Sales of such Combination Product (using the above provisions) and then such amount shall be multiplied by the fraction A/(A+B), where A is the invoice price of the Licensed Product containing only the Licensed Compound, if sold separately, and B is
the total invoice price of any other active pharmaceutical molecule or delivery device in the combination if sold separately. If any other active pharmaceutical molecule or delivery device in the combination is not sold separately, Net Sales shall
be calculated by multiplying actual Net Sales of such Combination Product by a fraction A/C where A is the invoice price of the Licensed Product containing only the Licensed Compound if sold separately, and C is the invoice price of the Combination
Product. If neither the Licensed Product containing only the Licensed Compound nor any other active pharmaceutical molecule or delivery device in the Combination Product is sold separately, the adjustment to Net Sales shall be determined by the
Parties in good faith to reasonably reflect the fair market value of the contribution of the Licensed Product containing only the Licensed Compound in the Combination Product to the total market value of such Combination Product. 

1.1.38 “Party” will have the meaning set forth in the preamble. 

1.1.39 “Permitted Sublicensee” means either an Affiliate of Kyowa Kirin or a Third Party, in each case who is granted a
sublicense by Kyowa Kirin to any of the Licensed Technology pursuant to Section 2.1.2 and Section 2.3.1. 

  
 8 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 1.1.40 “Person” means any individual, corporation, association, partnership
(general or limited), joint venture, trust, estate, limited liability company, limited liability partnership, unincorporated organization, government (or any agency or political subdivision thereof) or other legal entity or organization. 

1.1.41 “Phase 1 Clinical Trial” means a human clinical trial performed in accordance with the Applicable Laws in the Territory
that provides for the first introduction of a Licensed Product into humans for the purpose of determining human toxicity, metabolism, biomarker, absorption, elimination and other pharmacological action. 

1.1.42 “Phase 2 Clinical Trial” means a human clinical trial performed in accordance with the Applicable Laws in patients with
a particular disease or condition which is designed to establish the safety, appropriate dosage, efficacy, and tolerability of a Licensed Product given its intended use and to initially explore its efficacy for such disease or condition and will
include such a clinical trial intended to be a pivotal trial. 
 (a) For purposes of triggering a Milestone Payment obligation, a
“Phase 2a Clinical Trial” includes a Phase 2 Clinical Trial that is specifically designed to assess, in whole or in part, dosing requirements for a Licensed Product for an Indication. 

(b) For purposes of triggering a Milestone Payment obligation, a “Phase 2b Clinical Trial” includes a Phase 2 Clinical Trial
that is specifically designed to assess, in whole or in part, the efficacy of a Licensed Product for an Indication. 
 1.1.43 “Phase
3 Clinical Trial” means a registration or pivotal clinical trial performed in accordance with the Applicable Laws and conducted in subjects with a particular disease or condition which is designed in a randomized, controlled fashion to
establish the efficacy and safety of a Licensed Product given its intended use and to define warnings, precautions and adverse events that are associated with Licensed Product in the dosage range intended to be prescribed. 

1.1.44 “Product Trademarks” means any trademarks for the Licensed Product itself selected by the JSC for use in connection
with the Commercialization of Licensed Products in the Territory in the Field (excluding, in any event, any trademarks, service marks, names or logos that include any corporate name or logo of the Parties or their Affiliates). 

1.1.45 “Reata Invention” means any invention or discovery that relates to a Licensed Product and that is conceived, made or
generated during the Term in the performance of activities undertaken pursuant to this Agreement by employees, agents, or independent contractors of Reata or its Affiliates (including any enhancement or modification of (a) a Licensed
Product’s use, dosage form or formulation or (b) the process or method for the manufacture of a Licensed Product). Reata has no obligation to include within Reata Inventions any inventions made or conceived solely by Reata’s licensees
or development partners. 

  
 9 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 1.1.46 “Reata Know-How” means Know-How owned or Controlled by Reata or its
Affiliates as of the Effective Date or during the Term regarding or specifically related to a Licensed Compound or Licensed Products, or the manufacture, development, commercialization or use thereof. For the avoidance of doubt, Know-how regarding
or specifically related to Reata’s (i) research activities, (ii) medicinal chemistry efforts, or (iii) other efforts aimed at identification or characterization of, or synthesizing or optimizing, molecules, other than with
respect to Licensed Compounds in all such cases of (i), (ii) and/or (iii), are excluded from “Reata Know-How.” 
 1.1.47
“Reata Patent Rights” means all patents and patent applications owned or Controlled by Reata or its Affiliates as of the Effective Date or during the Term which claim, or, but for the license granted herein, would be infringed by, a
Licensed Compound or Licensed Products, or the manufacture, use or sale thereof, including the patents and patent applications listed on Exhibit A attached hereto, and any and all substitutions, divisionals, continuations,
continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, or extensions of such patents and patent applications, and any foreign counterparts of the foregoing, and any patents issuing therefrom within the Territory.

 1.1.48 “Reata Regulatory Data” means all regulatory filings made by or on behalf of Reata (including by its Affiliates
and licensees other than Kyowa Kirin) with respect to Licensed Products and all data generated by or on behalf of Reata (including by its Affiliates and licensees) in the performance of non-clinical and clinical development activities or regulatory
activities, including any information contained in any regulatory filings with respect to Licensed Products and the results of, and all information generated in connection with, any non-clinical or clinical studies or regulatory activities performed
by or on behalf of Reata with respect to Licensed Products. 
 1.1.49 “Reata Trademark” means any trademark or trade name,
including registrations and applications therefor, owned or Controlled by Reata covering Reata’s corporate name and/or company logo. 

1.1.50 “Regulatory Approvals” means, with respect to any country or region in the Territory, any approval, product and
establishment license, registration or authorization of any Regulatory Authority required for the manufacture, use, storage, or Commercialization of a Licensed Product in such country or region. 

1.1.51 “Regulatory Authority” means any applicable government regulatory authority involved in granting approvals for the
manufacture, Commercialization, reimbursement and/or pricing of Licensed Product in the Territory. “Regulatory Authority” in the Territory includes the MHLW in Japan or the applicable governmental regulatory authority for each other
country in the Territory, or any successor agency of the foregoing having regulatory jurisdiction over the manufacture, distribution and sale of drugs in any country or region in the Territory. 

1.1.52 “Regulatory Filings” means any filings that may be required for any Regulatory Approval or otherwise filed or submitted
to a Regulatory Authority in the Territory in an effort to comply with Applicable Laws with respect to the Commercialization of Licensed Products in the Territory. 

  
 10 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 1.1.53 “Royalty Term” means, with respect to each country in the Territory,
the period of time commencing on the date of the First Commercial Sale in that country and continuing until the later of (a) the expiration of the last to expire Valid Claim in that country covering the manufacture, use or sale of such Licensed
Product in such country, or (b) ten (10) years from the date of the First Commercial Sale in that country. 
 1.1.54 “RTA
402” means bardoxolone methyl, also known as methyl 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO methyl ester), together with any of its salt, free base, acid, polymorph, hydrate, solvate, chelate, stereoisomer, enantiomer, racemate,
or tautomer forms. 
 1.1.55 “RTA 402 Class” means any compound that is structurally related to RTA 402 and that is claimed
by, or the manufacture, use or sale of which, but for the licenses granted herein, would infringe, any patents or patent applications in the Territory listed in Exhibit A as of the Effective Date (or any patent or patent application in the
Territory claiming priority back to any such patents or patent applications). 
 1.1.56 “Specifications” means the
specifications of Licensed Product and API, as determined and updated in accordance with Section 8.5, that include the minimum shelf life therefore and the tests, references to analytical procedures, and appropriate acceptance criteria that
(a) are numerical limits, ranges, or other criteria for the tests, analytical procedures and other criteria described, and (b) establish the set of criteria to which the Licensed Product or API should conform when tested by the tests,
analytical procedures and acceptance criteria listed in the Specification. 
 1.1.57 “Specification Update Costs” means all
reasonable costs incurred by Reata and directly associated with (and reasonably allocable to) Specification change requests by Kyowa Kirin in accordance with Section 8.5.2, including manufacturing change costs, labeling change costs, packaging
change costs, and costs associated with obtaining Regulatory Approval for the modifications. 
 1.1.58 “Tax” or
“Taxes” means (a) any taxes, assessments, fees, including income, profits, gross receipts, net proceeds, sales, alternative or add on minimum, ad valorem, turnover, property, personal property (tangible and intangible),
environmental, stamp, leasing, lease, user, duty, franchise, capital stock, transfer, registration, license, withholding, social security (or similar), unemployment, disability, payroll, employment, social contributions, fuel, excess profits,
occupational, premium, windfall profit, severance, estimated, or other charge of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not and (b) any liability of for the payment of any amounts of the
type described in clause (a) as a result of the operation of law or any express obligation to indemnify any other person. 

  
 11 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 1.1.59 “Territory” means Japan, China (including Hong Kong and Macao), South
Korea, Taiwan, Thailand, Singapore, Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia, unless and solely in the event any such country is removed from the Territory in accordance with the express terms and conditions of
Section 5.9 or Section 15.4 of this Agreement. 
 1.1.60 “Third Party” means a Person other than Kyowa Kirin,
Reata or their respective Affiliates. 
 1.1.61 “Valid Claim” means any of the method of use claims stated in any of the
patents or patent applications listed on Exhibit A as of the Effective Date, or any method of use claims stated in any future patent or patent application claiming priority back to a patent application listed on Exhibit A as of the
Effective Date, or any composition of matter claim, in all such cases which claims are claims of (i) an issued and unexpired patent within the Reata Patent Rights, which patent (a) has not been finally cancelled, withdrawn, abandoned or
rejected by any administrative agency or other body of competent jurisdiction whose ruling is unappealable or unappealed within the time allowed for appeal, (b) has not been permanently revoked, held invalid, or declared unpatentable or
unenforceable in a decision of a court or other body of competent jurisdiction whose ruling is unappealable or unappealed within the time allowed for appeal, (c) has not been rendered unenforceable through disclaimer, and (d) is not lost
through an interference or opposition proceeding, which proceeding is unappealable or unappealed within the time allowed for appeal; or (ii) a pending patent application within the Reata Patent Rights listed on Exhibit A as of the
Effective Date, or filed in the future and claiming priority back to a patent or patent application listed on Exhibit A as of the Effective Date, solely to the extent any such claim therein is itself still pending, and not withdrawn,
abandoned, finally rejected or otherwise no longer pending, in the course of prosecution of such patent application. Valid Claims are limited to claims described above that would preclude using or selling Licensed Compounds and/or Licensed Product
in the Territory or, but for the licenses granted in this Agreement, would be infringed by Kyowa Kirin (or its Affiliates or Permitted Sublicensees) by the development, manufacture, commercialization, use or sale of Licensed Compounds and/or
Licensed Products. 
 1.2 Additional Definitions. In addition, each of the following definitions will have the respective
meanings set forth in the section of this Agreement indicated below: 
  

					
	 Definitions
	  	Section	 
	 Agreement
	  	 	Preamble	  
	 API
	  	 	8.5.1	  
	 Chairman
	  	 	16.5	  
	 CKD
	  	 	3.4.4(a)	  
	 Clinical Development Activities
	  	 	4.1	  
	 Combination Product
	  	 	1.1.37	  
	 Commercial Supply Agreement
	  	 	8.3.1	  
	 Delivery
	  	 	8.2.3	  
	 Dispute
	  	 	16.1	  

  
 12 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

					
	 Definitions
	  	Section	 
	 Effective Date
	  	 	Preamble	  
	 Financing Sources
	  	 	11.1.3	  
	 ICC
	  	 	16.3	  
	 Indemnifying Party
	  	 	14.3	  
	 Indemnitee
	  	 	14.3	  
	 In-License Agreements
	  	 	12.3.10	  
	 Insolvent Party
	  	 	15.10.1	  
	 JSC
	  	 	3.1	  
	 Kyowa Kirin
	  	 	Preamble	  
	 Kyowa Kirin Clinical Data
	  	 	4.2.1	  
	 Kyowa Kirin Indemnitees
	  	 	14.2	  
	 Losses
	  	 	14.1	  
	 Marketing Plan
	  	 	6.2	  
	 Mediation Rules
	  	 	16.3	  
	 Medical Affairs Plan
	  	 	6.7	  
	 MHLW
	  	 	1.1.36	  
	 Notice
	  	 	17.6	  
	 Notice of Disagreement
	  	 	3.4.2	  
	 Publication
	  	 	11.4.1	  
	 Reata
	  	 	Preamble	  
	 Reata Clinical Data
	  	 	4.2.3	  
	 Reata Indemnitees
	  	 	14.1	  
	 Regulatory Activities
	  	 	5.1.1	  
	 Regulatory Milestone Payments
	  	 	7.2.1	  
	 Rules
	  	 	16.4	  
	 Sales and Marketing Activities
	  	 	6.1	  
	 Sales Milestone Payments
	  	 	7.2.2	  
	 Sales Royalties
	  	 	7.3	  
	 Technical Review Panel
	  	 	3.4.4	  
	 Term
	  	 	15.1	  
	 Third Party Manufacturer
	  	 	8.4.1	  
	 Trademark License
	  	 	2.1.1	  
	 Tribunal
	  	 	16.5	  
	 Upfront Payment
	  	 	7.1	  
	 USBC
	  	 	15.10.1	  
	 VAT
	  	 	7.8.2	  

 1.3 Financial Terms. All financial and accounting terms not otherwise defined in this Agreement,
whether capitalized or not, will have the meanings assigned to them in accordance with GAAP. 

  
 13 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 ARTICLE II 

LICENSES 
 2.1
Licenses Regarding Licensed Compounds and Licensed Products.  
 2.1.1 Subject to the terms and conditions of this Agreement
and to Dartmouth College’s reservation of rights in the Dartmouth License, Reata hereby grants to Kyowa Kirin an exclusive, royalty-bearing (as described in ARTICLE VII) license under the Licensed Technology to research, develop, use, sell,
offer for sale, import, and export (and to have such actions taken on its behalf by its agents, contractors, service providers or authorized representatives in accordance with this Agreement) Licensed Compounds and Licensed Products in the Field in
the Territory. 
 2.1.2 Subject to the terms and conditions of this Agreement and to Dartmouth College’s reservation of rights in the
Dartmouth License, Reata hereby grants Kyowa Kirin the right to sublicense the rights granted under Section 2.1.1 to its Affiliates and to Third Parties, subject to the following conditions and requirements: 

(a) With respect to sublicenses to one of its Affiliates, Kyowa Kirin must provide Reata with prior Notice of the name and country of the
Affiliate and the rights to be sublicensed, and such Affiliate must agree in writing to comply with the terms and conditions of this Agreement that are applicable to such sublicensee’s activities. Kyowa Kirin shall remain fully liable for the
performance of such sublicensee in accordance with this Agreement. Any sublicense granted by Kyowa Kirin to one of its Affiliates shall terminate if such entity is no longer an Affiliate of Kyowa Kirin and Reata’s approval is not obtained for
the continuation of such sublicense in accordance with subsection (b) below. 
 (b) With respect to Third Parties, (i) Kyowa
Kirin’s proposed sublicensee must be approved in writing and in advance by Reata, such approval not to be unreasonably withheld; (ii) each sublicensee must agree in writing to comply with the term and conditions of this Agreement that are
applicable to such sublicensee’s activities; (iii) Kyowa Kirin shall remain fully liable for the performance of such sublicensee in accordance this Agreement; and (iv) Kyowa Kirin shall not have the right to sublicense to any Third
Party any of its rights to make or have made the Licensed Products or Licensed Compounds under Section 2.1.3. 
 2.1.3 Subject to the
terms and conditions of this Agreement and to Dartmouth College’s reservation of rights in the Dartmouth License as of the Effective Date, Reata hereby grants to Kyowa Kirin and its Affiliates a nonexclusive license under the Licensed
Technology to make and have made (anywhere in the world) Licensed Compounds and Licensed Products solely for Commercialization in the Field in the Territory; provided, however, Kyowa Kirin agrees that it will not exercise such manufacturing rights
except to the extent provided for in Sections 8.3.3, 8.4.6, and/or 8.5 (and/or pursuant to the corresponding terms and conditions of the Commercial Supply Agreement). 

  
 14 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 2.2 License Regarding RTA 402 Class.  

2.2.1 Subject to Sections 2.2.2 and 4.6 and the terms and conditions of this Agreement and to Dartmouth College’s reservation of rights in
the Dartmouth License, Reata hereby grants to Kyowa Kirin an exclusive, royalty-bearing (as described in ARTICLE VII) license under the Licensed Technology to use, sell, offer for sale, import, and export (and to have such actions taken on its
behalf by its agents, contractors, service providers or authorized representatives) compounds within the RTA 402 Class, and products containing compounds within the RTA 402 Class, in the Field in the Territory. 

2.2.2 Kyowa Kirin covenants that it will not, nor will it sublicense to any Third Party the right under the license granted in
Section 2.2.1 to, sell, offer for sale, make or have made, in the Field in the Territory any compound within the RTA 402 Class other than the Licensed Compound; provided, however, notwithstanding the foregoing, Kyowa Kirin may enforce its
rights hereunder to prevent Third Parties from using, selling, offering for sale, making or having made any compound within the RTA 402 Class in the Field in the Territory. 

2.3 Reata Trademarks.  

2.3.1 Reata grants to Kyowa Kirin a non-exclusive license to use the Reata Trademarks solely in connection with Kyowa Kirin’s exercise of
the license granted to it pursuant to Section 2.1 above, including the limited right to sublicense to Permitted Sublicensees as provided for in such license (the “Trademark License”). Kyowa Kirin will use the Reata Trademarks
(a) solely in the manner specified in this Agreement in connection with Licensed Product and not for any other goods or services, and (b) only in the form and manner as reasonably prescribed in writing to Kyowa Kirin in advance from time
to time by Reata (provided, however, that Kyowa Kirin shall have a reasonable period of time to modify any of its promotional, marketing, regulatory or other practices, including in light of Applicable Laws, and/or cease use of the Reata Trademarks,
as may be reasonably necessary to comply with any such form and manner prescriptions and/or any changes thereto). Without limiting the foregoing, any use by Kyowa Kirin of a Reata Trademark for Licensed Product should be accompanied by a trademark
notice that states that such Reata Trademark is a trademark (or a registered trademark, if applicable) of Reata Pharmaceuticals, Inc. Any use by Kyowa Kirin of the Reata Trademarks, and Reata’s maintenance of the Reata Trademarks, shall be in
compliance with all Applicable Laws, including those relating to the licensing of trademarks, in the Territory. Kyowa Kirin agrees to promptly correct any failure to comply with this Section 2.3. For the avoidance of doubt, (x) Kyowa Kirin
shall have no responsibility or obligation for (and Reata shall be solely responsible for) the maintenance, registration, prosecution and enforcement of the Reata Trademarks, which shall be at Reata’s sole cost and expense, and (y) Kyowa
Kirin shall have no obligation hereunder to use the Reata Trademarks (any such use, in accordance with the foregoing, shall be at Kyowa Kirin’s sole option, to be exercised or not at Kyowa Kirin’s sole discretion). 

2.3.2 Kyowa Kirin acknowledges Reata’s ownership of all right, title and interest in and to the Reata Trademarks, and agrees that it will
do nothing inconsistent with such ownership, that all use of the Reata Trademarks by Kyowa Kirin will inure to the benefit of and be 

  
 15 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
on behalf of Reata, and that any goodwill associated with the use of any Reata Trademark by Kyowa Kirin will inure to the benefit of Reata. Kyowa Kirin agrees that nothing in this Agreement will
give Kyowa Kirin any right, title or interest in the Reata Trademarks other than the right to use the Reata Trademarks in accordance with this Agreement. Anything in this Agreement to the contrary notwithstanding, if by virtue of Kyowa Kirin’s
use of the Reata Trademarks, Kyowa Kirin acquires any equity, title or other rights in or to the Reata Trademarks, Kyowa Kirin hereby agrees all such equity, title or other rights in or to the Reata Trademarks belong to Reata upon creation of the
value, and Kyowa Kirin agrees to and hereby does assign and transfer any such Reata Trademark rights to Reata. Kyowa Kirin agrees not to use or file any application to register any trademark or trade name that is confusingly similar to any Reata
Trademark. 
 2.4 Kyowa Kirin Trademarks. Reata acknowledges Kyowa Kirin’s ownership of all right, title and interest in
and to the Kyowa Kirin Trademarks, and agrees that it will do nothing inconsistent with such ownership. Kyowa Kirin reserves the right to use Kyowa Kirin Trademarks for Licensed Products in the Territory. Reata agrees not to use or file any
application to register any trademark or trade name that is confusingly similar to any Kyowa Kirin Trademark. 
 2.5 Product
Trademarks. Subject to the JSC’s review, approval, and oversight of the Development Plan as provided in Section 3.2, Kyowa Kirin will coordinate and collaborate with Reata to secure all rights to Reata or Kyowa Kirin, as determined
by the JSC (taking into account Applicable Law and the requirements of applicable Regulatory Authorities), in the Product Trademarks for use in connection with the Commercialization of Licensed Products in the Territory for use in the Field (which
Product Trademarks may or may not be the same as the names, marks and logos used for the Licensed Product outside the Territory). The JSC will discuss the selection of the Product Trademark and also discuss (without decision-making authority) the
names, marks and logos to be used for the Licensed Products outside the Territory so that the Parties can discuss and consider the prospect of having a global brand. Reata shall consider recommendations provided by Kyowa Kirin to Reata regarding the
selection of the names, marks and logos to be used for Licensed Products outside the Territory for purposes of selecting such names, marks and logos that can also be used within the Territory as part of a global brand, but Reata is under no
obligation to adopt or use any such recommendations. The Party determined by the JSC to own the Product Trademarks by the JSC will be responsible for (and shall control) the filing, prosecution, maintenance and defense of all registrations of the
Product Trademarks in the Territory, and will be responsible for the payment of any costs incurred by such Party relating to filing, prosecution, maintenance, defense and enforcement of the Product Trademarks in the Territory; provided, however,
that the non-owning Party may elect at its expense to participate in the defense or enforcement of the Product Trademarks in the Territory (and shall have the right to lead such defense or enforcement in the event the owning Party fails to do so).
In any event, each Party will provide to the other Party prompt written Notice of any actual or threatened infringement of Product Trademarks in the Territory. In the event Reata owns the Product Trademarks in the Territory, Reata hereby grants to
Kyowa Kirin an exclusive license to use the Product Trademarks solely in connection with Kyowa Kirin’s exercise of the license granted to it pursuant to Section 2.1, including the limited right to sublicense provided for in such license.

  
 16 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 2.6 Reservation of Rights. Except for the rights and licenses specifically
granted in this Agreement, Reata reserves all rights to the Licensed Technology, Confidential Information of Reata, and Reata Regulatory Data, and any regulatory filings owned or held by Reata, and, except for such specifically granted rights and
licenses, this Agreement does not include the grant of any right or license, express or implied, to any other intellectual property or other rights owned or Controlled by Reata. Notwithstanding any provision to the contrary, Reata retains any rights
under the Licensed Technology, Confidential Information of Reata, and Reata Regulatory Data, and any regulatory filings owned or held by Reata, as may be required for Reata to perform its express obligations under this Agreement. Except for the
rights and licenses specifically granted in this Agreement, Kyowa Kirin reserves all rights to the Confidential Information of Kyowa Kirin, and the Kyowa Kirin Regulatory Data, and any Regulatory Filings owned or held by Kyowa Kirin and, except for
such specifically granted rights and licenses, this Agreement does not include the grant of any right or license, express or implied, to any other intellectual property or other rights owned or Controlled by Kyowa Kirin. 

ARTICLE III 
 JOINT
STEERING COMMITTEE 
 3.1 Establishment and Membership. Within thirty (30) days of the Effective Date, the Parties
will establish a joint steering committee (the “JSC”), to coordinate and oversee the development and commercialization of Licensed Products hereunder. 

3.2 Purpose of JSC. The purposes of the JSC will be (a) to coordinate the management and implementation of the Parties’
activities hereunder, including the Clinical Development Activities, Regulatory Activities, and Sales and Marketing Activities; (b) to review, approve, and oversee the Development Plan, (c) to review, approve, and oversee the Marketing
Plan, (d) create and oversee any subcommittees or working groups as the JSC may deem appropriate, it being understood that there shall be at least one such subcommittee or working group specifically for Licensed Product clinical and regulatory
development matters, (e) to address any issues expressly delegated to the JSC under this Agreement (for example and without limitation, the selection of Product Trademarks under Section 2.5), and (f) to consult and coordinate with
respect to License Product development and commercialization outside the Territory (but neither the JSC nor Kyowa Kirin shall have any decision-making authority with respect to such activities and matters outside the Territory). Kyowa Kirin will
submit a Development Plan to the JSC for its approval, with respect to anticipated Clinical Development Activities and Regulatory Activities with respect to Licensed Products for use in the Field, within [***] of the Effective Date of this
Agreement, which Development Plan will include Kyowa Kirin’s preliminary development plans for China. Kyowa Kirin may thereafter periodically submit updates or modified versions of the Development Plan to the JSC for its review and approval.

 3.3 Membership and Procedures. 

3.3.1 Membership. Each Party will designate an equal number of representatives, to be three (3) each unless the Parties agree
otherwise, with appropriate expertise to serve as members of the JSC. Each Party may replace its representatives on the JSC at any time upon written Notice to the other Party. 

  
 17 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 3.3.2 Administrative Chair. One member of the JSC will serve as Administrative Chair.
The Administrative Chair will be responsible for organizing meetings and preparing and circulating an agenda in advance of each meeting of the JSC and preparing minutes of each meeting, to be approved by both the Parties. For the first year, [***]
will appoint the Administrative Chair of the JSC. Thereafter, [***] will appoint the Administrative Chair for an initial one year term; and thereafter [***] will appoint the Administrative Chair on an annual basis unless [***] wishes to appoint such
chair, in which case [***] may appoint the Administrative Chair for a twelve (12) month term, and thereafter the Parties will alternate in appointing the Administrative Chair for twelve (12) month terms. 

3.3.3 Meetings. During the first year after the Effective Date, the JSC will hold meetings on a [***] basis; and thereafter the JSC will
hold meetings at least [***] (i.e., roughly [***]), or more frequently as the Parties may agree; provided that either Party may also call a special meeting of the JSC on an ad hoc basis upon at least seven (7) days prior Notice to
address urgent matters which cannot be reasonably postponed until the next JSC meeting. The first two (2) meetings will be held in person; one (1) meeting in the United States and one (1) meeting in Japan. Subsequent meetings may be
held in person or by means of telecommunication (telephone, video, or web conferences). Other employees of each Party involved in the development, manufacture or Commercialization of Licensed Products may attend meetings of the JSC as non-voting
participants, and, with the consent of each Party, consultants, representatives, or advisors involved in the development, manufacture or commercialization of the Licensed Product may attend meetings as non-voting observers; provided, however,
that any such Third Party JSC meeting attendees are under obligations of confidentiality and non-use applicable to the Confidential Information of each Party that are at least as stringent as those set forth in ARTICLE XI. Following any JSC meeting,
the Administrative Chair will be responsible for preparing and issuing minutes of such meeting within thirty (30) days thereafter. Such minutes will not be finalized until a representative of the other Party has reviewed and confirmed the
accuracy of such minutes in writing. If a disagreement regarding the accuracy of such minutes cannot be resolved, the minutes will reflect such disagreement. 

3.3.4 Limitations of Powers. The JSC will have only such powers as are specifically delegated to it hereunder and will not be a
substitute for the rights of the Parties. Without limiting the generality of the foregoing, the JSC will not have any power to amend this Agreement (without limiting its right to approve amendments to the Development Plans) and the JSC is otherwise
subject to the express terms and conditions of this Agreement. Any amendment to the terms and conditions of this Agreement may only be implemented pursuant to Section 17.7 below. 

  
 18 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 3.4 Decision-Making. 

3.4.1 Subject to the terms of this Section 3.4, the JSC will take action by [***] with each Party having [***], irrespective of the number
of representatives actually in attendance at a meeting, or by a written resolution signed by the designated representatives to the JSC of each of the Parties. The JSC members shall use good faith efforts to reach agreement on any and all matters
submitted to it. If the JSC fails to reach unanimous consent on a particular matter within thirty (30) days of a Party having requested a formal vote on such matter (or, if such matter is urgent, within seven (7) days of such request),
then such dispute will be subject to the resolution procedures described in Section 3.4.2. 
 3.4.2 In the event of any dispute in the
JSC that is not resolved pursuant to the terms of Section 3.4.1, either Party may provide written Notice of such failure (a “Notice of Disagreement”) to the other Party in order to refer such dispute to the Chief Executive
Officer of Reata and the Chief Operating Officer or Kyowa Kirin for potential resolution. Following any such Notice of Disagreement, the Chief Executive Officer of Reata and the Chief Operating Officer of Kyowa Kirin will meet at least once in
person or by means of live telecommunication (telephone, video, or web conferences) to discuss the matter on which the JSC failed to reach unanimous consent and use their good faith efforts to resolve the matter within thirty (30) days after
receipt of the Notice of Disagreement by the applicable Party. If any such disagreement is not resolved by the Chief Executive/Operating Officers or their designees within such thirty (30) day period, then, subject to the restrictions in
Section 3.4.4 below, [***] will have the final decision-making authority with respect to any such disagreement relating to any Commercialization in the Territory. In making any such final decision, [***] shall reasonably consider, in good
faith, any issues raised by [***] concerning risks that such decision could have a material adverse effect on [***]. 
 3.4.3 Notwithstanding
this Section 3.4, any dispute regarding the interpretation of this Agreement, the performance or alleged nonperformance of a Party’s obligations under this Agreement, or any alleged breach of this Agreement will be resolved in accordance
with the terms of ARTICLE XVI and shall not be subject to the JSC decision-making. 
 3.4.4 With respect to any and all JSC decisions
regarding clinical studies for Licensed Products within the Field by Kyowa Kirin, the following shall apply: 
 (a) For clinical studies
within the protocols already established in studies by Reata (subject to variations in dose and dosing within the parameters of subsections (i) and (ii) below) and related to the development of Licensed Product for the treatment of chronic
kidney disease (“CKD”), [***] shall have final decision-making authority to conduct any such clinical studies that [***]; 
 (b)
For clinical studies for the Indication of CKD, but outside of the protocols and parameters described in Section 3.4.4(a), Kyowa Kirin shall provide summaries of such clinical studies and their proposed protocols to Reata. Upon review, if Reata
reasonably believes those studies have the potential to adversely affect the safety profile of the Licensed Compound or to adversely impact patient safety, then Reata shall have the right to require an independent panel of medical and scientific
reviewers evaluate the proposed study (the “Technical Review Panel”), at Reata’s expense. The Technical Review Panel shall be comprised of three unaffiliated, independent members, and will act by majority vote. The members of
the 

  
 19 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
Technical Review Panel will be appointed as follows: (i) within [***] days of Reata’s request for a Technical Review Panel, each Party shall designate (in its sole discretion) an expert
with technical expertise in the relevant area to be a member of the Technical Review Panel; (ii) within [***] days of each Party making their member designation, those designated members shall designate another expert with technical expertise
in the relevant area to be the third member of the Technical Review Panel, who will serve as the chairman of the panel. Within [***] days of the designation of the entire three-member Technical Review Panel, each Party shall submit a written
statement detailing its positions with respect to the safety concerns of Reata that prompted the request for a review by the Technical Review Panel. Promptly after the submission of each Party’s written statements, the Technical Review Panel
shall deliver to the Parties, in writing, the Technical Review Panel’s conclusions regarding the safety concerns of Reata, and its recommendations (if any) for modification of Kyowa Kirin’s proposed protocol to address such safety concerns
(taking into consideration the requirements for Commercialization Regulatory Approval). In the event the Technical Review Panel agrees with Reata’s safety concerns, [***]. 

(c) For any animal studies proposed by Kyowa Kirin, and for all proposed Kyowa Kirin clinical studies outside of the CKD indication, Kyowa
Kirin shall provide summaries of such clinical studies and their proposed protocols to Reata. Upon review, Reata has final authority to veto the studies if Reata determines, in its sole but reasonable discretion, that Reata has a reasonable basis to
believe that the proposed studies present a risk of adversely affecting the safety profile of the Licensed Compound or adversely impacting patient safety. 

3.5 Expenses. Each Party will be responsible for all of its own travel and other costs and expenses for its respective members,
designees and non-JSC invitees to attend meetings of, and otherwise participate on, the JSC and any subcommittees or working groups. 
 3.6
Relationship of Parties. Nothing contained in this Agreement shall be deemed to constitute any member of the JSC (or any other committees or sub-teams of the JSC) a partner, agent or legal representative of the other Party, or to
create any fiduciary relationship for any purpose whatsoever. Except as may be explicitly provided in this Agreement, no member of the JSC (or any other committee or sub-team of the JSC) shall have any authority to act for, or to assume any
obligation or responsibility on behalf of, any other member of the JSC (or any other committee of sub-team of the JSC) of the other Party. For the avoidance of doubt, this Agreement is not intended to create and may not be construed to create a
partnership, joint venture, or entity of any kind between the Parties. 
 ARTICLE IV 

CLINICAL DEVELOPMENT 
 4.1
Kyowa Kirin Clinical Development Activities. Subject to, and in accordance with, the terms and conditions of this Agreement and the requirements of all Applicable Laws, Kyowa Kirin will be responsible for, [***], and will use
Commercially Reasonable Efforts to conduct (or have conducted), all pre-clinical and clinical trial activities necessary (and those determined by the JSC to be useful and worth pursuing under the circumstances) for the Commercialization of Licensed
Product in each country in the Territory as overseen by the JSC in accordance with ARTICLE III (“Clinical Development Activities”). [***]. 

  
 20 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 4.2 Clinical Development Data. 

4.2.1 Obligations of Kyowa Kirin. All results of all Clinical Development Activities for Licensed Products and any and all other
information or data generated by Kyowa Kirin, its Affiliates, Permitted Sublicensees, or any Third Party on behalf of Kyowa Kirin with respect to and in the course of conducting any Clinical Development Activities for Licensed Products, including
all data collected or analyzed with respect thereto, and all study reports analyzing such data (collectively, “Kyowa Kirin Clinical Data”) will be (a) used by or for Kyowa Kirin and its Affiliates (and Third Parties acting on
their behalf) to support necessary Regulatory Approvals and Commercialization in the Territory, as and to the extent applicable, and (b) provided to Reata (in electronic form if requested by Reata and in or reasonably convertible to such
electronic form) by Kyowa Kirin in a reasonable manner (subject to Applicable Laws), which in any event shall not require translation thereof into English by Kyowa Kirin. 

4.2.2 Use of Kyowa Kirin Clinical Data. Kyowa Kirin hereby agrees that Reata may use Kyowa Kirin Clinical Data for the performance of
its obligations and exercise of its rights under this Agreement and that Reata and its Affiliates, licensees and development partners will have a right of access, a right of reference and a right to use and incorporate all Kyowa Kirin Clinical Data
in any regulatory filings for Licensed Products or for other uses with respect to Licensed Products in accordance with Applicable Laws, outside the Territory. For the avoidance of doubt, Reata may provide the foregoing information (and extend the
foregoing rights) to its licensees or development partners. 
 4.2.3 Obligations of Reata. During the Term, and subject to Applicable
Laws, Reata will provide Kyowa Kirin with copies (in electronic form if requested by Kyowa Kirin and in or reasonably convertible to such electronic form) of all information or data with respect to Licensed Product (including non-clinical and
clinical study data and results, and including all other information or data with respect to and generated in the course of conducting any clinical development activities for Licensed Products, together with all data collected or analyzed with
respect thereto, and all study reports analyzing such data) that is (or was prior to the Effective Date) generated by Reata or any Affiliates or licensees or development partners of Reata, or by any Third Parties acting on their behalf, which is
necessary or useful for Kyowa Kirin to conduct Clinical Development Activities, obtain any required Regulatory Approvals or perform such other Regulatory Activities under this Agreement or as otherwise reasonably requested in writing by Kyowa Kirin
(collectively “Reata Clinical Data”). Reata Clinical Data generated by any Reata Affiliates, licensees or development partners will be provided to Kyowa Kirin reasonably promptly upon receipt by Reata after completion by such
Affiliate, licensee or development partner of the final study reports (including individual patient listings) for the relevant data set (and Reata shall require its Affiliates, licensees and development partners to provide such Reata Clinical Data
to Reata so as to facilitate such timing and otherwise on a reasonable basis), provided that any Reata Clinical Data generated by an Affiliate, licensee or development partner that is not connected to any such final study reports and not otherwise
provided pursuant to other provisions of this Agreement shall be provided to Kyowa Kirin within a reasonable time. 

  
 21 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 4.2.4 Use of Reata Clinical Data and Other Licensee Clinical Data. Reata hereby agrees
that Kyowa Kirin may use Reata Clinical Data for the performance of its obligations and exercise of its rights under this Agreement and that Kyowa Kirin will have a right of access, a right of reference and a right to use and incorporate all Reata
Clinical Data in any Regulatory Filings or for other uses with respect to Licensed Products in accordance with Applicable Laws and this Agreement (including to perform its obligations and exercise its rights hereunder), in the Territory. For the
avoidance of doubt, Kyowa Kirin may provide the foregoing information (and extend the foregoing rights) to its Permitted Sublicensees for use within the scope of the permitted sublicense to such Permitted Sublicensee. 

4.3 No Debarred Personnel. In performing the Clinical Development Activities, Kyowa Kirin will not use the services of any
employee or consultant, who has been debarred by the FDA or any Regulatory Authority, or, to the best of Kyowa Kirin’s Knowledge, is the subject of debarment proceedings by the FDA or any other Regulatory Authority. 

4.4 Use of Animals. In connection with any development or Commercialization activities, including Clinical Development Activities
undertaken by Kyowa Kirin in connection with Licensed Product, Kyowa Kirin will comply with all Applicable Laws regarding the care and use of experimental animals. All animals used by Kyowa Kirin to evaluate Licensed Compounds will be provided
humane care and treatment in accordance with applicable codified veterinary practices in the jurisdiction where such animals are used. 
 4.5
Development Outside the Territory. As between Kyowa Kirin and Reata, Reata shall be solely responsible and shall have sole discretion and control (at Reata’s sole cost and expense) for all non-clinical, clinical and other
development or commercialization activities (including regulatory activities) with respect to Licensed Products outside the Territory. Reata, through the JSC, will keep Kyowa Kirin reasonably informed of all material events and developments,
including any Adverse Events, occurring in the course of the non-clinical, clinical and other development activities for Licensed Products outside the Territory. Reata will consider recommendations that Kyowa Kirin may make to Reata regarding
aspects of non-clinical and clinical trial and other development activities for Licensed Products outside the Territory that would be particularly helpful in obtaining Commercialization Regulatory Approval for Licensed Products within the Territory,
provided, however, Reata shall be under no obligation to accept or act on any such recommendations, and Reata shall have the final decision-making authority with respect thereto. [***]. 

4.6 Development of the Licensed Compound. Kyowa Kirin agrees that it shall only conduct Clinical Development Activities and other
Commercialization activities in the Field in the Territory under this Agreement (and the licenses granted hereunder) for the Licensed Compound and formulations of Licensed Compounds (and Licensed Products comprised of or containing such Licensed
Compounds). Reata acknowledges that the exact form of RTA 402 or any Backup Compound, or formulation thereof, may vary, as circumstances warrant, from the exact forms and 

  
 22 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
formulation developed or commercialized outside the Territory. Kyowa Kirin agrees that the Development Plan shall reflect the foregoing, and Reata has full veto rights to halt development by
Kyowa Kirin or its Affiliates or Permitted Sublicensees of any compound that is not a Licensed Compound or a formulation thereof. 

ARTICLE V 
 REGULATORY
MATTERS 
 5.1 Regulatory Activities.  

5.1.1 Regulatory Activities. Subject to, and in accordance with, the terms and conditions of this Agreement and the requirements of all
Applicable Laws, Kyowa Kirin, at its sole cost and expense, will use Commercially Reasonable Efforts to (a) take (or have taken) all actions necessary and file (or have filed) all Regulatory Filings with respect to Licensed Product required to
obtain Commercialization Regulatory Approvals in each country in the Territory; (b) respond in a timely fashion to requests for data and information from Regulatory Authorities with respect to Licensed Product; and (c) meet with officials
of Regulatory Authorities at such times as may be requested by such Regulatory Authorities with respect to Licensed Product (“Regulatory Activities”). [***]. Without limiting the applicability of the foregoing and the remainder of
this ARTICLE V, Kyowa Kirin, through the JSC, will keep Reata reasonably informed of all material events and developments occurring in the course of the Regulatory Activities, including scheduled Kyowa Kirin regulatory strategy discussions and
meetings with Regulatory Authorities in the Territory relating to Licensed Product. 
 5.1.2 Reata Assistance. Upon written request of
Kyowa Kirin, Reata will use Commercially Reasonable Efforts to assist Kyowa Kirin in connection with any meetings with, or requests from, Regulatory Authorities in the Territory related to Licensed Product. 

5.2 Kyowa Kirin Regulatory Data and Regulatory Approvals. 

5.2.1 Regulatory Filings. 

(a) Review. The JSC shall create a subcommittee or working group to coordinate communication and the exchange of information between
the Parties with respect to Regulatory Filings to be prepared and submitted by or for Kyowa Kirin in the Territory; and without limiting the foregoing, Kyowa Kirin will provide Reata with summaries, overviews or excerpts (including the framework or
description of any protocols to be included in such filings) (in English) of all Regulatory Filings prior to filing thereof. It is acknowledged by the Parties that given time constraints, the Regulatory Filing actually submitted by Kyowa Kirin to a
Regulatory Authority may vary from the matters discussed by the Parties in the JSC subcommittee or working group because of changes resulting from interactions with Regulatory Authorities and from continued work on such filings by Kyowa Kirin’s
regulatory personnel. 

  
 23 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 (b) Accelerated Reporting. In the event that Applicable Laws require Kyowa Kirin to
report information related to any Regulatory Activity on an accelerated basis such that Kyowa Kirin is unable to comply with Section 5.2.1(a), Kyowa Kirin will nonetheless provide to Reata a prompt and detailed description of the event that
triggered the accelerated reporting obligation as soon as reasonably practicable, but in no event later than three (3) Business Days after Kyowa Kirin obtains actual knowledge of such triggering event. 

(c) Copies. Subject to Applicable Laws, Kyowa Kirin will provide to Reata: (i) compact discs containing each Regulatory Filing as
submitted to Regulatory Authorities and all Kyowa Kirin Regulatory Data specific thereto (in the original language in which it was filed) promptly following such submission, (ii) synopses (in English) of material written communications to Kyowa
Kirin from any Regulatory Authority in the Territory with respect to Regulatory Filings, reasonably promptly following receipt thereof (taking into account the time required to prepare such summaries after such submission of such Regulatory
Filings), and (iii) a brief statement of any material changes in the final Regulatory Filings from the summaries previously provided by Kyowa Kirin to Reata. Reata will have a right of access, a right of reference and the right to use and
incorporate all Kyowa Kirin Regulatory Data in connection with Licensed Products and in a manner consistent with the terms of this Agreement (e.g., outside the Territory except to the extent required to perform any of its obligations hereunder). For
the avoidance of doubt, Reata may provide copies of Regulatory Filings (and extend its right of access, right of reference and the right to use and incorporate all Kyowa Kirin Regulatory Data in connection with Licensed Products into regulatory
submissions outside of the Territory) to its licensees or development partners with respect to Licensed Products. 
 5.2.2 Regulatory
Meetings in the Territory. Kyowa Kirin will provide Reata (through the JSC) with advance notice of any formal, scheduled meetings with any Regulatory Authority in the Territory (including any meetings related to the final positioning of labeling
and safety claims within the original and subsequent regulatory submissions), and Kyowa Kirin will provide a brief description of the topics to be presented or discussed at that meeting. Subject to Applicable Laws, Kyowa Kirin shall allow Reata to
attend any such meeting as an observer (without any obligation on Reata to do so). 
 5.2.3 Ownership of Kyowa Kirin Regulatory Data.
Kyowa Kirin will hold title to all Kyowa Kirin Regulatory Data, including Regulatory Filings and Regulatory Approvals; provided, that, Kyowa Kirin will file for and obtain Regulatory Filings and Regulatory Approvals in such manner as may be required
under (but solely to the extent reasonably practicable under) the Applicable Laws of the applicable countries within the Territory to allow for (if reasonably practicable) the expeditious transfer thereof to Reata or Reata’s designee pursuant
to Section 15.8 upon certain terminations of this Agreement. 
 5.3 Provision of Regulatory Information to Kyowa Kirin.
Reata will use Commercially Reasonable Efforts to assist Kyowa Kirin in connection with its conduct of all Regulatory Activities. Without limiting the foregoing, Reata shall (a) provide Kyowa Kirin with copies of any United States and European
(including for both the EU and for countries within Europe) regulatory filings for Licensed Product filed by or on behalf of Reata as necessary or useful for Kyowa Kirin to make Regulatory Filings for Licensed Product in the Territory,
(b) provide Kyowa Kirin with copies of any United States and European (including for both the EU 

  
 24 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
and for countries within Europe) regulatory filings for Licensed Product filed by or on behalf of Reata’s licensees or development partners as necessary or useful for Kyowa Kirin to make
Regulatory Filings for Licensed Product in the Territory, and (c) supply, and grant Kyowa Kirin the right to reference to, any other data that is Controlled by Reata or its licensees or development partners (anywhere in the world) that is
necessary or required by Applicable Laws to allow Kyowa Kirin to meet its regulatory filing obligations with respect to Licensed Products in the Territory. Kyowa Kirin will have a right of access, a right of reference and the right to use and
incorporate all regulatory filings and information provided to it pursuant to this Section 5.3 and any other Reata Regulatory Data solely to support Kyowa Kirin’s Regulatory Activities and Commercialization of Licensed Product in the
Territory (and otherwise perform its obligations and exercise its rights hereunder) and in accordance with the terms of this Agreement. For the avoidance of doubt, Kyowa Kirin may provide the foregoing information (and extend the foregoing rights)
to its Permitted Sublicensees for use within the scope of the permitted sublicense to such Permitted Sublicensee. 
 5.4 Safety;
Adverse Event Reporting. 
 5.4.1 Pharmacovigilance and Drug Safety Data. Kyowa Kirin will be responsible, at its sole
cost and expense, for: (a) collecting all pharmacovigilance and other drug safety data for Licensed Product in the Territory as required by Applicable Laws; and (b) reporting any such data, including Adverse Events in the Territory, to the
applicable Regulatory Authorities in the Territory, as appropriate to be in compliance with all Applicable Laws, including entry into the global safety database in CIOMS format (in English). Kyowa Kirin will provide Notice, including by email or by
notification systems built into such database, to Reata of such global database entries within the time period required by FDA regulations for the type of event involved. Kyowa Kirin expressly acknowledges Reata can and will provide information
received by Reata pursuant to this Section 5.4 to any Affiliates, licensees or development partners engaged in commercialization activities outside of the Territory. Upon reasonable prior notice and during normal business hours (and no more
than once per year), Reata has the right to review Kyowa Kirin’s internal processes and procedures for the collection and processing of safety data relating to Licensed Product. Reata will set up, hold and maintain (at Reata’s sole cost
and expense) the global safety database for Licensed Products. Reata shall enter into such database all pharmacovigilance and other drug safety data for Licensed Product (including Adverse Events) outside the Territory as required by Applicable Laws
(including any such data collected by licenses and collaboration partners). Reata shall provide Kyowa Kirin with ready access to such database, including to the Adverse Event information contained therein and Reata expressly acknowledges that Kyowa
Kirin can and will provide information received by Kyowa Kirin from such database to any Permitted Sublicensees engaged in Commercialization activities in the Territory. 

5.4.2 Safety Agreement. Within [***] months of the Effective Date of this Agreement, the JSC will develop a mutually acceptable safety
agreement (to be agreed upon and executed by both Parties) setting forth the Parties’ respective obligations in detail regarding pharmacovigilance and the exchange of drug safety data. 

  
 25 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 5.5 Recalls and Voluntary Withdrawals.  

5.5.1 For each country in the Territory, Kyowa Kirin and Reata will, through the JSC, confer and coordinate regarding their respective internal
standard operating procedures (and any changes thereto) regarding product recalls and the treatment of and response to product complaints and inquiries as to safety, quality or efficacy that would be relevant to the Licensed Products. 

5.5.2 If either Party becomes aware of information about a Licensed Product indicating that it may not conform to the Specifications or that
there are potential adulterations, misbranding and/or other material adverse issues regarding safety of a Licensed Product (or otherwise that a recall or withdrawal of a Licensed Product is potentially at issue), it will as soon as practical (but in
any event within such period as the Parties may mutually establish to ensure their respective compliance with Applicable Law) so notify the other Party. With respect to the Territory, the Parties will promptly meet to discuss such circumstances and
to consider appropriate courses of action, including Licensed Product recalls. Unless agreed by the Parties in writing, Kyowa Kirin will make any decisions regarding, and implement and be responsible, at its sole expense (except as provided below),
for all recalls of Licensed Product in the Territory, and will maintain complete and accurate records of any Licensed Product recall for such periods as may be required by legal requirements. Notwithstanding the foregoing, Reata shall reimburse
Kyowa Kirin for the reasonable and necessary out-of-pocket expenses incurred by Kyowa Kirin for any recalls of Licensed Products (or API) manufactured or supplied by or for Reata to Kyowa Kirin hereunder to the extent attributable to the failure of
such Licensed Product or API to conform to the Specifications or to be manufactured in compliance with Applicable Laws, which failure was due to negligence or was known to Reata (or its suppliers) or could reasonably have been discovered by Reata
(or its suppliers) with the application of reasonable and customary quality assurance and quality control practices or the application of GMPs, and such failure could not have been identified or detected by Kyowa Kirin (or if applicable its
Permitted Sublicensees) through its application of reasonable and customary quality assurance and quality control practices, or other inspections or activities required under Applicable Law with respect to such Licensed Products, prior to
distribution of the Licensed Product in the Territory. 
 5.6 Inspection Rights. Not more than [***], if Reata has any
reasonable concerns regarding Kyowa Kirin’s storage or handling of any Licensed Products, Reata will have the right, at Reata’s expense and on not less than [***] days prior notice, to inspect the facilities where Kyowa Kirin or its
Affiliates store or handle, or have stored or handled, any Licensed Products and to audit the procedures of Kyowa Kirin or its Affiliates for the storage and handling of Licensed Products for purposes of quality control. 

5.7 Governmental Inspections and Inquiries. Kyowa Kirin will advise Reata promptly, but in no event later than [***] days after
Kyowa Kirin’s receipt of notice thereof, of any planned Regulatory Authority visit to the portion of the facilities of Kyowa Kirin or its Affiliates where Licensed Product is stored or handled or any material written inquiries by a Regulatory
Authority concerning such facilities, the procedures of Kyowa Kirin or its Affiliates for the storage or handling of Licensed Products, or the Commercialization of Licensed Product in the Territory. 

  
 26 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
If the Regulatory Authority makes an unannounced or unplanned visit, or if Kyowa Kirin does not have at least [***] days notice of the visit, Kyowa Kirin will inform Reata of the visit as soon as
reasonably practicable, but in no event later than [***] Business Days after Kyowa Kirin obtains actual knowledge of the visit. Kyowa Kirin will inform Reata, as soon as practicable, regarding the purpose and result of such visit or inquiry, and
will provide to Reata copies of any minutes of the inspection generated by Kyowa Kirin (in English if available, without any obligation to translate) promptly following such inspection and any report or correspondence (in English if available,
without any obligation to translate) provided by Kyowa Kirin, or any Affiliate, as the case may be, to the Regulatory Authority or issued by or provided by the Regulatory Authority to Kyowa Kirin, or any Affiliate, as the case may be, in connection
with such visit or inquiry. If English translations of these materials are not available, then Kyowa Kirin will advise Reata of the material aspects of such minutes and correspondence at the JSC meetings. 

5.8 Regulatory Matters Outside the Territory. Reata, through the JSC, will keep Kyowa Kirin reasonably informed of all material
events and developments occurring in the course of the regulatory activities with respect to Licensed Products outside the Territory, including the overall content and outcome of any strategy discussions and meetings with applicable regulatory
authorities outside the Territory relating to Licensed Product. 
 5.9 Development in China. Within [***] of the approval of
the NDA for the Licensed Product in the United States and the FDA’s issuance of the Certificate of Pharmaceutical Product for such Licensed Product (with such [***] period commencing on the first date when both of the foregoing events has
occurred), or within such other time period as agreed between the Parties, Kyowa Kirin shall file an IND in China for the Licensed Product within the Field and thereafter Kyowa Kirin shall use Commercially Reasonable Efforts to obtain Regulatory
Approval of such Licensed Product in China. In the event that Kyowa Kirin has not submitted an IND within the [***] period specified above (and Kyowa Kirin has failed to cure such breach within [***] days following notice thereof), or in the event
that Kyowa Kirin has breached its obligation to use Commercially Reasonable Efforts to obtain Regulatory Approval of such Licensed Product in China (and Kyowa Kirin has failed to cure such breach following notice thereof in accordance with
Section 15.4), and in either case Reata elects to regain its rights under this Agreement as to China, Reata will provide Notice to Kyowa Kirin and reversion of all rights granted under this Agreement, as to China (but with no effect on the rest
of the Territory hereunder), will be immediately effective upon the giving of such notice. 
 ARTICLE VI 

SALES AND MARKETING; DILIGENCE OBLIGATIONS 

6.1 Sales and Marketing Activities. Subject to, and in accordance with, the terms and conditions of this Agreement and the
requirements of all Applicable Laws, Kyowa Kirin, at its sole cost and expense, will have the sole responsibility, and will use Commercially Reasonable Efforts, to develop (or have developed) a sales force and to market and sell (or have marketed
and sold) the Licensed Product(s) in each country in the Territory (“Sales and Marketing Activities”); and in any event Kyowa Kirin will achieve the First Commercial Sale in each country in the Territory reasonably promptly after
obtaining Commercialization Regulatory Approval for such Licensed Product in such country. 

  
 27 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 6.2 Marketing Plan. Without limiting the generality of the other provisions of
this ARTICLE VI, Kyowa Kirin will prepare and submit to Reata a plan containing the strategy and proposed activities (described generally) for marketing and selling Licensed Product in each country in the Territory (as updated pursuant to this
Section 6.2, the “Marketing Plan”). Kyowa Kirin will submit a proposed draft of the Marketing Plan for a country to the JSC for approval by the JSC no later than [***] prior to the anticipated date of the First Commercial Sale
of any Licensed Product in such country. Kyowa Kirin will deliver to the JSC an update of the relevant sections of the Marketing Plan from time to time during the Term, and in no case less than [***] during the [***] following the First Commercial
Sale in the applicable country. Updates to the Marketing Plan will reflect, among other things, each new Indication in the Field for which the Licensed Product has received Commercialization Regulatory Approval. All decisions regarding the
day-to-day conduct of Sales and Marketing Activities within the Territory in a manner consistent with the Marketing Plan will be determined solely by Kyowa Kirin. 

6.3 Sales Forecasts. Pursuant to ARTICLE VIII, Kyowa Kirin will provide certain forecasts with respect to its commercial
requirements for sale of Licensed Products in the Territory in accordance with the terms and conditions therein. 
 6.4
Pricing. Kyowa Kirin will have full authority to determine prices for the sale of Licensed Products in the Territory. 
 6.5
Labeling and Patent Rights Marking. Subject to Applicable Law, Kyowa Kirin will identify Reata as the licensor or manufacturer of the Licensed Product using the Reata Trademarks designated by Reata for such use in certain mutually
agreed promotional materials for Licensed Product in the Territory where such identification is appropriate, in a manner approved in advance in writing by both Parties and in accordance with (and subject to) the Trademark License set forth in
Section 2.3. To the extent reasonably and customary in the industry for such products, Kyowa Kirin will mark all Licensed Product sold by Kyowa Kirin with appropriate Product Trademarks and patent numbers to the extent permitted by Applicable
Law in the country within the Territory where such Licensed Product is sold. Kyowa Kirin may, in its sole discretion, include any Kyowa Kirin Trademarks on the Licensed Products, and on the labels, packaging, promotional materials and other
materials therefor. 
 6.6 Medical Affairs Activities. Subject to, and in accordance with, the terms and conditions of this
Agreement and the requirements of all Applicable Laws, Kyowa Kirin will be responsible for and will bear all costs of execution of all Medical Affairs Activities in the Territory performed by or for Kyowa Kirin. Such activities will be conducted in
a manner consistent with the Medical Affairs Plan and coordinated by the JSC in accordance with ARTICLE III. Except as required or permitted by Applicable Law, Kyowa Kirin acknowledges that it cannot conduct an investigation or initiate a
post-marketing clinical study that is not specifically related to any Indication in the Field included on the label or in the package insert for Licensed Products. 

  
 28 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 6.7 Medical Affairs Plan. Kyowa Kirin will prepare and submit to the JSC for
JSC’s review a plan containing the strategy and proposed Medical Affairs Activities (described generally) in the Territory with respect to Licensed Products for use in the Field (as updated pursuant to this Section 6.7, the
“Medical Affairs Plan”). Kyowa Kirin will submit a proposed draft of the Medical Affairs Plan to the JSC no later than [***] prior to the anticipated date of the First Commercial Sale of each Licensed Product and will submit an
updated Medical Affairs Plan to the JSC no later than [***] prior to the anticipated date of the First Commercial Sale of each Licensed Product. Kyowa Kirin will deliver an update of the relevant sections of the Medical Affairs Plan from time to
time during the Term, and in no case less than [***] following the First Commercial Sale. Updates to the Medical Affairs Plan will reflect, among other things, each new Indication in the Field for which the Licensed Product has received
Commercialization Regulatory Approval and countries within the Territory in which Medical Affairs Activities will be conducted for Licensed Product. The Medical Affairs Plan and all updates will be reviewed and discussed by the JSC. Kyowa Kirin will
in good faith consider the reasonable comments provided by Reata to the Medical Affairs Plan in light of potential risks that such Medical Affairs Plan; and if such risks could have, or are having, a material adverse scientific, clinical, medical,
regulatory or commercial impact on (a) obtaining regulatory approval for the manufacture, use or sale of Licensed Product outside the Territory, or (b) commercialization of Licensed Product outside of the Territory, then subject to
Section 3.4, the JSC may decide to revise the applicable Medical Affairs Plan to address such concerns and resubmit it to the JSC for review in the same manner. Kyowa Kirin will make Commercially Reasonable Efforts to carry out and perform the
plan, strategy and activities set forth in the Medical Affairs Plan within any applicable timelines contained therein. Kyowa Kirin will not engage in any Medical Affairs Activities with respect to Licensed Product in a manner that is inconsistent
with or outside the scope of the Medical Affairs Plan. 
 6.8 Marketing and Promotional Literature. All marketing and
promotional literature related to Licensed Product and prepared for use in the Territory by Kyowa Kirin will be prepared in a manner consistent with Applicable Laws. In certain marketing and promotional literature (as provided for in
Section 6.5), Reata will be presented and described as the Party who developed the Licensed Product. 
 6.9 Marketing and Sales
and Medical Affairs Outside the Territory. Beginning [***], Reata, through the JSC, will keep Kyowa Kirin reasonably informed of all material activities and developments with respect to the marketing and sale of Licensed Products outside the
Territory. Furthermore, Reata will provide to Kyowa Kirin (a) summaries of marketing plans of Reata (but excluding those of its Third Party licensees and collaboration partners) containing the strategy and proposed activities (described
generally) for marketing and selling Licensed Products outside the Territory (together with updates at least [***]), and (b) summaries of medical affairs plans of Reata (but excluding those of its Third Party licensees and collaboration
partners) containing the strategy and proposed medical affairs activities (described generally) outside the Territory with respect to Licensed Products for use in the Field (together with updates from time to time). Reata shall reasonably discuss
and consult with Kyowa Kirin through the JSC with respect to the foregoing activities and such marketing and medical affairs plans. 

  
 29 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 ARTICLE VII 

FINANCIAL TERMS 
 7.1
Upfront Payment. Within fifteen (15) Business Days after the Effective Date of this Agreement, Kyowa Kirin will pay to Reata a non-refundable, non-creditable, initial license fee of thirty-five million United States dollars
(US$35,000,000) (“Upfront Payment”). 
 7.2 Milestone Payments.  

7.2.1 Regulatory Milestones. In consideration for the rights granted to Kyowa Kirin under this Agreement, Kyowa Kirin will make the
following one-time, non-refundable, non-creditable payments to Reata within thirty (30) days after the first achievement by Kyowa Kirin or its Affiliate of each of the following milestone events for a Licensed Product (each a
“Regulatory Milestone Payment”). If any given Regulatory Milestone Payment is due (except for any of the Regulatory Milestone Events for countries other than Japan, which shall not trigger any of the preceding milestones), and one
or more preceding Regulatory Milestone Payments have not been paid for any reason, then payment of all preceding unpaid Regulatory Milestone Payments will be paid at such time as well. For the avoidance of doubt, each of the following milestones
(and corresponding Regulatory Milestone Payment) shall be payable only once. 
  

					
	 Regulatory Milestone Event
	  	Regulatory
Milestone
Payment
(US$)	 
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  

 7.2.2 Sales Milestones. In addition to the milestone payments contemplated by Section 7.2.1, Kyowa
Kirin will make each of the following one-time, non-refundable, non-creditable payments to Reata within sixty (60) days from the end of the Calendar Quarter in which the Milestone Event (each a “Sales Milestone Payment”)
described in the table below is first achieved by Kyowa Kirin and its Affiliates with respect to Net Sales of Licensed Products. If two or more of the following events occur within the same Calendar Year, the later Milestone

  
 30 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
Event will be deemed to be achieved on the first day of the next Calendar Year and the corresponding payments will be made within sixty (60) days of that date. For the avoidance of doubt,
each of the following milestones (and corresponding Sales Milestone Payment) shall be payable only once. 
  

					
	Sales Milestone Event (US$)	  	Sales
Milestone
Payment
(US$)	 
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  
	 [***]
	  	$	[***]	  

  
 31 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 7.3 Sales Royalties. During the Royalty Term for each country in the Territory,
Kyowa Kirin will pay to Reata royalties (“Sales Royalties”) based on the aggregate Net Sales of Licensed Products in each Calendar Year at the rates set forth below (annual Net Sales are determined on a Calendar Year basis): 

 

					
	 Annual Net Sales in Japan ( Japanese ¥)
	  	Royalty (%)	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  

  

					
	 Annual Net Sales in China (US$)
	  	Royalty (%)	 
	 [***]
	  	 	[***]	  
	 [***]
	  	 	[***]	  
		
	 Annual Net Sales in other countries in the Territory (not including Japan and China) (US$)
	  	Royalty (%)	 
	 [***]
	  	 	[***]	  

 Each royalty payment will be non-refundable and non-creditable against any other payments due hereunder. Kyowa Kirin will make
royalty payments to Reata hereunder in arrears, within sixty (60) days from the end of each Calendar Quarter in which the underlying Net Sales occur. Each royalty payment will be accompanied by a report for each country in the Territory in
which sales of any Licensed Products occurred in the Calendar Quarter, specifying: (a) the gross sales (if available) and Net Sales (including a statement of the aggregate deductions taken from gross sales in the calculation of Net Sales) on a
Licensed Product-by-Licensed Product and country-by-country basis, in each country’s currency; (b) the applicable royalty rate under this Agreement; (c) the royalties payable in the country’s currency where the Net Sales
occurred; (d) the applicable exchange rate to convert from each country’s currency to United States dollars under Section 7.7; and (e) the royalties payable in United States dollars. For the avoidance of doubt, no royalties shall
be due or payable by Kyowa Kirin with respect to Net Sales of Licensed Products in a given country after the end of the Royalty Term in such country. 

  
 32 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 7.4 Royalty Adjustments. The Sales Royalties payable by Kyowa Kirin hereunder
shall be reduced in certain circumstances as follows: 
 7.4.1 Adjustments For Generic Competition. If a Generic Product (as defined
below) is commercially launched or sold in a country in the Territory, and the sales of such Generic Product (in terms of quantities of units sold) in such country reaches or exceeds a specified percentage (“Specified Percentage”)
of the quantities of Licensed Products sold by Kyowa Kirin or its Affiliates in such country (as measured by IMS data or similar metrics) in a given Calendar Quarter, then the Sales Royalties payable with respect to any Net Sales of Licensed
Products in such country shall be reduced in the Calendar Quarter in which the Specified Percentage is first reached and in all subsequent Calendar Quarters during the Royalty Term for such country, by reducing the base royalty rate otherwise
applicable in Section 7.3 by the percentage amount specified below as follows: 
  

					
	 Specified Percentage
	  	Reduction in Base Royalty Rate	 
	 Below [***]%
	  	 	[***]	% 
	 At [***]% and between [***]% and [***]%
	  	 	[***]	% 
	 At [***]% and between [***]% and [***]%
	  	 	[***]	% 
	 At or above [***]%
	  	 	[***]	% 

 The reduced royalty rate will be rounded to the nearest [***]% when calculating the Sales Royalties due
hereunder. 
 Examples: 

If the Specified Percentage is [***]% in Japan, then the applicable royalty rate for Japan for the first tier of sales would be
reduced from [***]% to [***]% (a [***]% reduction); and the royalty rates for Japan for the other tiers would be reduced similarly. Royalty rates in other countries would not be affected. 

If the Specified Percentage later increases to [***]% in Japan, then the applicable royalty rate for Japan for the first tier
of sales would be reduced from [***]% to [***]% (a [***]% reduction); and the royalty rates for Japan for the other tiers would be reduced similarly. Royalty rates in other countries would not be affected. 

If the Specified Percentage reaches [***]% in Japan, then the applicable royalty rates for Japan for all tiers would be reduced
to [***] (a [***]% reduction) and [***] royalties shall be due for Japan. Royalty rates in other countries would not be affected. 
 For purposes of the
foregoing, a “Generic Product” means a Third Party product (a) that contains the same Licensed Compound as the applicable Licensed Product; and (b) has received Commercialization Regulatory Approval through an expedited
regulatory approval process governing approval of generic products. 

  
 33 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 7.4.2 Third Party Royalty; Anti-Royalty Stacking Adjustment. Reata shall be solely
responsible for any and all amounts due to any Third Party under any agreement entered into by and between Reata and such Third Party, including under the Dartmouth License and any other agreements listed on Exhibit B hereto. Except as
otherwise provided in Section 13.7, with respect to royalties payable by Kyowa Kirin or its Permitted Sublicensees to a Third Party under a license for a patent that claims or covers the Licensed Product, on account of sales of such Licensed
Product in a particular country, Kyowa Kirin may offset up to [***] percent ([***]%) of such Third Party royalties against the Sales Royalty payments that would otherwise have been payable by Kyowa Kirin to Reata with respect to Net Sales of such
Licensed Product in such country pursuant to Section 7.3 above, provided that the maximum reduction effected pursuant this Section 7.4.2 shall not exceed [***] percent ([***]%) of the royalties otherwise payable to Reata under such
Section 7.3 above after application of any additional reductions under Section 7.4.1 above (if any). 
 7.5 Method of
Payment. Unless otherwise expressly provided, each Party will make payments owed to the other Party hereunder in arrears, within thirty (30) days from the end of each calendar month in which such payment accrues. All payments due to
Reata hereunder, including Upfront Payments, Milestone Payments, Sales Royalties and Licensed Product supply payments, will be made by wire transfer of immediately available funds in United States dollars to a bank account or bank accounts
designated by Reata. 
 7.6 Interest on Overdue Payments. Any amounts not paid by either Party when due under this Agreement
will be subject to interest from and after the date payment is due through and including the date upon which such Party makes such payment in immediately available funds at an annual rate equal to the sum of [***] basis points over the prime rate of
interest quoted in the Money Rates section of the Wall Street Journal (New York Edition), calculated daily on the basis of a three hundred sixty (360) day year, or similar reputable data source, or if lower, the maximum rate permitted by
Applicable Law. 
 7.7 Foreign Currency Exchange. For any currency conversion from the currency of one country in which
Licensed Products are sold into United States dollars (or another currency if applicable) required in determining the amount of Net Sales or any royalties due hereunder, such conversion shall be calculated at the conversion rate as reported in the
Wall Street Journal (New York Edition) (or if that is no longer published, at the exchange rate reported by The Bank of Tokyo-Mitsubishi UFJ, Ltd.) on the last Business Day of the applicable quarterly period in which the Net Sales are
determined. 
 7.8 Taxes.  

7.8.1 No Withholdings. All payments required to be made by one Party to the other Party under this Agreement shall be made free and
clear of, and without reduction for, withholding Tax or similar Taxes; provided, however, that if a Party or any of its Affiliates shall be 

  
 34 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
required to deduct or withhold any such Taxes from payments made under this Agreement under Applicable Law, then such Party or its Affiliates, as applicable, shall make such deduction or
withholding form such payment and pay the full amount deducted or withheld to the relevant governmental authority in accordance with Applicable Law. If under Applicable Law such Tax is required to be deducted or withheld, the paying Party or its
Affiliates will promptly furnish the other Party with reasonable evidence of such deduction or withholding and payment thereof to the relevant governmental authority, in electronic or written form. The Parties will reasonably cooperate in completing
and filing documents required under the provisions of any Applicable Law in connection with the making of any required Tax payment or withholding payment, or in connection with any claim to an exemption from, reduction of, or a refund of or credit
for any such payment to the extent available under Applicable Law. 
 7.8.2 Other Tax Liability. Except as provided to the contrary in
this Agreement, each Party shall be solely responsible for all federal, state and local Tax liability arising from this Agreement imposed on such Party by the taxing authority of a jurisdiction in which such Party is resident or is otherwise subject
to such Tax liability. In the case of value added or similar taxes incurred by a Party with respect to payments made to a Party hereunder or the activities underlying such payments (“VAT”), each Party and their Affiliates will use
Commercially Reasonable Efforts to secure available exemption(s) from VAT and/or to cooperate with the other Party’s efforts to obtain maximum recovery of VAT paid or incurred by such Party or any Affiliate, to the extent permitted by
Applicable Law. 
 7.8.3 Payments Treated as Royalties for Tax Purposes. The Parties agree that, to the extent consistent with
Applicable Law, the Upfront Payment, the Milestone Payments, and the Sales Royalties are payments received as consideration for the use of, or the right to use, a patent or patents, a secret process, or information concerning industrial, commercial
or scientific experience within the meaning of the Income Tax Convention for the Avoidance of Double Taxation between Japan and the United States. Accordingly, the Upfront Payment, the Milestone Payments, and the Sales Royalties constitute
“royalties” for Tax purposes, and the Parties intend and agree (to the extent consistent with Applicable Law) to treat them as such for Tax purposes. 

7.9 Prohibited Payments. Notwithstanding any of the provision of this Agreement, if Kyowa Kirin is prevented from paying any
payments by virtue of the statutes, laws, codes or governmental regulations of the country from which the payment is to be made, then such payment may be paid by depositing funds in the currency in which it accrued to Reata’s account in a bank
reasonably acceptable to Reata in the country whose currency is involved. 
 ARTICLE VIII 

REATA SUPPLY OF LICENSED PRODUCT; SPECIFICATIONS 

8.1 Reata Obligation to Supply Licensed Product. Kyowa Kirin will obtain [***] percent ([***]%) of its and its Affiliates’
requirements of Licensed Product for Commercialization in the Territory from Reata, and Reata agrees to manufacture or have manufactured and supply to Kyowa Kirin [***] of Kyowa Kirin’s and its Affiliates’ requirements of Licensed Product
for Commercialization in the Territory, in all such cases except to the extent otherwise provided in, and in any event subject to and in accordance with, the terms of, this ARTICLE VIII. 

  
 35 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 8.2 Supply of Licensed Product for Development. Subject to the terms and
conditions of this Agreement, Reata shall use Commercially Reasonable Efforts to supply Kyowa Kirin with quantities of Licensed Product required for Kyowa Kirin’s and its Affiliates’ development of Licensed Products in the Territory
(including for use in Clinical Development Activities and non-clinical studies) in accordance with Kyowa Kirin’s forecasts and orders therefor, as provided below. Kyowa Kirin shall use Licensed Product supplied by Reata under this provision
solely to conduct its development activities in accordance with the terms and conditions of this Agreement, and shall not use such Licensed Product for any other purpose. 

8.2.1 Forecasts and Orders. Kyowa Kirin shall keep Reata reasonably informed of its anticipated requirements of Licensed Products for
Clinical Development Activities and other development activities in the Territory through the JSC and the Development Plan. Kyowa Kirin shall order Licensed Products for use in development from Reata by providing Reata with a binding purchase order
(consistent with the terms and conditions of this Agreement) indicating the quantities of Licensed Products ordered for development purposes, the requested delivery date (at least [***] days after the date of the purchase order) and the destination
delivery location. Upon receipt of any such binding purchase order, Reata shall use reasonable efforts to manufacture and supply the Licensed Products in accordance therewith. Within [***] business days of receiving a binding purchase order, Reata
shall notify Kyowa Kirin with confirmation of such purchase order and also with the expected shipping and delivery dates (using reasonable efforts to designate such expected delivery dates close to the delivery dates requested by Kyowa Kirin). Reata
shall make deliveries of Licensed Product as soon as practicable, and shall use reasonable efforts to meet any expedited dates requested by Kyowa Kirin, provided that Kyowa Kirin shall be liable for any additional costs related to any requested
expedited delivery schedule. 
 8.2.2 Cost of Supply of Licensed Product for Development. The price for Licensed Product provided by
Reata to Kyowa Kirin for use in development (including Clinical Development Activities) in the Territory shall be at [***], plus applicable sales tax (if any). 

8.2.3 Delivery by Reata. Reata shall (a) deliver the Licensed Products FCA Reata’s or the Third Party Manufacturer’s
facility (Incoterms 2000), (b) if requested by Kyowa Kirin arrange delivery of Licensed Product to the location designated in Kyowa Kirin’s order and arrange insurance covering Licensed Product during delivery pursuant to Kyowa
Kirin’s written instructions and obtain any necessary export permits for such delivery, at Kyowa Kirin’s sole expense, (c) deliver all Licensed Product by the delivery dates established under Section 8.2.1 and otherwise in
conformance with Kyowa Kirin’s order (except that Reata may elect to split the order into multiple shipments so long as the delivery dates for the entire order are not materially delayed thereby). Title to and risk of loss in Licensed Product
shall pass to Kyowa Kirin upon delivery to the common carrier for delivery to Kyowa Kirin (each, a “Delivery”), and Kyowa Kirin shall be responsible for freight, delivery and insurance charges incurred in delivering the Licensed
Product to Kyowa Kirin’s designated delivery destination(s) (to the extent not already included in the Manufacturing Costs). Reata shall provide appropriate documentation (including certificates of analysis, GMP declaration statements and other
documentation required by Regulatory Authorities or otherwise to comply with Applicable Laws) with all shipments of Licensed Products hereunder. 

  
 36 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 8.2.4 Responsibility of Kyowa Kirin. Kyowa Kirin shall have the responsibility, at its
own expense, for (a) obtaining any necessary permits for the import into the Territory; (b) all customs, duties and other governmental charges relating to import of Licensed Product from the manufacturing site to Kyowa Kirin; (c) the
importation and sale of Licensed Product in the Territory; (d) storing and clearing Licensed Product through all customs and importation requirements for the Territory; (e) having Licensed Product delivered to Kyowa Kirin’s labeling
and packaging facility; and (f) conducting quality control testing, retention of samples and lot release, labeling and packaging of Licensed Product for distribution in the Territory, and conducting any and all release testing required in the
Territory, all in full compliance with all Applicable Laws. 
 8.2.5 Manufacturing Compliance and Quality Assurance by Reata. Reata
shall manufacture or have manufactured all Licensed Products in accordance with GMP and other Applicable Laws. For all Licensed Products delivered to Kyowa Kirin under this Section 8.2, Reata will conduct quality control, or will cause its
Third Party Manufacturing contractor to conduct such testing, for compliance with Specifications and testing required for compliance with Applicable Laws, including GMP. Reata will conduct a quality assurance review of all applicable documents and
activities for compliance with Applicable Laws, including GMP, with respect to Licensed Products prior to shipment thereof. 
 8.2.6
Limited Warranties. Reata represents and warrants to Kyowa Kirin that the Licensed Product supplied pursuant to this Section 8.2 shall (a) be manufactured in accordance with GMP and other Applicable Laws, and (b) conform with
the Specifications therefore in all material respects. 
 8.2.7 Nonconforming Licensed Product.  

(a) Acceptance and Rejection by Kyowa Kirin. Each shipment of Licensed Product shall contain such quality control certificates and
other documentation as are necessary to show that Licensed Product conforms to the Specifications in all material respects at the time of Delivery and were manufacturing in compliance with GMP and other Applicable Laws. In the event that Kyowa Kirin
determines within [***] days of Kyowa Kirin’s receipt of each shipment of Licensed Products that any such Licensed Product did not materially conform with the Specifications at the time of Delivery or otherwise comply with the product warranty
in Section 8.2.6 or the requirements of the order (such as matching the quantities ordered), Kyowa Kirin shall provide Notice to Reata thereof, and, if requested by Reata, ship a sample portion of the affected Licensed Products to Reata or its
designated Third Party manufacturing site, freight prepaid and properly insured, along with a reasonably detailed statement of the claimed non-conformity and copy of Reata’s invoice therefor. Kyowa Kirin shall retain the balance of the Licensed
Product that is subject to review subject to resolution of the rejection and further disposition in accordance with this Section. 

  
 37 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 (b) Replacement by Reata. In the event that Reata agrees that the returned Licensed
Product was non-conforming (or such non-conformance is confirmed under Section 8.2.7(c) below), Reata shall replace all of such non-conforming units of Licensed Product, at no cost to Kyowa Kirin, and Reata shall as soon as practicable deliver
to Kyowa Kirin, freight prepaid, all replacement units of Licensed Product, along with reimbursement of the shipment and insurance charges for return of the non-conforming Licensed Product. Kyowa Kirin shall dispose of all non-conforming Licensed
Product at its own expense, or return such non-conforming Licensed Product to Reata at Reata’s expense, as directed by Reata in its sole discretion. In the event that the quantities of Licensed Products delivered to Kyowa Kirin (in one or more
shipments) do not match the quantity ordered in any material respect, Kyowa Kirin may, at its option, (i) reject the entire shipment if Reata fails to correct such error within a reasonable period of time after its receipt of Notice of such
error, in which case it shall have no obligation to pay for it and, upon Reata’s request and at Reata’s sole expense, such shipment shall be returned to Reata, (ii) accept the entire shipment (and pay for the quantities shipped in
accordance with this Agreement) and, if (and only if) Kyowa Kirin so requests in the event of a shortfall in such shipment, Reata shall promptly ship (such shipping at Reata’s sole expense) the additional Licensed Products required to make up
such shortfall, or (iii) if the amount shipped exceeds the amount ordered by a material amount, accept only the amount ordered, in which case upon Reata’s request and at Reata’s sole expense, such additional quantities shall be
returned to Reata. 
 (c) Disputes Over Non-Conforming Licensed Product. In the event that Reata disagrees with Kyowa Kirin’s
rejection because the Licensed Products are in fact conforming, the Parties shall cooperate to have both Kyowa Kirin’s returned samples and Reata’s retained samples from the same production batch of Licensed Products in dispute analyzed by
a mutually acceptable independent testing laboratory of recognized reputation in the pharmaceutical industry, using the analytical methods, tests and criteria for conformance set forth in the Specifications. The out-of-pocket external costs of such
arrangement shall be shared equally by the Parties, unless and until an alternative determination is made as provided below. The results of such laboratory testing shall be conclusive and binding on the Parties on the issue of compliance of such
units of Licensed Product with the Specifications at the time of Delivery. If such independent testing laboratory determines that Kyowa Kirin’s returned samples of such Licensed Product conform to the Specifications, then (i) the
applicable Licensed Product shall be deemed to have been improperly rejected by Kyowa Kirin, and (ii) Kyowa Kirin shall bear the cost of the independent laboratory testing and, solely if Kyowa Kirin so requests the return shipment thereof, all
out-of-pocket external costs and expenses of returning the improperly rejected Licensed Product to Kyowa Kirin. If such independent testing laboratory determines that Kyowa Kirin’s returned samples of such Licensed Product did not conform to
the Specifications and that such returned samples conform to the samples for such batch retained by Reata, then Reata shall bear the cost of the laboratory testing, as well as the costs associated with properly-rejected Licensed Product described in
subsection 8.2.7(b) above. If such independent testing laboratory determines that Kyowa Kirin’s returned samples do not meet the Specifications but are different than the Reata retained samples, then additional samples shall be tested, or the
Parties will mutually establish alternative tests to determine if the Licensed Product delivered to Kyowa Kirin was conforming or not. 

  
 38 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 (d) Sole Remedy. The remedies expressly provided in this Section 8.2.7 shall be
Kyowa Kirin’s sole and exclusive remedy for the breach of Section 8.2.6 as a result of the delivery by Reata of non-conforming Licensed Product. 

(e) No Liability for Subsequent Events. In no event shall Reata be liable under this Section 8.2.7 for Licensed Product that
conformed to the Specifications at the time of Delivery but that ceased to so conform as a result of any event or occurrence, or any action or omission by Kyowa Kirin, its Affiliate or a Third Party, following Delivery of such License Product. 

8.2.8 Invoice and Payment. Reata shall invoice Kyowa Kirin for each shipment of Licensed Product upon shipment to Kyowa Kirin at a price
equal to the Manufacturing Costs of such Licensed Product. Kyowa Kirin shall pay each invoice within [***] days of the date of the invoice, unless rejected before such due date in accordance with Section 8.2.7 (in which case no payment shall be
due therefore unless and until conforming replacement products are delivered). 
 8.3 Commercial Supply of Licensed Product.
Subject to the terms and conditions of this Agreement, Kyowa Kirin and its Affiliates and Permitted Sublicensees shall purchase, and Reata shall supply Kyowa Kirin and its Affiliates and Permitted Sublicensees, with [***] quantities of Licensed
Product required for Kyowa Kirin’s and its Affiliates’ and Permitted Sublicensees’ marketing and sale (including post-approval studies) of Licensed Products in the Territory. Kyowa Kirin shall use Licensed Product supplied by Reata
under this provision solely to conduct its Commercialization activities, in accordance with the terms and conditions of this Agreement, and shall not use such Licensed Product for any other purpose. 

8.3.1 Commercial Supply Agreement. Prior to the Initiation of the final Phase III Clinical Trial for a Licensed Product in the
Territory, the Parties shall negotiate and execute a definitive commercial supply agreement (“Commercial Supply Agreement”) for the supply of Licensed Products to Kyowa Kirin and its Affiliates for marketing and sale (including
post-approval studies) of such Licensed Products in the Territory. Such Commercial Supply Agreement shall contain the terms and conditions set forth in this Section 8.3, terms and conditions consistent with those set forth in the remainder of
this ARTICLE VIII (except as provided otherwise in this Section 8.3) and other reasonable and customary terms and conditions. In the event the Parties fail to enter into such a commercial supply Agreement prior to the Initiation of the final
Phase III Clinical Trial for a Licensed Product in the Territory, and without diminishing the Parties’ obligation to enter into such agreement, Kyowa Kirin shall be obligated to purchase from Reata, and Reata shall be obligated to sell to Kyowa
Kirin, [***] of the requirements of Kyowa Kirin and its Affiliates and Permitted Sublicensees for Licensed Products pursuant to the terms of this ARTICLE VIII, and either Party may refer the matter for resolution as a Dispute under ARTICLE XVI so
that any unresolved issues in the negotiation of such a Commercial Supply Agreement can be determined with the end result being a binding Commercial Supply Agreement between the Parties. 

8.3.2 Commercial Supply Price. During the Term of this Agreement, Reata shall supply Licensed Product to Kyowa Kirin and its Affiliates
for use in marketing and sales (including post-approval studies) in the Territory at [***]. After the Term of this Agreement, the price for the Licensed Products shall be [***]. 

  
 39 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 8.3.3 Term. The term of Commercial Supply Agreement will be co-terminus with the Term
of this Agreement (plus any extensions as described below), unless the Parties mutually agree to extend the term to cover periods after this Agreement is terminated or expires. The Commercial Supply Agreement will provide that the term of that
agreement will be automatically extended on an annual basis after the end of the Term of this Agreement, unless either Party elects to terminate such Commercial Supply Agreement with at least [***] years advance notice (e.g., if either Party wants
the Commercial Supply Agreement to end at the end of the Term of this Agreement, such Party must notify the other Party at least [***] years prior to the end of such Term); provided that Reata’s obligation to supply Licensed Product thereunder
shall expire upon the earlier of the end of such [***]-year notice period or the date on which Kyowa Kirin has transitioned the manufacture of Licensed Products to a new facility or manufacturer. If Kyowa Kirin so requests within [***] days of any
such [***]-year notice of termination, Reata shall provide the manufacturing technology transfer and assistance described in Section 8.4.6(b) (except at Kyowa Kirin’s expense) so that Kyowa Kirin can continue to manufacture or have
manufactured Licensed Products. 
 8.3.4 Supply and Sales Forecasts. At least [***] months prior to the anticipated date of the First
Commercial Sale of Licensed Products in the Territory, Kyowa Kirin will provide Reata with a sales forecast which sets forth its projected monthly requirements for the supply of Licensed Products and the projected monthly sales (by quantity and
estimated Net Sales) of each Licensed Product in the Territory, in each case for the [***] month period commencing upon the anticipated date of the First Commercial Sale (and, with respect to supply requirements, for any portion of the pre-launch
period for which Licensed Products will be ordered and delivered to Kyowa Kirin). Thereafter, Kyowa Kirin will update and provide to Reata such supply requirements and sales forecast at least Calendar Quarterly (though Kyowa Kirin may update such
forecast as often as monthly) covering a rolling [***] month basis. The first [***] months of such forecast (solely with respect to forecasted amounts to be ordered and purchased from Reata) shall represent binding purchase commitments with the
latter months of such forecast being subject to variable degrees of adjustment before becoming binding, all as to be mutually agreed to by the Parties in the Commercial Supply Agreement. 

8.3.5 Equal Priority Status. To the extent the available supply of, or capacity to manufacture, Licensed Products is less than the
requirements of Kyowa Kirin and its Affiliates hereunder together with the requirements of Reata and its Affiliates and their licensees, Reata shall allocate the available Licensed Product [***]. 

8.3.6 Second Source Supply. The Commercial Supply Agreement shall contain arrangements for Reata to establish a second source supplier
for the Licensed Products as well as certain inventory buffers and other mechanisms to support security of supply. A portion of the costs of such arrangement incurred by Reata that is reasonably allocable to the proportion of Licensed Products made
for the Territory as compared to outside the Territory, shall be included in [***]. 

  
 40 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 8.4 General Manufacturing and Supply Provisions. 

8.4.1 Third Party Manufacturer. Kyowa Kirin hereby acknowledges and agrees that Reata shall be entitled, in its sole discretion, to
perform any or all of its obligations under this ARTICLE VIII by subcontracting any or all of such obligations to Third Party manufacturers (each, a “Third Party Manufacturer”) in any country. Any such subcontracting arrangement
shall be subject to the following: (a) such Third Party Manufacturer (excluding any Third Party Manufacturer already used by Reata as of the Effective Date) shall be subject to Kyowa Kirin’s prior approval, not to be unreasonably withheld;
(b) any use of a Third Party Manufacturer shall not limit Reata’s obligations hereunder and Reata shall remain fully liable to Kyowa Kirin for its obligations under this ARTICLE VIII and for all actions or omissions of any such Third Party
Manufacturer; (c) Reata shall enter into an agreement with such Third Party Manufacturer that is subject to and consistent with the terms and conditions of this Agreement, under which such Third Party Manufacturer agrees to be subject to the
applicable terms and conditions of this Agreement and which allows Reata to fully comply with its obligations hereunder, including by providing for any data, information or intellectual property generated by such Third Party Manufacturer with
respect to Licensed Products to be included within the rights and licenses granted to Kyowa Kirin hereunder, by requiring the applicable provisions of this ARTICLE VIII to apply to such Third Party Manufacturer (including Kyowa Kirin’s back-up
manufacturing rights and other provisions of this Section 8.4), and by imposing confidentiality restrictions at least to the extent provided for in ARTICLE XI. 

8.4.2 Inspections and Records. Upon Kyowa Kirin’s prior written notice, Reata shall, and shall cause its Third Party Manufacturer
to, during normal business hours, permit Kyowa Kirin or its designee to audit the facilities, systems and personnel involved in manufacturing Licensed Product supplied to Kyowa Kirin hereunder. Such audits shall occur a maximum of once per [***]
period; provided, however that Kyowa Kirin (or its designee) shall have the right to conduct additional audits on an ad hoc basis in the event that a significant defect in the Licensed Product arises and/or a Regulatory Authority requires an
audit to be conducted by Kyowa Kirin, provided that Kyowa Kirin uses commercially reasonable efforts to co-ordinate and align any such audit with any audit it undertakes pursuant to the preceding sentence. Reata shall consider in good faith any
guidance given by Kyowa Kirin based on such audit in respect of manufacture of Licensed Product for Kyowa Kirin hereunder, however Reata is not obligated to follow or adopt such guidance except to correct departures from GMPs or other failures to
comply with Applicable Laws. Reata shall (and shall cause its Third Party Manufacturers to) also permit Regulatory Authorities (and the FDA) to audit the facilities, systems and personnel involved in manufacturing Licensed Product supplied to Kyowa
Kirin hereunder and make any corrections or improvements, and take any actions, required as a result of such audit. Reata shall maintain (and shall cause its Third Party Manufacturers to maintain), all records and documents necessary to comply with
all Applicable Laws (including GMP) relating to the manufacture of Licensed Products (including all manufacturing records, standard operating procedures, equipment log books, batch records, laboratory notebooks and all raw data relating to the
manufacture of Licensed Product), which shall be retained for such period as may be required by Applicable Laws. 

  
 41 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 8.4.3 Audit of Manufacturing Costs. Reata shall prepare and maintain (for a period of
at least [***] years or such longer period as required by Applicable Laws) complete and accurate records in sufficient detail to permit the Kyowa Kirin to confirm the accuracy of the calculation of Manufacturing Cost under this Agreement. Upon
reasonable prior notice, such records for prior periods covering no more than the last [***] full calendar years shall be available during regular business hours for examination by Kyowa Kirin at Kyowa Kirin’s expense, and not more often than
[***], by an independent certified public accountant selected by Kyowa Kirin and reasonably acceptable to Reata, for the sole purpose of verifying the accuracy of the Manufacturing Cost and associated payments by Kyowa Kirin for any Licensed Product
supplied pursuant to this Agreement. Subject to Reata’s right to dispute such findings, any amounts shown to have been overpaid by Kyowa Kirin as a result of such audit shall be refunded by Reata to Kyowa Kirin within [***] days from the
accountant’s report, or, at Kyowa Kirin’s sole option in its discretion, shall be credited against future invoices to Kyowa Kirin for Licensed Product. Kyowa Kirin shall bear the full cost of such audit unless such audit discloses an
overpayment by Kyowa Kirin for Licensed Product during the applicable Calendar Year of more than [***] percent ([***]%), in which case Reata shall bear (and reimburse Kyowa Kirin for) the reasonable out-of-pocket cost of such independent accountant.

 8.4.4 Manufacturing Regulatory Filings. Reata shall assist Kyowa Kirin and its Affiliates in preparing (including by providing
required documentation, information and materials), the manufacturing portions of any Regulatory Filings or related documents in Territory as required for obtaining Regulatory Approvals for Licensed Products in the Territory. Kyowa Kirin shall
reimburse Reata’s external, out-of-pocket costs and expenses in connection with such preparation and assistance. 
 8.4.5 Quality
Agreement. Within [***] months following the Effective Date but in any event prior to [***], the Parties shall enter into a reasonable and customary GMP quality agreement with respect to Licensed Product to be manufactured by or for Reata and
supplied to Kyowa Kirin hereunder for use in development of the Licensed Product in the Territory. 
 8.4.6 Back-Up Manufacturing
Rights. 
 (a) Notification. Should Reata or any of its Third Party Manufacturers experience manufacturing difficulties
that, or have reason to believe that it is likely to experience difficulties that would, result in a significant delay in delivery of Licensed Products to Kyowa Kirin or make Reata otherwise unable to supply [***] Kyowa Kirin’s requirements in
a given Calendar Quarter, Reata shall promptly notify Kyowa Kirin of such delay or shortage and work together with Kyowa Kirin in good faith to develop a manufacturing difficulty resolution to minimize such delay or shortage and any impact thereof.

 (b) Kyowa Kirin Back-up Manufacturing Rights. In the event that Reata fails to supply [***] of Kyowa Kirin’s requirements of
Licensed Products up to the amounts forecast by Kyowa Kirin, and Reata’s failure is not cured within [***] days of its receipt of a Notice from Kyowa Kirin that it wants to exercise its rights under this Section to manufacture Licensed
Products, then upon Kyowa Kirin’s written request and direction, Reata shall (and shall 

  
 42 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
cause any of its Third Party Manufacturers) to reasonably cooperate with Kyowa Kirin and/or its designated manufacturers to transfer manufacturing of Licensed Products and provide information,
know-how, documentation and reasonable assistance as may be required for Kyowa Kirin and/or its designated manufacturer to manufacture Licensed Products for Kyowa Kirin’s requirements of Licensed Product for the Territory. If Kyowa Kirin
exercises such back-up manufacturing right (by written notice thereof), then promptly following Kyowa Kirin’s written request, Reata shall, subject to Applicable Laws, transfer to Kyowa Kirin or its designee such manufacturing technology
(including protocols, analytical methods, materials, and processes) that is necessary for Kyowa Kirin or its designee to replicate the process(es) employed by or on behalf of Reata (and its Third Party Manufacturers) to manufacture Licensed Product
to enable Kyowa Kirin or its designee ability to manufacture Licensed Product, and Reata shall, subject to Applicable Laws, provide reasonable consultation and process transfer and assistance to Kyowa Kirin in respect of such transfer. The costs
incurred by Reata in relation to the above activities will be borne by Reata. The foregoing provisions of this Section shall apply regardless of whether Reata itself is manufacturing Licensed Product or whether an Affiliate, licensee or Third Party
Manufacturer is manufacturing Licensed Product. Reata shall be responsible for ensuring that any such Affiliates or Third Parties take such actions as are required for Reata to comply with this Section. If circumstances so warrant (e.g.,
Reata’s failure to supply triggering the foregoing backup manufacturing rights is of a temporary nature and Reata has presented Kyowa Kirin with a reasonable plan to resume supplying Kyowa Kirin in a reasonable time so that Kyowa Kirin can
implement an interim, rather than permanent, back-up manufacture and supply arrangement, such as using a Third Party manufacturer who can easily switch back and forth from Kyowa Kirin to Reata as the primary contractor), Kyowa Kirin will not
unreasonably withhold its consent to transition manufacture and supply of Kyowa Kirin’s requirements for Licensed Products back to Reata when Reata is able to resume such responsibilities (provided, however, that Kyowa Kirin shall not be
required to transition back such manufacture and supply responsibilities if Kyowa Kirin has made a significant investment in manufacturing capacity for the Licensed Products in the absence of a reasonable and credible plan from Reata (at the time of
the initial transition of manufacturing to Kyowa Kirin) to resume manufacture and supply in a reasonable period of time). 
 8.5
Specifications. The JSC will work diligently to, as soon as is practical, finalize Specifications for the Licensed Product for the Territory (subject to the final approval of both Parties, not to be unreasonably withheld), which such
Specifications shall in any event shall be based on Reata’s current specifications for the Licensed Product and shall be consistent with Applicable Laws and the Development Plan and requirements for obtaining Commercialization Regulatory
Approval. The Specifications shall include methods of analysis required to confirm conformance of the Licensed Product as well as the minimum shelf life of the Licensed Product. 

8.5.1 Changes by Reata.  

(a) Subject to the conditions herein, Reata shall be entitled, at its sole cost, to change the Specifications and/or the manufacturing
processes for Licensed Products if such change is necessary to keep the specifications and/or manufacturing processes of all units of Licensed Product consistent or identical as between the Territory and countries outside of the

  
 43 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
Territory. Before making a decision to proceed with any such change in Specifications or any material change in manufacturing process for the Licensed Product (including the raw materials used to
make Licensed Products) and/or the active pharmaceutical ingredient form of the Licensed Compound (“API”) therein, regardless of whether before or after the First Commercial Sale, such change must first be discussed at the JSC to
enable a thorough assessment of its impact, including potential unexpected or unintended ramifications. 
 (b) If such change is ultimately
deemed necessary or advisable by Reata in its sole but reasonable discretion, Reata shall regardless of whether before or after the First Commercial Sale, give advance written Notice of implementation of such change to Kyowa Kirin with a lead time
reasonably sufficient for Kyowa Kirin to apply for, and obtain, required approval of such change from the Regulatory Authority. If after using Commercially Reasonable Efforts Kyowa Kirin is unable to obtain such approval from Regulatory Authorities
in any country in the Territory for such change, or if Kyowa Kirin declines to seek such approval in a given country in the Territory because such change would have a substantial adverse impact on the marketability or commercial viability of such
Licensed Product in such country in the Territory, Kyowa Kirin will provide written Notice thereof to Reata. 
 (c) If after [***] days from
receipt of such Notice Reata determines conclusively that it cannot continue to supply Licensed Product according to the Specifications and/or manufacturing processes in effect prior to such proposed change, Kyowa Kirin shall have the right to
obtain from a Third Party (or manufacture or have manufactured such Licensed Product in accordance with Section 8.4.6) Licensed Product only for the jurisdiction(s) in which Kyowa Kirin is unable to obtain (or so declines to obtain as provided
above) approval for modified Specifications and/or manufacturing processes from Regulatory Authorities. In such a case: (i) Reata shall continue to supply Licensed Product to Kyowa Kirin in accordance with the prior Specifications until Kyowa
Kirin (using Commercially Reasonable Efforts) is able to secure such supply of Licensed Products from its own, or such Third Party’s, manufacturing efforts; (ii) Reata shall supply Licensed Products to Kyowa Kirin under the new
Specifications for those countries in the Territory where Kyowa Kirin did obtain the required approvals (or where Kyowa Kirin did not need to obtain any approvals and did not decline to implement the new Specifications for the reasons described
above), and (iii) so that Kyowa Kirin can manufacture or have manufactured Licensed Products under the prior Specifications for the applicable countries in the Territory, Reata shall transfer its manufacturing-related Know-How to Kyowa Kirin or
a Third Party designated by Kyowa Kirin, at Kyowa Kirin’s expense and subject to the terms of this Agreement (and Reata shall provide the manufacturing technology transfer and assistance described in Section 8.4.6(b) in connection
therewith, except at Kyowa Kirin’s expense), with any such Third Party manufacturer subject to confidentiality restrictions at least as protective as those contained herein. Subject to the foregoing, Reata shall not be required to manufacture
or deliver to Kyowa Kirin any units of Licensed Product that do not conform to the Specifications, as modified by Reata and Kyowa Kirin’s rights to make or have made Licensed Products under this Section 8.5.1 shall be limited to Licensed
Products which conform (or which were intended to conform) in all material respects to (I) the Specifications as modified by Reata, (II) the Specifications as they existed prior to such modification, and/or (III) the Specifications as
subsequently modified by 

  
 44 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
Kyowa Kirin upon prior notice to Reata (in which case Kyowa Kirin shall reasonably consider providing Reata an opportunity to resume manufacture and supply of Licensed Products for the applicable
countries in the Territory in accordance with such newly modified Specifications if reasonable under the circumstances). 
 8.5.2 Change
Requests by Kyowa Kirin.  
 (a) At any time and from time to time during the Term, Kyowa Kirin may request changes to the
Specifications for one or more countries within the Territory based on the requirements of a Regulatory Authority in such country(ies) in the Territory or based on marketing requirements in such country(ies). Following receipt of such request, Reata
shall notify Kyowa Kirin whether such changes are technically feasible, commercially feasible and/or consistent with requirements of Regulatory Approvals in countries outside the Territory. If the changes, in Reata’s sole but reasonable
discretion, are technically and commercially feasible, Reata shall notify KHK thereof, provide good faith estimates for the complete implementation of the changed specifications, and change the Specifications accordingly for Licensed Products to be
sold in such country(ies) and the Specification Update Costs therefore shall be paid by Kyowa Kirin. In such event, the Specifications as revised may not be consistent with the Specifications of the Licensed Products sold outside the Territory or in
other country(ies) within the Territory for which no request for changes to the Specifications was made by Kyowa Kirin. 
 (b) If the change
is not technically and commercially feasible, Reata will provide written Notice thereof to Kyowa Kirin, and Kyowa Kirin shall have the right to obtain from a Third Party (or manufacture or have manufactured such Licensed Product in accordance with
Section 8.4.6) Licensed Product only for the jurisdiction(s) in which Kyowa Kirin requests updated Specifications based on the requirements of a Regulatory Authority or marketing requirements in the Territory. In such a case: (i) Reata
shall continue to supply Licensed Product to Kyowa Kirin in accordance with the prior Specifications for those countries in the Territory where Kyowa Kirin did not request changes to the Specifications, and (iii) so that Kyowa Kirin can
manufacture or have manufactured Licensed Products under the new changed Specifications for the applicable countries in the Territory, Reata shall transfer its manufacturing-related Know-How to Kyowa Kirin or a Third Party designated by Kyowa Kirin,
at Kyowa Kirin’s expense and subject to the terms of this Agreement (and Reata shall provide the manufacturing technology transfer and assistance described in Section 8.4.6(b) in connection therewith, except at Kyowa Kirin’s expense),
with any such Third Parry manufacturer subject to confidentiality restrictions at least as protective as those contained herein. Subject to the foregoing in Section 8.5.2(a), Reata shall not be required to manufacture or deliver to Kyowa Kirin
any units of Licensed Product that reflect the newly changed Specifications requested by Kyowa Kirin under this Section 8.5.2 and Kyowa Kirin’s rights to make or have made Licensed Products under this Section 8.5.2 shall be limited to
Licensed Products which conform (or which were intended to conform) in all material respects to (I) the Specifications as changed by Kyowa Kirin, (II) the Specifications as they existed prior to such modification, and/or (III) the
Specifications as subsequently modified by Kyowa Kirin upon prior notice to Reata (in which case Kyowa Kirin shall reasonably consider providing Reata an opportunity to resume manufacture and supply of Licensed Products for the applicable countries
in the Territory in accordance with such newly modified Specifications if reasonable under the circumstances). 

  
 45 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 ARTICLE IX 

RECORDS AND REPORTING 
 9.1
Reports.  
 9.1.1 In addition to the reports regarding Net Sales and Sale Royalties to be provided in accordance with
Section 7.3, Kyowa Kirin will provide reports to Reata within [***] during the Term summarizing Kyowa Kirin’s Commercialization activities under this Agreement [***], including a general description of any Clinical Development Activities,
Regulatory Activities, and Sales and Marketing Activities by Kyowa Kirin [***], and the date of the First Commercial Sale in a country (if applicable) , if such occurred [***]. 

9.1.2 Reata will provide reports to Kyowa Kirin within [***] during the Term summarizing development and commercialization activities with
respect to Licensed Products outside the Territory, including a general description of any clinical development activities, regulatory activities, and sales and marketing activities with respect to Licensed Products outside the Territory [***]. 

9.2 Royalty Records. Kyowa Kirin will keep and maintain, and shall cause its Permitted Sublicensees to maintain, complete and
accurate books and records necessary to permit calculation and verification of Sales Royalties due under Section 7.3. Kyowa Kirin will maintain such books and records for [***] years after the applicable book or record was created, or such
longer period as may be required by Applicable Law. 
 9.3 Audits.  

9.3.1 Upon not less than [***] days prior written Notice to Kyowa Kirin, Reata may have an independent certified public accountant selected by
Reata and reasonably acceptable to Kyowa Kirin, examine during regular business hours the books and records required to be maintained under Section 9.2 of Kyowa Kirin and its Permitted Sublicensees at Reata’s expense, [***], for the sole
purpose of verifying the accuracy of the Sales Milestone Events and Sales Royalties payable to Reata hereunder and the associated reports furnished by Kyowa Kirin with respect thereto solely for prior periods covering no more than the last [***]
full calendar years. Any amounts shown to be owed but unpaid as a result of such audit shall be paid within [***] days from the accountant’s report (plus interest on such amounts pursuant to Section 7.6), unless challenged as provided
below. Any amounts shown to have been overpaid shall be refunded to Kyowa Kirin within [***] days from the accountant’s report. Reata shall bear the full cost of such audit unless such audit discloses an underpayment of the amount of Sales
Royalties actually owed during the applicable Calendar Year of more than [***] percent ([***]%) or a Sales Milestone Event for which Kyowa Kirin failed to make the corresponding Sales Milestone Payment, in which case Kyowa Kirin shall bear the full
out-of-pocket, external cost of such audit. 

  
 46 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 9.3.2 If Kyowa Kirin challenges the results of the audit in good faith, Kyowa Kirin shall be
entitled at its own cost and expense to obtain a second independent certified public accountant to confirm the accuracy of the first audit. If the results of the confirmatory audit are substantially similar to the results of the first audit, any
amounts owed or overpaid by the Audited Party shall be paid or refunded in accordance with the procedures above. If the results of the confirmatory audit are not substantially similar to the results of the first audit, each Party shall cause its
respective auditors to identify the discrepancy and to agree on a final amount owed or overpaid (as the case may be) by Kyowa Kirin that shall be final and binding on the Parties. If the auditors cannot resolve the discrepancy, the Parties shall
mutually agree on a third independent certified public accountant (the cost of which shall be shared by the Parties) to audit the discrepancy and provide a final amount owed or overpaid (as the case may be) by Kyowa Kirin, which shall be binding on
the Parties. The costs of such third audit shall be shared equally by the Parties. Amounts owed or overpaid as determined by such final audit shall be paid or refunded in accordance with the procedures above. 

ARTICLE X 
 INTELLECTUAL
PROPERTY PROVISIONS 
 10.1 Patent Prosecution and Maintenance. Reata will have the option but not the obligation to
prepare, file, prosecute and maintain the Reata Patent Rights at Reata’s sole cost and expense. Reata will consider in good faith the requests and suggestions of Kyowa Kirin with respect to strategies for filing and prosecuting the Reata Patent
Rights in the Territory and will keep Kyowa Kirin informed of progress with regard to the preparation, filing, prosecution and maintenance of Reata Patent Rights, including by providing Kyowa Kirin with a copy of material communications to and from
any patent authority in the Territory regarding such Reata Patent Rights, and by providing Kyowa Kirin drafts of any material filings or responses to be made to such patent authorities in the Territory sufficiently in advance of submitting such
filings or responses so as to allow for a reasonable opportunity for Kyowa Kirin to review and comment thereon. In the event that Reata decides not to prepare, file, prosecute or maintain a Reata Patent Right in the Territory, Reata will provide
reasonable prior written Notice to Kyowa Kirin of such intention (which notice will, in any event, be given no later than [***] days prior to the next deadline for any action that may be taken with respect to such Reata Patent Right in the
Territory), and subject to the rights of Dartmouth under the Dartmouth License, Kyowa Kirin will thereupon have the option, in its sole discretion, to assume the control and direction of the preparation, filing, prosecution and maintenance of such
Reata Patent Rights in the Territory on Reata’s behalf, and the costs of such preparation, filing, prosecution and maintenance shall be the sole responsibility of Kyowa Kirin. In such event, Reata shall reasonably cooperate with Kyowa Kirin
with respect to the preparation, filing, prosecution and maintenance of such Reata Patent Rights in the Territory, and such Reata Patent Rights and all claims therein shall be excluded from Valid Claims hereunder for purposes of determining the
Royalty Term and Sales Royalties hereunder. 

  
 47 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 10.2 Ownership of Inventions.  

10.2.1 Reata will retain ownership of all Reata Inventions and Kyowa Kirin shall retain ownership of all Kyowa Kirin Inventions, except that
both Parties shall retain joint ownership of any Inventions that are conceived, made or generated jointly by both Parties. The Parties shall reasonably cooperate with respect to, and share the out-of-pocket external cost of, the preparation, filing,
prosecution and maintenance of any patents or patent applications on any such jointly-owned Inventions based on the Territory involved (i.e., Kyowa Kirin pays such costs for prosecution and maintenance in the Territory and Reata pays such costs for
prosecution and maintenance outside the Territory, and the Parties share equally any such costs that are not attributable to any particular territory). In connection with the foregoing, the Parties shall agree upon a lead Party to administer such
filing, prosecution and maintenance of any such patent applications or patents on jointly-owned Inventions and the Parties shall provide the non-lead Party a reasonably opportunity to review, comment on and approve (not to be unreasonably withheld)
in advance any material filings and correspondence with applicable patent offices with respect thereto. Subject to the licenses granted to each Party hereunder in their respective territories, each Party shall have full rights to exploit and license
such jointly-owned Inventions (and any patent rights therein), without any obligation or requirement of an accounting to the other Party and each Party hereby consents to such exploitation and licensing of the other Party for jointly-owned
Inventions. For the avoidance of doubt, all Reata Inventions (including Reata’s rights to any jointly-owned Inventions) shall be included within the Licensed Technology hereunder and licensed to Kyowa Kirin under Section 2.1. 

10.2.2 Subject to the terms and conditions of this Agreement, Kyowa Kirin hereby grants to Reata and its Affiliates a non-exclusive,
royalty-free, sublicenseable (except as provided below) license under the Kyowa Kirin Inventions (including Kyowa Kirin’s rights to any jointly-owned Inventions) to develop, use, sell, offer for sale, make, import, and export (and to have such
actions taken on its behalf by agents, contractors and other Third Party service providers) Licensed Compounds and Licensed Products for all indications and all fields solely outside the Territory. The foregoing license shall not be sublicenseable
by Reata (directly or indirectly) to any Third Party licensee or collaboration partner of Reata that does not grant to Reata a reciprocal license to such licensee’s and partner’s inventions and discoveries with respect to Licensed Products
which license is sublicenseable to Kyowa Kirin hereunder. 
 10.2.3 Each Party will cause all Persons who perform clinical development
activities or regulatory activities for such Party under this Agreement (or outside of this Agreement with respect to Reata’s development and regulatory activities for Licensed Products outside the Territory) to be under an obligation to assign
their rights in any inventions resulting therefrom to such Party, except where Applicable Law requires otherwise and except in the case of governmental, not-for-profit and public institutions which have standard policies against such an assignment
(in which case a suitable license, or right to obtain such a license, shall be obtained). 
 10.3 Disclosure. Each Party will
promptly disclose to the other Party, in writing, and will cause its Affiliates, agents, and independent contractors to so disclose to the other Party, any Inventions conceived, made or generated by such Party which are, in such Party’s
reasonable judgment, potentially patentable. 

  
 48 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 10.4 Cooperation. Each Party agrees to cooperate fully in the preparation,
filing, prosecution and maintenance of the Reata Patent Rights in the Territory under this Agreement and in the obtaining and maintenance of any patent extensions, supplementary protection certificates and the like with respect to the Reata Patent
Rights in the Territory. Such cooperation includes, but is not limited to: (i) executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as to effectuate the ownership of
Inventions set forth in Section 10.2, and Patents claiming or disclosing such Inventions, and to enable the other Party to apply for and to prosecute patent applications in any country, to the extent provided for in this Agreement;
(ii) consistent with this Agreement, assisting in any license registration processes with applicable governmental authorities that may be available in the Territory for the protection of a Party’s interests in this Agreement; and
(iii) promptly informing the other Party of any matters coming to such Party’s attention that may materially affect the preparation, filing, prosecution or maintenance of any such Reata Patent Rights in the Territory. Kyowa Kirin agrees to
provide support services, including technical translation and administrative support, for the preparation, filing, prosecution, and maintenance of the Reata Patent Rights in the Territory, with the out-of-pocket costs and expenses thereof to be
shared equally between the Parties. Kyowa Kirin also agrees to use reasonable efforts to promptly provide to Reata Notice and copies of (or citations to) any publications that Kyowa Kirin’s intellectual property personnel (and Kyowa
Kirin’s scientific and technical personnel working with such intellectual property personnel) involved in either the intellectual property diligence review conducted by Kyowa Kirin in anticipation of executing this Agreement, or involved in the
patent prosecution or enforcement related activities provided for in this Agreement, reasonably believe would constitute prior art required to be disclosed in any patent applications within the Reata Patent Rights (to the extent not already
disclosed therein) to the extent such personnel become reasonably aware of such publications and their relationship to the Reata Patent Rights. 

10.5 Enforcement of Reata Patent Rights against Infringement in the Territory. 

10.5.1 Initiation. Kyowa Kirin and Reata will each promptly notify the other in writing of any alleged or threatened infringement of the
Reata Patent Rights by a Third Party, or any alleged or threatened assertion of invalidity of any of the Reata Patent Rights by a Third Party, in all such cases in the Territory and of which such Party becomes aware (including infringement based on
the development, commercialization or an application to market a product containing a Licensed Compound in the Territory). Reata will have the first right, but not the obligation, to prosecute any such infringement at its own expense. Kyowa Kirin
shall have the right to join as a party to such suit to recover its damages and participate with its own counsel; provided that Reata shall retain control of the prosecution of such suit. If Reata does not commence an infringement action against the
alleged or threatened infringement (i) within ninety (90) days following the first notice provided above with respect to such alleged infringement, or (ii) provided such date occurs after the first such notice of infringement is
provided, ten (10) Business Days before the time limit, if any, set forth in appropriate laws and regulations for filing of such actions, whichever comes first, then, subject to Dartmouth’s rights under the Dartmouth Agreement, Kyowa Kirin
may commence litigation with respect to the alleged or threatened infringement at its own expense. Notwithstanding any of the foregoing to the contrary, to the extent the Dartmouth License or other Third Party license agreement entered into after
the Effective Date restricts or does not allow Kyowa Kirin to initiate an enforcement action in the Territory with respect to any patent within the 

  
 49 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
Reata Patent Rights licensed thereunder (whether by itself, on Reata’s behalf or otherwise), Reata agrees to take such reasonable actions (such as initiating or conducting such enforcement
action on Kyowa Kirin’s behalf and at Kyowa Kirin’s expense or obtaining consents or clarifications from the applicable licensor to effectuate such enforcement rights of Kyowa Kirin) as are required to afford Kyowa Kirin the benefits of
the foregoing enforcement rights to the maximum extent allowed for under such Dartmouth License and/or Third Party license agreement, in the event Kyowa Kirin elects to exercise such enforcement rights. Unless Kyowa Kirin declines to exercise its
enforcement rights above (and without limiting the foregoing sentence), Reata shall not waive or decline to exercise its enforcement rights under the Dartmouth License so as to allow the licensors under the Dartmouth License to settle and/or grant
licenses under the infringed Reata Patent Rights with and/or to an infringing Third Party in the Territory (in accordance with the provisions of the Dartmouth License). 

10.5.2 Cooperation. In the event a Party brings an infringement action pursuant to this Section 10.5, the other Party will
cooperate fully, including, if required to bring such action, the furnishing of a power of attorney solely for such purpose or to join or be named as a party such action as a necessary party. Neither Party will have the right to settle any patent
infringement litigation under this Section 10.5 in a manner that diminishes the rights or interest of the other Party , or in a manner that imposes any costs or liability on, or involves any admission by, the other Party without the express
written consent of such other Party, not to be unreasonably withheld. The Party commencing the litigation will provide the other Party with copies of all pleadings and other documents filed with the court (with Kyowa Kirin also providing, at no cost
to Reata, upon Reata’s request, English translations of all such material documents (or reasonable summaries thereof) if Kyowa Kirin is the Party commencing the litigation) and will consider reasonable input from the other Party during the
course of the proceedings. 
 10.5.3 Recovery. Subject to the relevant provisions of the Dartmouth License and except as otherwise
agreed by the Parties in connection with a cost sharing arrangement, any recovery realized as a result of such litigation described in Section 10.5.1 (whether by way of settlement or otherwise) will be (a) first, allocated to reimbursement
of unreimbursed legal fees and expenses incurred by the Party initiating the proceeding, then toward reimbursement of any of unreimbursed legal fees and expenses of the other Party reasonably incurred in connection with such proceeding,
(b) second, allocated to reimbursement of any monies due to Dartmouth College, if any, according to the relevant provisions of the Dartmouth License, and (c) third, the remainder will be divided between the Parties as follows:
(i) settlements, damages or other monetary awards recovered pursuant to a suit, action or proceeding brought by Reata will be [***], except that any quantities awarded to Reata on the basis of [***], will be [***] and will be allocated and paid
[***], less the [***] due thereon to Reata in accordance with [***]; and (ii) settlements, damages or other monetary awards recovered pursuant to a suit, action or proceeding brought by Kyowa Kirin, or awarded to Kyowa Kirin in connection with
its participation in any suit brought by Reata pursuant to this Agreement, will be [***] except that any quantities awarded to Kyowa Kirin on the basis of [***], or will be [***] and subject to the [***] obligations set forth in [***]. 

  
 50 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 10.6 Defense of Infringement Claims.  

10.6.1 If the manufacture, sale or use of a Licensed Product pursuant to this Agreement results in, or may result in, any claim, suit, or
proceeding by a Third Party alleging patent infringement by Kyowa Kirin (or its Affiliates), Kyowa Kirin will promptly notify Reata thereof in writing. Subject to the provisions of Section 10.6.2, Kyowa Kirin will have the first right, but not
the obligation to defend and control the defense of any such claim, suit or proceeding at its own expense, using counsel of its own choice. Reata may participate in any such claim, suit or proceeding with counsel of its choice at its own expense. If
Kyowa Kirin elects (in a written communication submitted to Reata within a reasonable amount of time after notice of the alleged patent infringement) not to defend or control the defense of, or otherwise fails to initiate and maintain the defense
of, any such claim, suit or proceeding, within such time periods so that Reata is not prejudiced by any delays, Reata may conduct and control the defense of any such claim, suit or proceeding at its own expense. Each Party will keep the other Party
reasonably informed of all material developments in connection with any such claim, suit, or proceeding. Each Party agrees to provide the other Party with copies of all pleadings filed in such action and to allow the other Party reasonable
opportunity to participate in the defense of the claims. If Kyowa Kirin is controlling the defense of any such claim, suit or proceeding, it agrees to provide English translations, or summaries thereof, of all pleadings, discovery-requests, and key
documents filed with the court reasonably promptly. Kyowa Kirin shall be entitled to deduct [***] percent ([***]%) of the out-of-pocket costs of defending such claim, suit or proceeding from the Sales Royalties due to Reata pursuant to
Section 7.3 of this Agreement; provided that such deductions (together with the reductions under Section 7.4.2 if applicable) shall in no event exceed either [***]% cap set forth in Section 7.4.2, and if any such costs cannot be
applied (due to such cap or the absence of Sales Royalties in the applicable period) such unapplied amounts shall accrue and be used to reduce Sales Royalties in future periods subject to the same overall cap until all such costs are applied against
the Sales Royalties. Any recoveries by Kyowa Kirin of attorneys fees or cost in defense of a claim under this Section 10.6, and any sanctions awarded to Kyowa Kirin and against a party asserting a claim being defended under this
Section 10.6, shall be divided evenly between the parties. 
 10.6.2 In addition to the Kyowa Kirin obligations set out in the preceding
paragraph, and regardless of whether Reata elects to participate as a Party in the claim, suit or proceeding, Kyowa Kirin further agrees that, in the event the claim, suit or preceding under 10.6.1 is brought by a Third Party that is pursuing or has
threatened in writing to the knowledge of Kyowa Kirin to pursue similar claims outside the Territory against Reata, its Affiliates, agents or marketing or development partners and such claim is related to any Licensed Compound or member of the RTA
402 Class, including any form or formulation thereof, Kyowa Kirin shall: (i) provide to Reata English translation drafts of all official papers or other statements (whether written or oral) prior to their submission to the court in the lawsuit,
in sufficient time to allow Reata to review, consider and substantively comment thereon; (ii) reasonably consider taking action to incorporate Reata comments on all such official papers and statements, (iii) not take positions in its
defense that are inconsistent or at odds with positions that Reata is taking in defense, or anticipated defense, of related claims outside the Territory, to the extent such positions 

  
 51 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
have been communicated to Kyowa Kirin; (iv) allow Reata the opportunity to participate in preparation of witnesses or other participants in the claim, suit or proceeding; (v) not settle
any such claim, suit or proceeding without Reata’s prior consent, which consent shall not be unreasonably withheld or delayed, and (vi) enter into a reasonable and customary joint defense agreement with Reata, upon request to do so by
Reata. 
 ARTICLE XI 

CONFIDENTIALITY, PUBLICATION AND PUBLICITY 

11.1 Confidentiality. All Confidential Information disclosed by or on behalf of one Party to the other Party hereunder will be
maintained in confidence by the receiving Party and will not be disclosed to a Third Party or used for any purpose other than for purposes of exercising a Party’s rights or performing a Party’s obligations hereunder pursuant to the terms
of this Agreement, except as follows: 
 11.1.1 If a Party reasonably believes that the Confidential Information is required to be disclosed
to governmental or other regulatory agencies in order to obtain patents, to obtain approval to conduct clinical trials or to market Licensed Product (or to otherwise perform a Party’s obligations hereunder), or to comply with applicable NASDAQ,
Securities Exchange or Securities and Exchange Commission regulations (or the regulations of counterpart agencies within the Territory), then such disclosure may be made only to the extent reasonably necessary to obtain patents or approval, to
perform such Party’s obligations or to comply with regulations as appropriate, and such receiving Party seeks confidential treatment to the extent reasonably practicable; 

11.1.2 If a Party reasonably believes it is necessary or useful to be disclosed to employees, agents, consultants, Affiliates and/or other
Third Parties for the purpose of conducting activities permitted or required under this Agreement in accordance with this Agreement, Confidential Information may be disclosed to such employees, agents, consultants, Affiliates and/or other Third
Parties only to the extent necessary, and only if such Persons agree to be bound by confidentiality obligations at least as protective of such Confidential Information as the terms herein; 

11.1.3 If a Party reasonably believes Confidential Information is necessary to be disclosed to actual or prospective investors, lenders, real
estate or equipment lessors or acquirers or other potential or current financing sources of a Party (collectively “Financing Sources”), such Confidential Information may be disclosed to such Financing Sources provided that the
Financing Sources agree to be bound by confidentiality obligations at least as protective of such Confidential Information as the terms herein; or 

11.1.4 If a Party reasonably believes that Confidential Information is required to be disclosed by law or court order, then provided that, to
the extent reasonably practicable, Notice of such disclosure is promptly delivered to the disclosing Party in order to provide an opportunity to challenge or limit the disclosure obligations, and provided further that the receiving Party works in
good faith with the disclosing Party to seek confidential treatment of such disclosure and to disclose only to the extent reasonably necessary to comply with the applicable law or court order, such Confidential Information may be disclosed to the
extent legally required. 

  
 52 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 11.2 Disclosure of this Agreement. Neither Party will release to any Third
Party or publish in any way any non-public information regarding the terms and conditions of this Agreement without the prior written consent of the other Party, which consent will not be unreasonably withheld, conditioned or delayed, except for the
disclosure to Financing Sources who are subject to a signed confidentiality agreement, and except pursuant to Section 11.4 and except to the extent required to comply with Applicable Laws. 

11.3 Disclosure of RTA 402 Class License. Notwithstanding anything in this Agreement to the contrary, Reata shall have the right
to fully disclose to any third party the terms of the rights granted herein as to the RTA 402 Class, including Sections 2.2, 4.6, 13.9, and definitions related to those sections. 

11.4 Publications.  

11.4.1 Peer Reviewed Journal Submissions. Both Parties will submit any proposed publication or presentation containing material
information regarding clinical or non-clinical trial results for, or similar information regarding, the safety or efficacy of, the Licensed Products (a “Publication”) to the other Party at least thirty (30) days prior to
submitting it to any Third Party (including any editing Person) for publication in a peer reviewed journal. For the avoidance of doubt, Publications exclude marketing materials. 

11.4.1.1 The other Party will have twenty (20) days after receipt of the draft Publication to review and comment on such draft. 

11.4.1.2 Upon Notice within such twenty (20) day period by the other Party that it reasonably believes the Publication would amount to
the public disclosure of such other Party’s Confidential Information and/or negatively impact such other Party’s intellectual property position, submission of the concerned Publication to Third Parties will be delayed for a sixty
(60) day period from the date of said Notice for appropriately deleting Confidential Information from the proposed Publication or drafting and filing a patent application with respect to any subject matter to be made public in such Publication.
Notwithstanding the foregoing, neither Party shall be restricted hereunder from making any publication or disclosure to extent required to comply with Applicable Law. 

11.4.2 Other Publications. For all other Publications, including but not limited to poster presentations, abstract submissions, investor
presentations and the like, both Parties will submit such proposed Publications at least ten (10) Business Days prior to submitting it to any Third Party (including any editing Person) for publication or disclosure. For the avoidance of doubt,
Publications exclude marketing materials. 
 11.4.2.1 The other Party will have five (5) Business Days after receipt of the draft
Publication to review and comment on such draft. 

  
 53 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 11.4.2.2 Upon Notice within such five (5) Business Day period by the other Party that
it reasonably believes the Publication would amount to the public disclosure of such other Party’s Confidential Information and/or negatively impact such other Party’s intellectual property position, submission of the concerned Publication
to Third Parties will be delayed for a sixty (60) day period from the date of said Notice for appropriately deleting Confidential Information from the proposed Publication or drafting and filing a patent application with respect to any subject
matter to be made public in such Publication. Notwithstanding the foregoing, neither Party shall be restricted hereunder from making any publication or disclosure to extent required to comply with Applicable Law. 

11.4.3 For all proposed Publications, each Party will cooperate in good faith with the other Party to achieve the business objectives of the
proposed Publication and the publishing Party will in good faith take into account reasonable comments from the other Party. 
 11.5
Publicity. Reata and Kyowa Kirin will issue a press release in a form mutually agreed to by the Parties within thirty (30) days of the execution of this Agreement. Any other publication, news release or other public announcement
regarding this Agreement or the terms hereof that either Party wishes to release will first be provided to the other Party for review at least seven (7) days in advance, and the submitting Party will in good faith take into account reasonable
comments from the other Party. Notwithstanding any other provision of this Agreement, (a) each Party will have the right, without consent of the other Party, to make disclosures regarding any matter related to this Agreement that such Party
reasonably believes is required to comply with Applicable Law, and (b) the requirement that a publication, news release or other public announcement be provided to the other Party for review seven (7) days in advance will not apply if such
Party reasonably believes that regulatory requirements require the issuance thereof sooner than seven (7) days and such Party is unable to contact the other Party in the required time, provided that such disclosure may only be made to the
extent reasonably necessary to comply with Applicable Law as appropriate. 
 11.6 Employees and Consultants. Each Party hereby
agrees and covenants that all of its employees and consultants and all of the employees and consultants of its Affiliates who participate in any activities under the this Agreement or have access to any Confidential Information are or will, prior to
their participation or access, be bound by written obligations to maintain such Confidential Information in confidence and not to use or transfer such information or materials except as expressly permitted hereunder. Each Party agrees to use, and to
cause its Affiliates to use, reasonable commercial efforts to enforce such obligations. 
 ARTICLE XII 

REPRESENTATIONS AND WARRANTIES 

12.1 Mutual Representations and Warranties. Each Party hereby represents and warrants to the other Party that as of the
Effective Date: 

  
 54 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 12.1.1 Corporate Existence and Power. It is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction in which it is incorporated, and has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being
conducted and as contemplated in this Agreement, including the right to grant the licenses granted hereunder. 
 12.1.2 Authority and
Binding Agreement. (a)It has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; (b) it has taken all necessary corporate action on its part required to authorize the
execution and delivery of this Agreement and the performance of its obligations hereunder; and (c) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party
that is enforceable against it in accordance with its terms. 
 12.1.3 No Conflict. It has not entered into any agreement with any
Third Party that is in conflict with the rights granted to the other Party under this Agreement, and has not taken any action that would in any way prevent it from granting the rights granted to the other Party under this Agreement, or that would
otherwise materially conflict with or adversely affect the rights granted to the other Party under this Agreement. Its performance and execution of this Agreement will not result in a breach of any other contract to which it is a Party. 

12.1.4 No Litigation. It is aware of no action, suit, inquiry or investigation instituted by any Third Party which questions or
threatens the validity or enforceability of this Agreement. 
 12.1.5 Consents. All necessary consents, approvals and authorizations
of all governmental authorities and other persons or entities required to be obtained by such Party in connection with the execution and delivery of this Agreement have been obtained. 

12.2 Kyowa Kirin’s Representations and Warranties. Kyowa Kirin hereby represents and warrants to Reata that as of the
Effective Date Kyowa Kirin has no Knowledge of any pending filing, complaint, matter or action against or involving either Kyowa Kirin or its Affiliates with any Regulatory Authority that could be reasonably anticipated to have a material adverse
effect on its ability to obtain Regulatory Approvals for the Licensed Products in any country or region of the Territory. 
 12.3
Reata’s Representations and Warranties. Reata hereby represents and warrants to Kyowa Kirin as of the Effective Date: 

12.3.1 Reata Patent Rights; Licensed Technology. Reata owns, or has an exclusive license to, the Reata Patent Rights listed on
Exhibit A, and Exhibit A is a complete list of all patents and patent applications owned or Controlled by Reata as of the Effective Date which claim or cover Licensed Compounds, or the manufacture or use thereof in the Territory. Reata
does not own and has not licensed any intellectual property that in each case would otherwise qualify as Licensed Technology hereunder but for the fact that such intellectual property is not licensable to Kyowa Kirin hereunder and therefore not
Controlled by Reata (i.e., due solely to such lack of Control despite owning or holding a license thereto, does not meet the definition of Licensed Technology). 

  
 55 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 12.3.2 Title; Encumbrances. Reata has sufficient legal and/or beneficial title,
ownership or license, free and clear from any mortgages, pledges, liens, security interests, conditional and installment sale agreements, encumbrances, charges or claims of any kind, of the Licensed Technology to grant the licenses to Kyowa Kirin as
purported to be granted pursuant to this Agreement. 
 12.3.3 No Conflict. Reata has not granted any assignment, license, covenant not
to sue, or other similar interest or benefit, exclusive or otherwise, to any Third Party relating to any patent, know-how or other proprietary right that conflicts with or limits the rights granted to Kyowa Kirin hereunder or which falls within the
scope of the licenses granted in ARTICLE II. 
 12.3.4 Non-Infringement of Reata Technology by Third Parties. To its Knowledge, Reata
is not aware of any activities by Third Parties that would constitute infringement or misappropriation of the Licensed Technology within the Territory. 

12.3.5 Non-Infringement of Third Party Rights. To Reata’s actual knowledge, the development, manufacture, use and sale of RTA402 in
the Field in the Territory does not actually infringe any existing patent of a Third Party, or misappropriate any trade secrets of a Third Party, however, Reata makes no representations or warranties with respect to patents or other information that
was disclosed to Kyowa Kirin by Reata in connection with Kyowa Kirin’s due diligence review of RTA 402. 
 12.3.6 No Claims of Third
Party Rights. Reata has not received any written notice, claim or demand from any person or entity (a) asserting that the research, development, manufacture, use and sale of any Licensed Product infringes a Third Party patent or
misappropriates any trade secrets of a Third Party, or (b) challenging the validity, enforceability or ownership of any patents issued from the Reata Patent Rights 

12.3.7 No Action or Claim. To Reata’s Knowledge, there are no actual, pending, alleged or threatened adverse actions, suits,
claims, interferences or formal governmental investigations involving the Licensed Product, Licensed Compounds and/or the Licensed Technology by or against Reata, any of its Affiliates, distributors, licensees or contractors in or before any court,
governmental entity or Regulatory Authority. In particular, to Reata’s Knowledge, there is no pending or threatened product liability action involving the Licensed Product. 

12.3.8 Compliance. To Reata’s Knowledge, Reata, its Affiliates, distributors, licensees and contractors have performed in all
material respects development work, including manufacturing, supply, packaging, and distribution of clinical supplies, in compliance with all Applicable Laws (including GMP); and there is no actual, pending, alleged or threatened adverse action of
any Regulatory Authority or IRB, with respect to the Licensed Products, the Licensed Compounds, the Licensed Technology and/or any development work. 

  
 56 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 12.3.9 Regulatory Materials. To Reata’s Knowledge, no Regulatory Authority has
commenced or threatened to initiate any action or proceeding to refuse to file, reject, not approve, or withdraw any regulatory filings related to Licensed Compounds and/or Licensed Products, nor has Reata received any notice to such effect; and to
Reata’s Knowledge, Reata is not in violation of any Applicable Laws that could reasonably be expected to form the basis for such an action. 

12.3.10 Third Party Agreements. Exhibit B contains a complete list of all agreements under which rights to a Licensed Technology
are granted, licensed or otherwise provided to Reata or its Affiliates as of the Effective Date (the “In-License Agreements”). All In-License Agreements and all other manufacturing, clinical trial and service agreements of Reata and
its Affiliates relating to the Licensed Technology or Licensed Products are in full force and effect and no material breach has occurred thereunder (and Reata and its Affiliates, licensees and contractors have not received any notice of any such
breach thereunder). 
 12.3.11 Licenses to Additional Dartmouth Patents. All patents and patent applications which (a) claim or,
but for the licenses granted in this Agreement would be infringed by, Licensed Products or RTA 402, (b) are owned by Dartmouth College and/or University of Texas M.D. Anderson Cancer Center as of the Effective Date, and (c) were invented,
generated or created under any agreements with Reata or otherwise subject to options or rights to license under such agreements (including [***] and corresponding PCT), have been exclusively licensed to Reata as of the Effective Date and are subject
to the licenses granted to Kyowa Kirin hereunder. 
 12.3.12 License Compound Data. Reata has made available to Kyowa Kirin all
material clinical and pre-clinical data and regulatory filings with respect to RTA 402 in Reata’s possession which data and filings Reata has provided, or is obligated to provide, to the FDA. 

12.4 Limitation on Warranties; No Implied Warranties. EXCEPT AS EXPRESSLY PROVIDED IN THIS AGREEMENT, EACH PARTY MAKES NO AND
EXPRESSLY DISCLAIMS ALL OTHER REPRESENTATIONS AND WARRANTIES WITH RESPECT TO LICENSED PRODUCT, THE LICENSED TECHNOLOGY, THE REATA PATENT RIGHTS OR ANY OTHER SUBJECT MATTER OF THIS AGREEMENT, WHETHER EXPRESS, IMPLIED, OR STATUTORY, INCLUDING
WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OR NON-MISAPPROPRIATION OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS. EXCEPT TO THE EXTENT EXPRESSLY PROVIDED FOR HEREIN, NOTHING IN THIS AGREEMENT WILL BE CONSTRUED AS
A REPRESENTATION OR WARRANTY BY REATA THAT THE REATA PATENT RIGHTS OR THE LICENSED TECHNOLOGY IS NOT INFRINGED BY ANY THIRD PARTY OR THAT THE PRACTICE OF SUCH RIGHTS DOES NOT INFRINGE ANY PUBLISHED INTELLECTUAL PROPERTY RIGHTS OF ANY THIRD PARTY.

  
 57 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 ARTICLE XIII 

OTHER COVENANTS AND AGREEMENTS 

13.1 Compliance with Law.  

13.1.1 Kyowa Kirin will comply with all Applicable Laws related to its Commercialization of the Licensed Products. Without limiting the
generality of the foregoing, Kyowa Kirin will not promote any of the Licensed Products in a manner that would conflict with Applicable Law. 

13.1.2 Kyowa Kirin will conduct all Medical Affairs Activities in a manner consistent with Licensed Product labeling, including all package
inserts for Licensed Product, except to the extent otherwise required by Applicable Law, and will conduct all Medical Affairs Activities in accordance with Applicable Law. 

13.1.3 Reata will comply with all Applicable Laws related to its development (including clinical and non-clinical studies), regulatory
activities, marketing and sale of the Licensed Products. Without limiting the generality of the foregoing, Reata will not promote any of the Licensed Products outside the Territory in a manner that would conflict with Applicable Law. 

13.2 Maintenance of Current License Agreements; No Inconsistent Rights. For the Term of this Agreement, Reata shall maintain its
rights, and comply with its obligations, under any license agreements under which it receives rights or licenses to any of the Reata Patent Rights or other Licensed Technology that exist as of the Effective Date (including the Dartmouth License),
including the payment of any fees or royalties due thereunder. Reata shall not terminate, modify or amend any such agreements, or any In-License Agreement, in a manner that would reduce, limit or restrict the rights and licenses granted to Kyowa
Kirin hereunder (or in a manner that would increase any obligations of Kyowa Kirin hereunder). Reata shall promptly notify Kyowa Kirin regarding any notices of breach or termination received by Reata with respect to any license agreements under
which Reata receives rights or licenses to any of the Reata Patent Rights or other Licensed Technology and shall reasonably consult with Kyowa Kirin with respect thereto. Without limiting the foregoing, if the Dartmouth License is terminated for any
reason, Reata shall promptly notify Kyowa Kirin thereof and shall facilitate Kyowa Kirin becoming a successor to Reata under such Dartmouth License (in accordance with the terms and conditions thereof) if Kyowa Kirin so requests, provided that Kyowa
Kirin, in its sole discretion consents in writing to be bound by all the terms and conditions of the Dartmouth License in the event of such termination. Reata covenants to Kyowa Kirin that, during the Term, it shall not grant a lien or other
encumbrances on any of the subject matter of this Agreement or on any of Reata’s rights, benefits, or obligations hereunder or on any of the Licensed Technology, which would conflict with the rights or licenses granted to Kyowa Kirin under this
Agreement. 
 13.3 Reata Restrictive Covenants. During the Term, Reata agrees that (a) it will not knowingly sell,
market, develop or distribute any Licensed Product in the Territory for use in the Field (or, except as otherwise provided in Section 13.5, for use outside the Field) nor license or authorize any Affiliates or Third Parties to do so;
(b) it will not appoint any Person, other than 

  
 58 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
Kyowa Kirin, as a licensee of Licensed Product in the Territory for use in the Field (or, except as otherwise provided in Section 13.5, for use outside the Field) during the Term;
(c) it will not provide any Licensed Product to any Third Party or Affiliate if Reata has actual Knowledge or reasonably believes that such Third Party or Affiliate, either directly or indirectly, is selling, or intends to sell such Licensed
Product inside the Territory; and (d) except as otherwise provided in Section 13.5, it will not develop any Licensed Product for indications outside the Field for sale in the Territory. 

13.4 Kyowa Kirin Covenants. Kyowa Kirin agrees it will Commercialize the Licensed Products solely within the Territory for use
in the Field pursuant to the authority, rights and licenses granted to Kyowa Kirin under this Agreement. Kyowa Kirin agrees and acknowledges that it has not been granted any rights to any Licensed Technology or Licensed Products under this Agreement
outside of the Territory (except for limited right to manufacture or have manufactured Licensed Products outside the Territory in certain circumstances solely for use or sale of such Licensed Products within the Territory as provided for herein),
and consequently Kyowa Kirin agrees that (except for such aforementioned limited manufacturing rights) during the Term it will not (a) Commercialize any Licensed Product outside of the Territory or within the Territory for sale by or for Kyowa
Kirin outside of the Territory, (b) provide any Licensed Product to any Third Party or Affiliate if Kyowa Kirin has actual Knowledge or reasonably believes that such Third Party or Affiliate, either directly or indirectly, is selling, or
intends to sell such Licensed Product outside the Territory; and (c) it will not Commercialize any Licensed Product in a manner intentionally directed for use of such Licensed Product outside the Field for sale anywhere in the world. 

13.5 Coordination of Uses Outside the Field.  

13.5.1 If either Party has an interest in developing any Licensed Product within the Territory for any indications outside the Field, then it
will promptly provide written Notice to the other Party describing in reasonable detail the indication(s) outside the Field for which it is interested and other relevant information that is available. If the other Party is interested in pursuing the
mutual development of Licensed Products for such additional indication(s), then the Parties will engage in good faith, exclusive negotiations related to such mutual development for such indication(s) within the Territory. Neither Party will be under
any obligation to reach an agreement on such mutual development. If the Parties fail to reach a mutual agreement for such development of Licensed Product for such additional indication(s) for sale within the Territory, then neither Party will have
the right to (and both Parties shall not) pursue the use, development or sale of the Licensed Products for such other indication(s) (or any other indication(s) outside the Field) in the Territory (whether by themselves or through Affiliates or Third
Parties) or license or authorize Third Parties to do so, except as provided in Section 13.5.2. 
 13.5.2 If Reata or its Affiliates or
licensees elects to initiate human clinical trials for Licensed Products for any indication(s) outside the Field outside the Territory, Reata shall notify Kyowa Kirin thereof and, at Kyowa Kirin’s option in its sole discretion, Kyowa Kirin may
elect enter into good faith negotiations with Reata to add such indication(s) to the Indications hereunder. If Kyowa Kirin so elects, each Party will negotiate in good faith regarding such 

  
 59 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
additional consideration for such new indications (including new regulatory and sales milestone payments and royalties applicable to the new indications), but otherwise the terms and conditions
of this Agreement will govern such new indications if added hereto through a mutually agreeable amendment. 
 13.5.3 Reata shall keep Kyowa
Kirin reasonably informed through the JSC of material developments with respect to any pre-clinical development or plans for clinical development of Licensed Products for indications outside the Field outside the Territory. 

13.6 Marketing Rights Outside of the Territory.  

13.6.1 Rights of Notice and Negotiation. If Reata has an interest in licensing to any Third Party any rights to sell, market or
distribute any Licensed Product outside of the Territory for use in the Field, then it will promptly provide written Notice to Kyowa Kirin describing the countries for which it is interested for such sales and marketing activities. [***]. If Reata
receives an offer (which would include sending or responding to a term sheet or draft agreement) from a Third Party regarding any sales or marketing rights for Licensed Products outside the Territory, whether solicited or unsolicited, then Reata
will inform Kyowa Kirin of its receipt of such offer (but will not be obligated to advise Kyowa Kirin of any of the terms or conditions of such offer), and will advise Kyowa Kirin of Reata’s anticipated timing of its consideration of such
offer. Prior to entering into any license or similar agreement granting a Third Party rights (including an option, right of first refusal or similar right) to sell, market or distribute Licensed Products outside of the Territory for use in the
Field, [***]. 
 13.6.2 Consistency with this Agreement. In any event, if development and/or marketing, sales or other
commercialization of Licensed Products in the Field outside the Territory is conducted by an Affiliate or licensee (or other collaboration partner) of Reata rather than Reata itself, Reata shall ensure that such arrangement is done in a manner that
is consistent with this Agreement and in a manner that allows Reata to fully comply with its obligations hereunder. Reata will not be obligated to provide such licensee’s marketing or commercialization plan or other confidential information
(except for any information expressly required to be shared under this Agreement) to Kyowa Kirin, and similarly, Reata will not provide Kyowa Kirin’s marketing or commercialization plan or other confidential information (except for any
information expressly required to be shared under this Agreement) to such licensee. Further, in accordance with Section 10.2.2 herein, Reata shall not provide (directly or indirectly) to any Third Party licensee or collaboration partner outside
of the Territory, a sublicense to any Kyowa Kirin Invention, unless that Third Party licensee or collaboration partner grants to Reata a reciprocal license to such licensee’s and partner’s inventions and discoveries with respect to
Licensed Products which license is sublicenseable to Kyowa Kirin hereunder. For the avoidance of doubt, any non-clinical and clinical data and regulatory filings with respect to Licensed Products shall be made available (and as applicable, licensed)
to Kyowa Kirin hereunder (under the terms and conditions of this Agreement) to the same extent as if directly made or generated by Reata. 

  
 60 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 13.7 Third Party Licenses. In the event that either Party believes, in its
reasonable discretion, that it is required to obtain a license from a Third Party under such Third Party’s patent(s) in order to manufacture, use, or sell Licensed Products for the Territory during the Term without infringing such patent(s),
such Party shall notify the other Party and the Parties shall discuss the same in good faith. If Reata decides to obtain such license, Kyowa Kirin may elect (in its sole discretion) to take a sublicense thereto (if available to be negotiated) or to
exclude such sublicense from the license granted hereunder (at any time). If Kyowa Kirin elects to take such a sublicense, unless and until subsequently disclaiming such sublicense hereunder by written notice to Reata, Kyowa Kirin will reimburse
Reata [***]% of all payments made by Reata under such license to the extent such payments are directly attributable or reasonably allocable to the Territory, including royalties on sales in the Territory and an allocable portion of licensee fees and
milestone payments (proportional to the size of the market in the Territory as compared to the size of the market outside the Territory), and all such reimbursement amounts shall be subject to the reduction of Sales Royalties under
Section 7.4.2 (as described more fully below); provided that Reata shall not negotiate financial terms that are disproportionately allocated to the Territory in an unreasonable manner. For purposes of applying the foregoing to the reduction of
Sales Royalties under Section 7.4.2, all such reimbursement amounts paid to Reata shall be treated as Third Party royalties under Section 7.4.2, and, to the extent such amounts are not applied to a reduction of Sales Royalties due to the
absence of Sales Royalties at the time of such reimbursement payments to Reata or due to the [***]% cap in Section 7.4.2, any such unapplied amounts shall accrue and be used to reduce Sales Royalties in future periods until all such
reimbursement amounts paid to Reata are applied to reduce Sales Royalties under Section 7.4.2. Reata will keep Kyowa Kirin reasonably informed of all material developments regarding negotiations with, and payments to, Third Parties regarding
such reimbursable payments (and Reata shall provide Kyowa Kirin with at least one draft of any such agreements for review and comment prior to execution thereof, as well as a copy of the executed version of any such agreements, which copies may be
redacted to remove commercial terms not relevant to the calculation of such offset, the scope of the license granted thereby or the terms and conditions applicable to sublicensees). All material matters relating to such Third Party reimbursable
payments and calculations will be discussed in good faith between the Parties. Nothing herein shall restrict Kyowa Kirin from seeking, negotiating or obtaining any license from any Third Party; however, if Kyowa Kirin obtains a license to Third
Party patents related to the Licensed Product without first following the procedures of this Section 13.7 (it being understood that if Reata does not obtain a sublicenseable license to such patents within [***] days of the first notice thereof,
Kyowa Kirin’s subsequent entering into of a license thereto shall be deemed to be following the procedures of this Section 13.7), then Kyowa Kirin shall not be entitled to the royalty reduction provisions of Section 7.4.2 with respect
to any royalties or other amounts paid under such license that was obtained without first following such procedures. 
 13.8
Compliance with Dartmouth License. Kyowa Kirin covenants that, with respect to its role and responsibilities as a sublicensee thereunder, it will not act in a manner that is inconsistent with Reata’s obligations under the
Dartmouth License, as such agreement exists and was disclosed to Kyowa Kirin as of the Effective Date. 

  
 61 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 13.9 Formal Notice of Identification of Backup Compound Required. In the event
of a significant development failure of RTA 402, Reata (or its Affiliate or licensee, if authorized by Reata) may, in its sole discretion, elect to pursue development of an alternative compound. Any such compound will only be considered a Backup
Compound under this Agreement upon Reata sending formal Notice to Kyowa Kirin designating that compound as a “Backup Compound” under this Agreement, such Notice to include information regarding the identity and clinical profile of such
Backup Compound (“Notice of Identification of Backup Compound”). Reata agrees to provide a Notice of Identification of Backup Compound to Kyowa Kirin with respect to a given alternative compound promptly after Reata (or its Affiliate,
licensee or collaboration partner) files an IND for such alternative compound. In all events, if there is a failure (or otherwise a decision to delay development) of RTA 402, and Reata (or its Affiliate, licensee or collaboration partner)
subsequently files an IND for a compound in the RTA 402 Class, in the Field, then Reata shall designate such compound as a Backup Compound and provide a Notice of Identification of Backup Compound with respect thereto. 

13.10 Performance Through Affiliates. Each Party may discharge any obligation and exercise any right hereunder through any of
its Affiliates (without an assignment of this Agreement); provided that with respect to Kyowa Kirin, Section 2.1.2(a) shall apply with respect to Kyowa Kirin’s exercise of any of its licensed rights hereunder. 

ARTICLE XIV 

INDEMNIFICATION AND INSURANCE 

14.1 Indemnity By Kyowa Kirin. Kyowa Kirin hereby agrees to defend, hold harmless and indemnify Reata and its Affiliates,
agents, directors, officers and employees (the “Reata Indemnitees”) from and against any and all Third Party suits, claims, actions and proceedings and associated expenses (including court costs, legal expenses and attorneys’
fees) and damages and recoveries awarded with respect thereto (collectively “Losses”) incurred by a Reata Indemnitee in connection with any and all Third Party claims arising or resulting from: (a) any misrepresentation (or
alleged misrepresentation) or breach (or alleged breach) of any of the representations, warranties, covenants or agreements made by Kyowa Kirin under this Agreement, or (b) any injury, damage or health complication suffered (or alleged to be
suffered) as a result of the Commercialization of Licensed Product by or for Kyowa Kirin or its Permitted Sublicensees in the Territory, or Kyowa Kirin’s use of any Reata Trademarks in connection with any Commercialization of any Licensed
Product in the Territory, except, in the case of either (a) or (b), to the extent such Losses arise from Reata’s breach of its representations, warranties or covenants under this Agreement or from Reata’s failure to supply Licensed
Products hereunder in conformance with the Specifications therefore and in compliance with Applicable Laws (including GMP) and such failure could not have been identified or detected by Kyowa Kirin (or if applicable its Permitted Sublicensees)
through its application of reasonable and customary quality assurance and quality control practices, or other inspections or activities required under Applicable Law with respect to such Licensed Products, prior to distribution of the Licensed
Product in the Territory, but in any event REGARDLESS OF THE CAUSE OF OR REASON FOR ANY SUCH LOSS(ES), INCLUDING BREACH OF WARRANTY, STRICT LIABILITY, OR THE SOLE OR CONCURRENT NEGLIGENCE, WHETHER ACTIVE OR PASSIVE, OF THE PARTY INDEMNIFIED.

  
 62 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 14.2 Indemnity by Reata. Reata hereby agrees to defend, hold harmless and
indemnify Kyowa Kirin and its Affiliates agents, directors, officers and employees (the “Kyowa Kirin Indemnitees”) from and against any and all any and all Losses incurred by a Kyowa Kirin Indemnitee in connection with any and all
Third Party claims arising or resulting from (a) any misrepresentation (or alleged misrepresentation) or breach (or alleged breach) of any of the representations, warranties, covenants or agreements made by Reata under this Agreement other than
such Losses arising from Reata’s failure to supply Licensed Products hereunder in conformance with the Specifications therefore and in compliance with Applicable Laws (including GMP) where such failure could have identified or detected by Kyowa
Kirin (or if applicable its Permitted Sublicensees) through its application of reasonable and customary quality assurance and quality control practices, or other inspections or activities required under Applicable Law with respect to such Licensed
Products, prior to distribution of the Licensed Product in the Territory, or (b) any injury, damage or health complication suffered (or alleged to be suffered) as a result of the development, commercialization, use, promotion, marketing,
distribution or sale of Licensed Product by or for Reata or its Affiliates or licensees outside the Territory, except, in the case of either (a) or (b), to the extent such Losses arise from Kyowa Kirin’s breach of its representations,
warranties or covenants, but in any event REGARDLESS OF THE CAUSE OF OR REASON FOR ANY SUCH LOSS(ES), INCLUDING BREACH OF WARRANTY, STRICT LIABILITY, OR THE SOLE OR CONCURRENT NEGLIGENCE, WHETHER ACTIVE OR PASSIVE, OF THE PARTY INDEMNIFIED.

 14.3 Procedure for Indemnification. If a Reata Indemnitee or a Kyowa Indemnitee (as the case may be, an
“Indemnitee”) wishes to seek indemnification hereunder, such Indemnitee will inform the Party obligated to indemnify the Indemnitee hereunder (the “Indemnifying Party”) of the Third Party claim giving rise to the
obligation to indemnify as soon as reasonably practicable after receiving Notice of such Third Party claim. The Indemnifying Party will have the right to assume and control the defense of any such Third Party claim for which it is obligated to
indemnify the Indemnitee under this Agreement. The Indemnitee will cooperate with the Indemnifying Party (and its insurer) as the Indemnifying Party may reasonably request, and at the sole cost and expense of the Indemnifying Party. The Indemnitee
will have the right to retain its own counsel, at the expense of the Indemnifying Party, if representation of such Indemnitee by the counsel retained by the Indemnifying Party would be inappropriate because of actual or potential differences in the
interests of such Indemnitee and any other Party represented by such counsel. In all other cases, the Indemnitee will have the right to participate in such defense, subject to the Indemnifying Party’s control, using its own counsel at its own
expense. The Indemnifying Party will have no obligation to indemnify any Indemnitee in connection with any settlement made without the Indemnifying Party’s prior written consent; provided, that the Indemnifying Party does not unreasonably
withhold or delay any such written consent. The Indemnifying Party shall seek the prior written consent of the Indemnified Party for any settlement of a Third Party claim subject to indemnification hereunder (such consent to not be unreasonably
withheld, delayed or conditioned) if such settlement would materially diminish or materially adversely affect the scope, exclusivity or duration of any intellectual property licensed under this Agreement, would require any payment by such
Indemnified Party, would require an admission of legal wrongdoing in any way on the part of an Indemnified Party, or would effect an amendment of this Agreement 

  
 63 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
(otherwise, no such consent shall be required). If the Indemnifying Party does not assume and conduct the defense of the Third Party claim as provided above, (a) the Indemnitee may defend
against, and consent to the entry of any judgment or enter into any settlement with respect to the claim in any manner the Indemnitee may deem reasonably appropriate (and the Indemnitee need not consult with, or obtain any consent from, the
Indemnifying Party in connection therewith), and (b) the Indemnifying Party will remain responsible to indemnify the Indemnitee as provided in this ARTICLE XIV. 

14.4 Insurance. Each Party will procure and maintain, at its sole cost and expense, comprehensive general liability insurance
(which may be self insurance), including product liability insurance, with bodily injury, death and property limits and amounts of coverage consistent with industry standards, including contractual liability and product liability coverage. It is
understood that such insurance will not be construed to create a limit of a Party’s liability with respect to its indemnification obligations hereunder. Each Party shall provide the other Party with written evidence of such insurance upon
request. 
 ARTICLE XV 

TERM AND TERMINATION 
 15.1
Term. The term (“Term”) of this Agreement will commence on the Effective Date and, unless earlier terminated as expressly provided below in this ARTICLE XV, will expire on the date that the Royalty Term has expired in
all countries in the Territory. 
 15.2 Termination by Reata. Reata may terminate this Agreement upon the failure of Kyowa
Kirin to pay any amount due hereunder, but solely in the event and after such failure continues for [***] days after Reata has provided Kyowa Kirin with written Notice of such failure, and (b) an additional [***] Business Days after Reata has
provided Kyowa Kirin with a second written Notice with respect to such failure (but no such termination shall occur if Kyowa Kirin cures such failure prior to the end of such additional three-Business Day period), and in any event subject to
Section 15.5. If the failure to pay at issue is specific to China or Japan and provided that such failure to pay does not materially and adversely affect any other country in the Territory or this Agreement as a whole, Reata’s right to
terminate under this Section 15.43 shall be either to terminate the Agreement just as to China or Japan, or to terminate the Agreement as a whole. 

15.3 Termination by Kyowa Kirin At Will. Kyowa Kirin shall have the right to terminate this Agreement in its entirety, or solely
with respect to a given country or countries in the Territory, for any or no reason, upon [***] days prior written notice to Reata. 
 15.4
Termination by Either Party for Breach or Insolvency. Either Party will have the right to terminate this Agreement prior to the expiration of the Term upon the occurrence of any of the following: 

15.4.1 Upon the material breach of any representations, warranties or obligations by the other Party if the breaching Party has not cured such
breach within [***] day after written Notice thereof (describing such breach in reasonable detail) by the non-breaching Party; and 

  
 64 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 15.4.2 Immediately upon written Notice, if the other Party has filed a petition in
bankruptcy, or if an involuntary petition in bankruptcy has been filed against the other Party and such petition will not be dismissed within sixty (60) days, or if a receiver or guardian has been appointed for the other Party, or upon or after
the cessations of operations of the other Party. 
 Notwithstanding the foregoing, in the event the alleged breach in question under Section 15.4.1 is
not reasonably capable of cure within the foregoing [***] days, the breaching Party may submit a reasonable cure plan prior to the end of such initial [***] day period, in which case, the other Party shall not have the right to terminate under this
Section 15.4 with respect to such alleged breach for so long as the breaching Party is diligently implementing such cure plan, provided, however, that if the breaching Party fails to cure such breach (even if diligently implementing a cure
plan) within [***] from the date of the written notice identifying the material breach in reasonable detail, then the non-breaching Party may terminate under this Section 15.4 upon expiration of the [***] period. If the material breach at issue
is specific to a country and provided that such material breach does not materially and adversely affect any other country in the Territory or this Agreement as a whole, each Party’s right to terminate under this Section 15.4 shall be
limited to the termination of this right with respect to such country. 
 15.5 Disputes Over Right to Terminate. With respect
to efforts to terminate this Agreement for non-payment, breach, insolvency or otherwise under Sections 15.2 or 15.4, if the alleged breaching Party (which includes Kyowa Kirin for alleged non-payment under Section 15.2 or insolvency under
Section 15.4.2) disputes in good faith the existence of a breach specified in a Notice provided by the other Party and/or the right to terminate this Agreement, then the non-breaching Party shall not have the right to terminate this Agreement
hereunder unless and until the arbitrator(s), in accordance with ARTICLE XVI, has determined that the alleged breaching Party has materially breached this Agreement and until such Party fails to cure such breach within [***] days following such
decision of such arbitrator(s) (except to the extent such breach involves the failure to make a payment when due, which breach must be cured within [***] days following such decision of such arbitrator(s)). It is understood and agreed that during
the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder. 

15.6 Effect of Expiration or Termination of this Agreement for Any Reason. Upon the expiration or termination of this Agreement
by either Party for any reason, the following provisions will apply: 
 15.6.1 Each Party will return the originals and any copies of the
other Party’s Confidential Information; provided, that, each Party may retain copies of any Confidential Information that is subject to a continuing license hereunder and one copy of the other Party’s Confidential Information in possession
of its legal counsel for the purposes of monitoring its obligations hereunder and exercising any surviving rights and complying with Applicable Laws; 

15.6.2 Neither Party will be relieved of any liability or obligation of such Party that accrued, or which arose during or relates to any
period, prior to the effective date of such termination, including any payment obligations; and 

  
 65 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 15.6.3 The provisions of ARTICLE I, ARTICLE XI, ARTICLE XIV (excluding Section 14.4),
ARTICLE XVI, and ARTICLE XVII, and Sections 9.2 (solely for the limited period provided for therein), 9.3 (solely for the limited period provided for therein), 10.2, 15.6, 15.7, and 15.8, and 15.10 as applicable will survive any expiration or
termination of this Agreement and remain in full force and effect in accordance with their terms. 
 15.7 Effect of Expiration at End
of Royalty Term. If this Agreement expires as provided for in Section 15.1, then the following shall apply: 
 15.7.1 After
expiration of this Agreement, Kyowa Kirin shall have an exclusive, royalty-free license, under the Licensed Technology to research, develop, use, sell, offer for sale, import, and export (and to have such actions taken on its behalf by its agents,
contractors, service providers or authorized representatives in accordance with this Agreement) Licensed Compounds and Licensed Products in the Field in the Territory, and furthermore: 

15.7.1.1 Any sublicenses granted under Section 2.1.2 prior to such expiration shall survive such expiration and Kyowa
Kirin shall have the right to grant further sublicenses after such expiration in accordance with Section 2.1.2. 

15.7.1.2 Kyowa Kirin’s manufacturing rights under Section 2.1.3 shall survive such expiration. 

15.7.1.3 Any license to Kyowa Kirin to Product Trademarks under Section 2.5 shall survive such expiration. 

15.7.2 The Parties obligation under the following provisions of this Agreement shall continue so long as the Licensed Product is Commercialized
by Kyowa Kirin: 
 15.7.2.1 Sections 4.2, 5.4, and 5.5 (with respect to sharing of certain data and information regarding
the Licensed Products); and 
 15.7.2.2 Section 8.3.3. 

15.8 Effect of Certain Terminations. Upon the termination of this Agreement by Reata pursuant to Section 15.2, by Kyowa
Kirin pursuant to Section 15.3 or by Reata for breach or insolvency by Kyowa Kirin pursuant to Section 15.4, the following provisions of this Section 15.8 will apply (in addition to the provisions of Section 15.6). To the extent
any such early termination concerns only a specific country or countries, the following shall apply solely with respect to such country(ies) and the Agreement shall otherwise remain in effect in accordance with its terms for all non-terminated
countries: 
 15.8.1 The rights and licenses granted by Kyowa Kirin to Reata hereunder will terminate; 

  
 66 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 15.8.2 Kyowa Kirin will immediately (a) cease conducting any Commercialization
activities with respect to Licensed Product, and (b) discontinue making any representation regarding its status as a licensee or distributor of Reata in the Territory for Licensed Product, subject, in either such case, to requirements of
Applicable Laws and to a reasonable wind-down and transition period (not to exceed [***] days); 
 15.8.3 Kyowa Kirin will grant to Reata as
of the effective date of the termination an exclusive sublicenseable license to use the Product Trademarks that were actually used during the Term in the Commercialization of Licensed Product in the Territory (and Reata shall thereupon be fully
responsible for all costs and expenses of, and shall have the right to control, the prosecution, maintenance, defense and enforcement of such Product Trademarks). 

15.8.4 Kyowa Kirin will promptly (but in any event subject to Applicable Laws): 

(a) transfer to Reata or Reata’s designee all Regulatory Filings and Regulatory Approvals owned by Kyowa Kirin for the Commercialization
of Licensed Products, if such transfer is possible, or, if such transfer is not possible, then at Reata’s discretion (i) withdraw any such Regulatory Filings and Regulatory Approvals for the Commercialization of Licensed Products in its
name and take all actions necessary or useful to support Reata’s or Reata’s designee’s submission of Regulatory Filings and the achievement of Regulatory Approvals in the name of Reata or Reata’s designee with respect to the
Commercialization of Licensed Products or (ii) provide Reata with access to, and grant Reata the right and license to use and to reference, such Regulatory Filings and Regulatory Approvals then in its name applicable to the Commercialization of
Licensed Products; 
 (b) provide Reata with copies of all material correspondence between Kyowa Kirin and Regulatory Authorities with
respect to such Regulatory Filings and Regulatory Approvals for Licensed Products any and all other clinical and non-clinical data, records and tabulations, in all such cases with respect to Licensed Products, that Kyowa Kirin holds as of the date
of termination with respect to Licensed Products; 
 (c) assign to Reata all agreements specific to the conduct of clinical trials for
Licensed Product (to the extent assignable and excluding any such agreements that also involve clinical trials for other Kyowa Kirin products that are not Licensed Products), including agreements or contracts with contract research organizations,
clinical sites and investigators, between Kyowa Kirin and any Third Party, subject to any consent required by such Third Party, which consent Kyowa Kirin will use Commercially Reasonable Efforts to obtain on behalf of Reata; and 

(d) provide Reata with copies of all reports and data obtained by Kyowa Kirin or its Affiliates pursuant to this Agreement (solely to the
extent in Kyowa Kirin’s possession or Control as of the date of termination and solely to the extent not previously provided to Reata) regarding the Commercialization of Licensed Products, including any Kyowa Kirin Clinical Data not already
provided to Reata hereunder. Kyowa Kirin hereby acknowledges and agrees that Reata will not be obligated to treat any information received pursuant to this Section 15.8.4(d) as Kyowa Kirin Confidential Information and may use such information,
data and Know-How for any purpose at Reata’s discretion. 

  
 67 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 As promptly as possible after any such termination, Kyowa Kirin will execute any and all documents of any
Regulatory Authorities, so as to allow Reata to make immediate use of any data, records, and Regulatory Filings transferred by Kyowa Kirin to Reata pursuant to this Section 15.8.4. 

15.9 Remedies Cumulative and Nonexclusive. All of the non-breaching Party’s remedies will be cumulative, and the exercise
of one remedy hereunder by the non-breaching Party will not be deemed to be an election of remedies. 
 15.10 Rights In
Bankruptcy.  
 15.10.1 In case of termination by Reata pursuant to Section 15.4.2 based on Kyowa Kirin becoming an
“insolvent party” (hereinafter “Insolvent Party”) as defined under applicable bankruptcy law, Reata’s rights under this Agreement will include, without limitation, those rights afforded by 11 U.S.C. § 365(n) of
the United States Bankruptcy Code (“USBC”) and any successor thereto, if applicable. If the bankruptcy trustee of the Insolvent Party as a debtor or debtor-in-possession rejects this Agreement under 11 U.S.C. § 365(o) of the
USBC, Reata may elect to retain its rights licensed from the Insolvent Party hereunder (and any other supplementary agreements hereto) for the duration of this Agreement and avail itself of all rights and remedies to the full extent contemplated by
this Agreement and 11 U.S.C. § 365(n) of the USBC, and any other relevant laws. The same will apply under any similar provisions of Japanese law, mutatis mutandis. 

15.10.2 In case of termination by Kyowa Kirin pursuant to Section 15.4.2 based on Reata becoming an Insolvent Party, Kyowa Kirin’s
rights under this Agreement will include, without limitation, those rights afforded by 11 U.S.C. § 365(n) of the USBC. If the bankruptcy trustee of the Insolvent Party as a debtor or debtor-in-possession rejects this Agreement under 11 U.S.C.
§ 365(o) of the USBC, Kyowa Kirin may elect to retain its rights licensed from the Insolvent Party hereunder (and any other supplementary agreements hereto) for the duration of this Agreement and avail itself of all rights and remedies to the
full extent contemplated by this Agreement and 11 U.S.C. § 365(n) of the USBC, and any other relevant laws. The same will apply under any similar provisions of Japanese law, mutatis mutandis. 

ARTICLE XVI 
 DISPUTE
RESOLUTION 
 16.1 Disputes. The Parties recognize that disagreements as to certain matters may from time to time arise
out of this Agreement. Parties agree that such disagreements are to be governed in accordance with this ARTICLE XVI. Disagreements that are claims, counterclaims, demands, causes of action, disputes or controversies both arising out of this
Agreement and related to the performance, enforcement, breach or termination of this Agreement are each, a “Dispute.” For the avoidance of doubt, Dispute does not include any claims, counterclaims, demands, causes of action,
disputes or controversies regarding a Party’s use of any intellectual property rights of the other Party, where such use is not expressly granted by the licenses hereunder, including (with respect to uses by Kyowa Kirin) any such use outside of
the Territory. 

  
 68 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 16.2 Informal Negotiation. It is the objective of the Parties to establish
procedures to facilitate the resolution of Disputes in an expedient manner by mutual cooperation and without resort to litigation. To accomplish this objective, the Parties agree that Disputes will be discussed first by the Chief Executive Officer
of Reata and the Chief Operating Officer of Kyowa Kirin (or an executive officer of either Party designated by such Chief Executive/Operating Officer). Either Party may, by written Notice to the other Party, have a Dispute referred to its respective
Chief Executive/Operating Officer (or executive officer designee, if applicable) for attempted resolution by good faith negotiations within [***] days after such Notice is received. If the Chief Executive/Operating Officers (or designees if
applicable) are not able to resolve such Dispute within such [***] day period, either Party may pursue the resolution of the issue pursuant to Section 16.3. 

16.3 Mediation. Subject to Section 16.1 and 16.2, if a Dispute remains unresolved, either Party may submit that Dispute to
mediation administered by the International Chamber of Commerce (“ICC”) in accordance with the ICC ADR Rules (the “Mediation Rules”). Unless otherwise agreed by the Parties, the mediator will be selected in
accordance with the Mediation Rules within ten (10) days of the initiation of mediation. If the Parties are unable to resolve such controversy or claim within thirty (30) days following the date on which such mediator is first available,
or within such other period as the parties may agree in writing, either Party may declare the mediation procedure terminated and refer the Dispute to arbitration pursuant to this ARTICLE XVI. 

16.4 Agreement to Arbitrate. If the Parties fail to resolve any Dispute pursuant to Sections 16.2 and 16.3, either party may
submit that Dispute for final resolution by binding arbitration administered by the International Chamber of Commerce in accordance with its Rules of Arbitration (the “Rules”) then in force, to the extent such Rules are not
inconsistent with the provisions of this Agreement. Each Party irrevocably stipulates that this Section 16.4 will satisfy the requirements for an agreement in writing pursuant to Article II of the United Nation Convention on the Recognition and
Enforcement of Foreign Arbitral Awards, done at New York on June 10, 1958. Each Party irrevocably stipulates that this Agreement and the relationship created thereby is commercial and that this provision constitutes an agreement in writing to
arbitrate for an international commercial dispute. 
 16.5 Number and Appointment of Arbitrators. Except as provided by this
clause, the appointment and confirmation of the arbitrators shall be made in accordance with the relevant provisions of the Rules. The arbitral tribunal shall be composed of three arbitrators (the “Tribunal”) to be appointed in
accordance with the Rules, except as expressly provided for herein. Each Party shall select one (1) arbitrator from the list of available ICC arbitrators and such arbitrators shall jointly appoint the third arbitrator who shall act as the
chairman of the Tribunal (the “Chairman”). In the event any arbitrator becomes unable to serve, that arbitrator will be replaced in the same manner in which he or she was appointed. If either Party fails to appoint an

  
 69 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
arbitrator within thirty (30) days of the initiation of arbitration, the other Party may request the ICC to appoint such co-arbitrator (for the non-responsive Party). Such appointment shall
be binding on the Parties. If the arbitrators selected by the Parties cannot agree on a Chairman within thirty (30) days after they have been selected, then either Party may request that the ICC to appoint the Chairman. 

16.6 Conduct of Arbitration. The arbitration shall be conducted and the award rendered in the English language. The Parties
agree that discovery and evidence in the arbitration shall be governed by the International Bar Association Rules on the Taking of Evidence in International Commercial Arbitration then in force to the extent such rules are not inconsistent with the
provisions of this Agreement or the Rules. Responses or objections to a document request will be served ten (10) days after receipt of the request. The Tribunal shall resolve any discovery disputes. If a Party fails or refuses to comply with an
order for discovery, the Tribunal may take that failure into account when deciding the issues and may infer that the documents not produced would have supported the opposing Party’s claims. Nothing herein will prevent the Parties from settling
any dispute by mutual agreement at any time. 
 16.7 Place of Arbitration. The arbitration shall be held at the location to
which the Parties agree; if the Parties cannot agree to an arbitration location, the arbitration shall be held in northern California, at a location mutually established by the Parties, or failing such agreement, in San Francisco, California. 

16.8 Powers of the Arbitrators, Limitations on Remedies. The Tribunal shall have the power to award all remedies available under
the Applicable Law, by a vote of at least two of the three arbitrators. The Tribunal shall not decide the Dispute ex aqueo et bono or as amiable compositeur or by reliance on any other doctrine or principle that would permit the
Tribunal to avoid the application of this Agreement and/or the governing law. The Tribunal shall not have the authority to modify or amend any term or provision of this Agreement. 

16.9 Arbitration Award. The Tribunal shall make all reasonable efforts to render a written, reasoned decision within forty-five
(45) days following the closing of the hearing. The decision of the Tribunal shall be final and binding on the Parties, and judgment upon the decision may be confirmed in, and judgment upon the award entered by, any court having jurisdiction
over the Parties. 
 16.10 Confidentiality. Except to the extent necessary for proceedings relating to enforcement of the
arbitration agreement, the award, or other related rights of the Parties, the fact of the arbitration, the arbitration proceeding itself, all evidence, written statements or other documents exchanged or used in the arbitration and the
Tribunal’s award shall be maintained in confidence by the Parties to the fullest extent permitted by law. However, a violation of this covenant shall not affect the enforceability of this agreement to arbitrate or of the Tribunal’s award.

  
 70 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 16.11 Costs. Each Party shall bear its own costs and expenses in connection
with any Dispute resolution under this ARTICLE XVI and shall share equally the fees, costs and expenses of the Tribunal and related Third Party arbitration expenses. Notwithstanding the foregoing, the prevailing Party may, as determined by the
Tribunal under the circumstances, be awarded its attorneys’ fees, costs and expenses of the arbitration, including the arbitrators’ fees and expenses, in full. The Tribunal may also fix such costs and expenses proportionate to the extent
each Party prevails in the arbitration, as the circumstances may warrant. If a Party fails to proceed with arbitration, unsuccessfully challenges the arbitration award, or fails to comply with the arbitration award, the other Party is entitled to
costs, including reasonable attorneys’ fees and disbursements, for having to compel arbitration or defend or enforce the award. 

16.12 Injunctive or Other Interim Relief. Notwithstanding the provisions of this ARTICLE XVI, the Parties agree that irreparable
harm might accrue with respect to a Dispute absent a temporary injunctive or other interim relief and the Parties therefore shall have the right to seek such injunctive or interim relief in a court of competent jurisdiction pending the outcome of
Dispute resolution hereunder. In the event interim or injunctive relief is sought by a Party as to a Dispute, and a court of competent jurisdiction grants such interim or injunctive relief, the Parties shall continue to be bound under this ARTICLE
XVI to resolve by arbitration such Dispute that is the subject of interim or injunctive relief. 
 16.13 Continued
Performance. Pending resolution of any Dispute covered by this ARTICLE XVI, both Parties will continue their performance under this Agreement of any obligations (including payment obligations) that are not the subject of such Dispute. 

16.14 Governing Law; Jurisdiction; Venue. Resolution of all Disputes arising out of or related to this Agreement or the
performance, enforcement, breach or termination of this Agreement and any remedies relating thereto, shall be governed by and construed under the substantive laws of the State of Delaware, U.S.A., without reference to any choice of law principles
thereof that would cause the application of the laws of a different jurisdiction. Without limiting the exclusivity of the alternative dispute resolution provisions of Sections 16.1 through 16.11 (including the arbitration of all unresolved Disputes
under Section 16.4), the Parties consent to the non-exclusive personal jurisdiction and venue of the federal and state courts located in Delaware, U.S.A., solely for effectuating the provisions of Sections 16.9 and 16.12. 

16.15 Separability and Survival of the Agreement to Arbitrate. The provisions of this agreement to arbitrate are independent of
the remaining provisions of this Agreement and the Parties intend that the remaining provisions shall continue in effect even though one or more of the provisions of the Agreement shall be determined to be null and void. This agreement to arbitrate
shall also survive the termination or expiration of this Agreement. 
 ARTICLE XVII 

OTHER PROVISIONS 
 17.1
Non-Solicitation of Employees. During the Term, neither Party nor its Affiliates shall, directly or through its representatives or agents, solicit for employment or hire any officer, director, or employee of the other Party or its
Affiliates with whom it has had contact in connection with, or who otherwise is known by it to participate in, the subject matter of this Agreement or the 

  
 71 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
development of a Licensed Compound or a Licensed Product; provided, however, a Party shall not be prohibited from soliciting and hiring through general public advertisement or other solicitation
that is not directed toward the employees of the other Party, and a Party may hire any former employee of the other Party as long as the discussions with the former employee are initiated after termination of employment by the other Party. 

17.2 Force Majeure. Both Parties will be excused from the performance of their obligations under this Agreement, other than the
obligation to make monetary payments, and neither Party will be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this
Agreement, to the extent that such performance is prevented by force majeure and the nonperforming Party promptly provides Notice thereof to the other Party. Such excuse will be continued so long as the condition constituting a force majeure event
continues and the nonperforming Party uses reasonable efforts to remove the condition. For purposes of this Agreement, a force majeure event will include conditions beyond the reasonable control and without the fault of a Party, such as an act of
God, voluntary or involuntary compliance with any regulation, law or order of any government, war, an act of terrorism, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of
production facilities or materials by fire, earthquake, storm or like catastrophe, inability to procure necessary raw materials in a commercially reasonable manner or default of suppliers or sub-contractors; provided, however, the payment of
invoices due and owing hereunder may not be delayed by the payor because of a force majeure affecting the payor. 
 17.3 Exclusions of
Consequential Damages. EXCEPT IN THE CASE OF A PARTY’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR LOST PROFITS OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE
OR EXEMPLARY DAMAGES OF THE OTHER PARTY IN CONNECTION WITH THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, HOWEVER CAUSED, UNDER ANY THEORY OF LIABILITY, AND WHETHER OR NOT SUCH PARTY HAD PRIOR NOTICE THEREOF. 

17.4 Assignment. Neither this Agreement nor any obligation of a Party hereunder may be assigned by either Party without the
prior written consent of the other Party; provided, however, that either Party may assign this Agreement in its entirety without such consent, to any of its Affiliates, to any purchaser of all, or substantially all, of its assets or to any successor
corporation resulting from any merger, consolidation, share exchange, or other similar transaction, and provided further that either Party may assign or sell its rights to receive any amounts due hereunder. This Agreement will inure to the benefit
of Kyowa Kirin and Reata and their respective successors and permitted assigns. Any assignment of this Agreement that is not made in accordance with this Section 17.4 shall be null and void and of no legal force or effect. 

  
 72 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 17.5 Severability. In the event any one or more of the provisions contained in
this Agreement should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby, unless the absence of the
invalidated provision(s) frustrates the purpose of this Agreement (in which case the Parties will attempt to replace such invalidated provision with an enforceable provision that most clearly implements such purpose). The Parties will in such an
instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) that, insofar as practical, implement the purposes of this Agreement. 

17.6 Notices. All notices, consents, approvals and other legally operative communications that are required or permitted
hereunder (“Notice”) will be in writing in the English language and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by
nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows: 

Reata Pharmaceutical, Inc. 

2801 Gateway Drive, Suite 150 

Irving, Texas 75063 
 Attention:
Business Development Department 
 Tel: (972) 865-2219 

Fax: (800) 998-3206 
 Kyowa
Hakko Kirin Co., Ltd. 
 1-6-1 Ohtemachi 

Chiyoda-ku, Tokyo, 100-8185, Japan 

Attention: Business Development Department 

Tel: +81-3-3282-0093 
 Fax:
+81-3-3282-0107 
 or to such other address as the Party to who Notice is to be given may have furnished to the other Party in writing in accordance
herewith. Any such communication will be deemed delivered (i) if sent by mail, as aforesaid, on the date upon which the return receipt is signed or delivery is refused or the Notice is designated by the postal authorities as not deliverable, as
the case may be, (ii) if sent by facsimile, as aforesaid, when sent (with confirmation of receipt), and (iii) if sent by courier or hand delivered, as aforesaid, when received. The cost of any translation into English of any communication,
document or Notice will be borne solely by the Party providing such communication, document or Notice. 
 17.7 Entire Agreement;
Amendments. This Agreement contains the entire understanding of the Parties with respect to the subject matter hereof. All express or implied agreements and understandings, either oral or written, heretofore made are expressly superseded by
this Agreement. Except as expressly set forth in this Agreement, this Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by both Parties. 

  
 73 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 17.8 Headings. The captions to the several Articles and Sections hereof are not
a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Articles and Sections hereof. 

17.9 Independent Contractors. It is expressly agreed that Reata and Kyowa Kirin will be independent contractors and that the
relationship between the two Parties will not constitute a partnership, joint venture or agency. Neither Reata nor Kyowa Kirin will have the authority to make any statements, representations or commitments of any kind, or to take any action, which
will be binding on the other, without the prior consent of the other Party. 
 17.10 Waiver. The waiver by either Party hereto
of any right hereunder or the failure to perform or of a breach by the other Party will not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 

17.11 Counterparts. This Agreement may be executed in identical duplicate copies exchanged by facsimile transmission. The
Parties agree to execute two identical original copies of this Agreement after exchanging signed facsimile versions. Each identical counterpart will be deemed an original, but all of which together will constitute one and the same instrument. 

17.12 Waiver of Rule of Construction. Each Party has had the opportunity to consult with counsel in connection with the review,
drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement will be construed against the drafting Party will not apply. 

17.13 Third Party Beneficiaries. Except as otherwise expressly provided in this Agreement, nothing herein expressed or implied
is intended or will be construed to confer upon or to give to any Third Party any rights or remedies by reason of this Agreement. Except as otherwise expressly provided in this Agreement, there are no intended Third Party beneficiaries under or by
reason of this Agreement. 
 17.14 Further Assurances. Upon the other Party’s request hereunder, each Party agrees to
execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

17.15 Construction of Agreement. Unless context otherwise clearly requires, whenever used in this Agreement: (i) the words
“include” or “including” shall be construed as incorporating, also, “but not limited to” or “without limitation;” (ii) the word “day” or “year” means a calendar day or calendar year
unless otherwise specified; (iii) the word “notice” means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other legally operative communications contemplated under this
Agreement; (iv) the words “hereof,” “herein,” “hereby” and derivative or similar words refer to this Agreement (including all Exhibits); (v) the word “or” shall be construed as the inclusive meaning
identified with the phrase “and/or;” (vi) provisions that require that a Party, the Parties or any committee or team hereunder “agree,” “consent” or “approve” or the like shall require that such
agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise; (vii)

  
 74 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 
words of any gender include the other gender; (viii) references to any specific Applicable Law or article, section or other division thereof shall be deemed to include the then-current
amendments thereto or any replacement Applicable Law thereof; and (ix) references to either Party include the successors and permitted assigns of that Party. If the terms of this Agreement conflict with the terms of any Exhibit, then the terms
of this Agreement will govern. 
 [Remainder of this page is intentionally left blank.] 

  
 75 

Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked
in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission. 

 Execution Version 

 

 IN WITNESS WHEREOF, the Parties have executed this License Agreement to be effective
as of the Effective Date. 
  

											
	KYOWA HAKKO KIRIN CO., LTD.	  	REATA PHARMACEUTICALS, INC.	  	
						
	 By:
	  	 /s/ Yazuru Matsuda
	  		  	By:	  	 /s/ J. Warren Huff
	  	
	 Name:
	  	Yazuru Matsuda	  		  	Name:	  	J. Warren Huff	  	
	 Title:
	  	Executive Director of the Board	  		  	 Title:
	  	President and	  	
		  	President and Chief Executive Officer	  		  		  	Chief Executive Officer	  	
						
	 Date:
	  	Dec. 24 2009	  		  	Date:	  	Dec. 23, 2009	  	

 Signature Page 

  
 Specific terms in this exhibit have
been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities
and Exchange Commission. 
  

 Execution Version 

 

 EXHIBIT A 

Reata Patent Rights 
 “Reata
Patent Rights” shall include the following patents and applications: 
 [***] 
  

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

 [***] 
  

					
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]
			
	[***]	  		  	
			
	[***]	  	[***]	  	[***]
	[***]	  	[***]	  	[***]

  
 Specific terms in this exhibit have
been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities
and Exchange Commission. 
  

 Execution Version 

 

 EXHIBIT B 

Third Party License Agreements 
  

	1.	The Dartmouth License (as defined in Section 1.1.13). 

  
 Specific terms in this exhibit have
been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities
and Exchange Commission.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]